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Abstract
Identification and Characterization of the P53-Induced Long Noncoding RNA
Isoform Pvt1b and Its Role in Stress-Specific Growth Inhibition via Myc
Repression
Christiane Elizabeth Olivero
2021
The tumor suppressor p53 and proto-oncogenic Myc transcription factors
are frequently deregulated in cancer, with common loss-of-function and gain-offunction mutations observed in the p53 and Myc networks, respectively. Referred
to as the ‘guardian of the genome,’ p53 regulates genes important for curtailing
cellular proliferation and tumorigenesis under conditions of stress, while the
proto-oncogene Myc induces genes that, in contrast, promote cellular growth and
can, in overcoming growth inhibitory signals, support cancer development. While
previous literature has documented decreased Myc expression in response to
cellular stress, researchers have long puzzled over identifying the specific
regulatory lever responsible. The work presented here identifies a novel regulatory
axis positioned at the intersection of the p53 and Myc pathways, which represses
Myc and restricts cellular proliferation downstream of p53 activation.
Long noncoding RNAs (lncRNAs) are a diverse class of transcripts lacking
protein-coding potential and implicated in gene expression regulation. Here I
present my work on the identification of an isoform of the lncRNA Plasmacytoma
variant translocation 1 (Pvt1) and the characterization of its role in the p53mediated response to stress. I found that the stress-specific Pvt1b, expressed 50
Kb downstream of the Myc locus, is induced by p53 in response to oncogenic and

genotoxic stress and accumulates at its site of transcription. I demonstrated that
production of the Pvt1b RNA is necessary and sufficient to repress Myc
transcription in cis without altering the chromatin organization of the locus. I
investigated the functional outputs of Pvt1b-mediated Myc downregulation and
found that inhibition of Pvt1b increased both Myc levels and transcriptional
activity and promoted cellular proliferation. Notably, Pvt1b loss accelerated tumor
growth, but not tumor progression, in an autochthonous mouse model of lung
cancer. Further examination of the Pvt1b mechanism of action failed to identify
Pvt1b-specific sequences required for its function, but uncovered a potential role
for histone deacetylation in Pvt1b regulation of Myc. Finally, I initiated
development of a suite of genetically engineered Pvt1 mouse models, the
characterization of which will shed light on Pvt1 function in vivo and benefit future
mechanistic studies.
Taken together, this work conceptually advances our understanding of
stress-induced growth inhibition orchestrated by p53. Specifically, I identify Pvt1b
as the primary mediator of stress-specific Myc repression, providing insight into
the long-standing question of how p53 activation triggers Myc downregulation. As
such, this work has far-reaching implications not only for our understanding of cisacting lncRNAs, which can fine-tune local gene expression downstream of broadly
active transcription programs, but also for the exciting therapeutic possibility of
restricting Myc levels in cancer via Pvt1b modulation.
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Chapter 1: Background
Long noncoding RNAs in gene regulation
Recent sequencing advances have revealed pervasive transcription of
mammalian genomes, far exceeding the level of RNA production required for
protein synthesis alone. Specifically, despite protein-coding sequences comprising
just 2% of the human genome, as much as 75% of the genome is transcribed
(Djebali et al., 2012). This discrepancy has largely upended one of the foundational
tenets of molecular biology: that RNA (with a few notable exemptions) provides
the cellular instructions, copied from DNA, to produce proteins (Rinn and Chang,
2012). Why cells expend the energy to transcribe a majority of the genome is still
not well understood, and some have speculated that these noncoding RNAs
(ncRNAs), not being destined for translation, may amount to nothing more than
extensive transcriptional noise. However, there is increasing evidence for
noncoding transcripts with critical roles in cellular homeostasis, implicating these
RNAs as having nuanced and previously unappreciated functions that go far
beyond mere messenger (reviewed in (Statello et al., 2020)).
Once simply referred to as “junk DNA,” recent years have seen a collective
reframing of noncoding DNA sequences as mysterious genomic “dark matter” with
unexplored functional depths. Breaking from a protein-centric view of cellular
operations, there has been growing interest in how the RNAs produced from these
enigmatic parts of the genome might impose an additional regulatory layer on
cellular activities. Constituting perhaps the most nebulous of these ncRNA classes,
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long noncoding RNAs (lncRNAs) encompass a heterogenous collection of
RNA molecules broadly defined as transcripts exceeding 200 nucleotides in length
and, like other ncRNAs, lacking protein-coding potential (Rinn and Chang, 2012).
In contrast to other ncRNAs classes, such as miRNAs (microRNAs), with their
comparatively well-defined role in post-transcriptional gene regulation, lncRNAs
have far more varied and versatile roles in biology, stemming in part from their
imprecise operational definition (Cech and Steitz, 2014).
LncRNA transcription and processing share many similarities with those of
protein-coding genes. For one thing, lncRNA genes possess chromatin marks
consistent with other actively transcribed genes: H3K4me3, H3K9ac, H3K27ac
(Guttman et al., 2009). Like mRNAs (messenger RNAs), many lncRNAs are
transcribed by RNA Pol II, and are often subject to 5’-capping, splicing, and
polyadenylation (Quinn and Chang, 2016). Following transcription, lncRNAs have
comparable stability to mRNAs, with slightly shorter half-lives on average (Clark
et al., 2012), and are also subject to nonsense-mediated decay (NMD), although
perhaps with increased susceptibility over mRNAs (Mendell et al., 2004).
However, there are several key features that distinguish lncRNAs from coding RNA
transcripts, apart from their lack of open reading frame (ORF). First, the structures
of lncRNA loci can vary widely, with lncRNA genes found overlapping, antisense
to, or divergent from protein-coding genes, or located in intronic or intergenic
regions (Rinn and Chang, 2012). Notably, lncRNAs can also undergo unique
processing events, including RNase P 3’ end cleavage (as in MALAT1 processing)
(Wilusz et al., 2008), RNA back-splicing to form circRNAs (circular RNAs)
(Salzman et al., 2012), and the trimming of snoRNAs (small nucleolar RNAs) from
2

the introns of protein-coding genes (Yin et al., 2012) (reviewed in (Quinn and
Chang, 2016)). Importantly, it is likely that our understanding of the full breadth
of diversity in lncRNA form, structure, and processing is incomplete.
LncRNA genes engulf protein-coding genes in abundance. While one study
identified roughly 60,000 lncRNA genes in the human genome (Iyer et al., 2015),
estimates of that number now approach 100,000, far outstripping the 21,000
known protein-coding genes (Fang et al., 2018). Interestingly, some have noted a
correlation between higher numbers of lncRNA genes and increasing organismal
complexity, suggesting lncRNAs may have played an outsized role in recent
evolutionary history (Jandura and Krause, 2017). Indeed, the ratio of noncoding
to protein-coding DNA sequences increases as a factor of developmental
complexity and is especially high in vertebrates (Mattick, 2004). This observation
highlights the importance of the expansion of the noncoding genome, although it
is still unknown whether this relationship between noncoding DNA and
organismal intricacy is causal or simply incidental.
Analyses of the human transcriptional landscape have determined that
lncRNAs are expressed with exquisite cell-type and disease-state specificity (Iyer
et al., 2015). While this may point to critical lncRNA functions in normal and
disease states, it is thus far from clear whether these specific lncRNA expression
patterns are a cause or consequence of underlying biology. To date, examination
of individual lncRNAs has revealed functions in cell cycle regulation (Dimitrova et
al., 2014; Marin-Bejar et al., 2013), nuclear organization (Hacisuleyman et al.,
2014; Sunwoo et al., 2009), and differentiation (Jain et al., 2016; Kretz et al.,
2013), among myriad other ubiquitous cellular processes (reviewed in (Statello et
3

al., 2020)). As a result of lncRNA-specific expression signatures, the putative
prognostic value of lncRNAs in disease is high. For example, several lncRNAs are
expressed at higher levels in accordance with increased tumor stage or metastasis
risk, and can provide valuable information about cancer severity (Lu et al., 2017;
Shi et al., 2015). UCA1 (Urothelial Cancer Associated-1) and HULC (Highly
Upregulated in Liver Cancer) have been proposed as biomarkers for bladder and
liver cancer, respectively, in keeping with the tissues in which they were originally
identified (Milowich et al., 2015; Xie et al., 2013). Surprisingly, the only lncRNA to
be used in an FDA-approved diagnostic test to date is PCA3 (Prostate Cancer
Antigen 3); its presence in patient urine samples enables prostate cancer diagnosis
with a high degree of accuracy and sensitivity, surpassing the previous diagnostic
standard, prostate-specific antigen (PSA) (Fradet et al., 2004; Hessels et al.,
2003). Continuing advances in our knowledge of the specificity of lncRNA
expression patterns in disease will provide ample occasion for lncRNA-based
diagnostic and prognostic test development moving forward.
Of the lncRNAs which have been functionally characterized, many regulate
gene expression, having described roles in modulating virtually every step of RNA
production (Dimitrova et al., 2014; Marin-Bejar et al., 2013), processing (Tripathi
et al., 2010; Yap et al., 2018), stability (Cao et al., 2017; Kretz et al., 2013), and
translation (Carrieri et al., 2012; Zhang et al., 2013) (reviewed in (Statello et al.,
2020)). Gene regulation by lncRNAs is an extensive area of research; there has
been significant interest in the role of lncRNAs in epigenetic modifications in
particular, with several studies describing lncRNAs interacting with polycomb
proteins to elicit gene repression (Khalil et al., 2009; Rinn et al., 2007; Tsai et al.,
4

2010). While recent work demonstrating the promiscuous binding of PRC2
(Polycomb Repressive Complex 2) to RNAs has cast doubt on the prevalence of this
mechanism of action (Davidovich et al., 2013), lncRNAs have been shown to
frequently associate with chromatin-modifying complexes to control transcription
of target genes (reviewed in (Statello et al., 2020)). It is important to note that
lncRNA functions are by no means restricted to gene regulation, and an increasing
number of studies highlight regulatory roles for lncRNAs in organizing subcellular
compartments and governing organelle activities (Clemson et al., 2009; Leucci et
al., 2016; Yap et al., 2018).
Despite immense growth in the field of lncRNA biology over the past three
decades, efforts to distinguish bona fide functional lncRNAs from transcriptional
noise have been bogged down by the sheer volume of uncharacterized lncRNA
transcripts, raising questions about how to best prioritize them for additional
study. Bioinformatic analyses have attempted to tackle this problem by examining
the molecular features and regulation of lncRNAs to provide clues about their
potential functions. One popular method involves assigning putative functions to
lncRNAs based on their co-expression with protein-coding genes (Guttman et al.,
2009; Hung et al., 2011). These so-called “guilt by association” studies use what is
known about different cellular pathways as a proxy for lncRNA function based on
whether a lncRNA is co-regulated with protein-coding genes in the same network.
The database decodeRNA catalogues lncRNAs based on this strategy (Lefever et
al., 2017), although these functional projections should be approached with
caution due to the correlative nature of these analyses. Others have attempted to
predict function by evaluating lncRNA composition. For example, one recent study
5

grouped lncRNAs based on short sequence motifs called kmers, finding functional
similarities between lncRNAs with related kmer profiles, despite an absence in
linear sequence homology (Kirk et al., 2018). Notwithstanding these advances in
computational methods, experimental validation of lncRNA candidates is the only
way to confirm their functional importance. As such, recent genome-wide screens
for functional lncRNAs that evaluate a specific cellular output following
perturbation, such as those that have been performed using CRISPR/Cas9 genome
editing, or its variants CRISPRa (CRISPR activation) or CRISPRi (CRISPR
inactivation), can provide useful insights into function (Bester et al., 2018; Joung
et al., 2017; Liu et al., 2017; Zhu et al., 2016).

Long noncoding RNA mechanisms of action
The study of lncRNAs poses unique challenges, but perhaps the most
irksome of these is the inability to define lncRNAs based on an unequivocal set of
characteristics. Unlike mRNAs, or indeed some other ncRNA classes, there is no
distinct (or even hazy) lncRNA model that can provide clear instructions for
functional characterization, because any two lncRNAs can vary greatly in form,
function, and mechanism of action. As a class, lncRNAs are extremely modular,
able to bind DNA, proteins, and other RNAs, and multifaceted in their regulatory
output, capable of eliciting either positive or negative feedback within a variety of
cellular pathways (reviewed in (Statello et al., 2020)). Therefore, while the existing
body of lncRNA literature can provide clues as to what a lncRNA might do, there
is no standard path to follow when it comes to experimental design. Many
frameworks have been developed which attempt to classify lncRNAs by their
6

modes of action (Rinn and Chang, 2012; Wang and Chang, 2011). For example,
some have proposed dividing lncRNAs by “mechanistic themes” into those which
act as either “decoys,” which interfere with DNA-protein interactions, “scaffolds,”
which bring together two or more proteins in a complex, or “guides,” which localize
proteins within a specific genomic area (Rinn and Chang, 2012). While these
groupings are certainly useful, there are many gray areas and potential for overlap
that preclude precise categorization.
One

framework

that

is

particularly

helpful

for

initial

lncRNA

characterization without extensive a priori knowledge of mechanism involves
broadly categorizing lncRNAs by their localization, or more specifically, based on
the cellular compartment in which they reside. Subcellular fractionation and single
molecule RNA fluorescence in situ hybridization (smRNA-FISH) are useful
experimental tools for determining lncRNA location within the cell (Cabili et al.,
2015; Conrad and Orom, 2017). Notably, the majority of lncRNAs are nuclearenriched, perhaps reflecting the large number of lncRNAs involved in some aspect
of gene expression regulation (Cabili et al., 2015; Derrien et al., 2012). LncRNA
localization patterns have significant bearing on the spectrum of potential
functions a lncRNA can execute, and can therefore guide further mechanistic
studies. As such, lncRNA subcellular position informs an extremely related
framework: categorization based on whether a lncRNA regulates in cis or in trans
(Kopp and Mendell, 2018; Quinn and Chang, 2016).
Cis-acting lncRNAs generally reside close to their site of transcription
and regulate genes located in cis, or which are expressed from the same
chromosome (Figure 1) (Gil and Ulitsky, 2020). These lncRNAs may act on their
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nearest neighbor, or cross large linear distances to enact regulation, with spatially
disparate genes brought in close proximity by long-range chromatin interactions
(Cai et al., 2016). These distant contacts are often, but not always, facilitated
between genes residing within the same topologically associated domain (TAD)
(Groff et al., 2018). While many cis-regulatory lncRNAs exert control over one or
more target genes, their effects can also be far more widespread.
One lncRNA with extensive regulatory influence is XIST (X-InactiveSpecific Transcript), a lncRNA which performs the critical task of dosage
compensation in females by coordinating epigenetic repression of the entire Xchromosome from which it is expressed in a process known as X-chromosome
inactivation (XCI) (reviewed in (Loda and Heard, 2019)). XIST becomes
upregulated in early development, eventually coating one of two X-chromosomes
to induce widespread chromosomal reorganization and a heterochromatic state
(Loda and Heard, 2019). Indispensable for gene silencing, XIST is responsible for
coordinating the repression of >1000 genes through functions encoded in discrete
and genetically separable elements of the XIST transcript (Loda and Heard, 2019).
For example, the repeat A region of XIST is essential for gene silencing (Wutz et
al., 2002), while other regions have been identified as necessary for recruitment of
PRC1 (Polycomb Repressive Complex 1) or its localization on the inactive Xchromosome, with some occasional redundancy (Colognori et al., 2019; Wutz et
al., 2002). The XIST sequences and RNA binding proteins (RBPs) required for the
establishment and maintenance of gene silencing, and the precise order of events
in XCI, are incompletely understood. Attempts to identify XIST interactors have
revealed numerous binding partners including various PcG (polycomb group)
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proteins, hnRNPs (heterogeneous ribonucleoproteins), and others with unknown
functional significance (Chu et al., 2015; McHugh et al., 2015). Different
approaches have defined different, albeit overlapping, sets of XIST interacting
proteins (Chu et al., 2015; McHugh et al., 2015). Notably, multiple studies have
identified SHARP (SMART/HDAC1-Associated Repressor Protein; also known as
Spen) as an XIST binding partner with a critical role in recruiting the nuclear
corepressor SMRT and the histone deacetylase HDAC3 to remove activating
histone acetylation marks from the X-chromosome (Chu et al., 2015; McHugh et
al., 2015). However, a recent study demonstrated that HDAC3 is not essential to
the establishment of XCI (Zylicz et al., 2019), raising questions about the role of
the XIST-SHARP interaction in gene repression. While study of XIST dates back
to the beginning of the lncRNA field itself (Brown et al., 1991), our understanding
of XIST’s mechanism of action is still expanding and evolving, 30 years later. This
highlights the complexity of lncRNA mechanisms and the importance of
employing multiple orthogonal approaches in lncRNA functional characterization.
The lncRNA Morrbid operates by a similar general mechanism of action,
although with a far more restricted regulatory output than XIST. Expressed
exclusively in a subset of myeloid cells, Morrbid influences cellular lifespan by
repressing the pro-apoptotic gene Bim in cis (Kotzin et al., 2016). This negative cisregulation is mediated by Morrbid recruitment of PRC2 to the Bim promoter
facilitated by chromatin contacts between the neighboring Morrbid and Bim loci.
XIST and Morrbid exemplify an archetype of cis-acting lncRNAs, namely those
that interact with chromatin-modifying complexes (either activating or repressive)
to engage in epigenetic regulation of target gene(s). Many lncRNAs, cis-regulatory
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or otherwise, execute their functions through their association with various RBPs
(reviewed in (Statello et al., 2020)). However, lncRNA-mediated cis-regulation
does not always require RNA-protein interactions, or indeed the RNA molecule
itself. A notable example of this is Airn (Antisense Igf2r ncRNA), a lncRNA
oriented overlapping and antisense to Igf2r (Insulin-like growth factor receptor
2); both genes are encoded in a paternally imprinted gene cluster that also includes
Slc22a2 and Slc22a3 (Statello et al., 2020). Airn expression from the paternal
allele, specifically transcription through the Igr2r promoter region, is required for
Igf2r silencing via transcriptional interference, a function which does not require
the Airn RNA molecule, only its production (Latos et al., 2012; Sleutels et al.,
2002). In this way, the placement and architecture of the Airn locus confers its
entire Igf2r-repressing function. However, the Airn RNA transcript has been
shown to play a role in epigenetically repressing Slc22a3 through the recruitment
of a histone methyltransferase G9a, revealing distinct transcript- and
transcription- based mechanisms (Nagano et al., 2008).
These difficulties in elucidating the mechanism by which Airn represses
genes in the Igf2r locus emphasize a key and pervasive challenge in the lncRNA
field; specifically, how can we accurately discern the element(s) of a lncRNA locus
required for its function(s)? Gene regulation by cis-acting lncRNAs can be
mediated by (1) DNA elements in the locus, (2) the act of transcription or RNA
processing, (3) the RNA molecule itself, or some combination thereof (Figure 1)
(Gil and Ulitsky, 2020). Employing either deletion of a lncRNA locus or insertion
of a premature polyadenylation signal downstream of its transcriptional start site
(TSS) can aid in dissociating the contributions of DNA elements in the locus from
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both the act of transcription and the activity of the RNA molecule (Engreitz et al.,
2016; Paralkar et al., 2016). However, differentiating between the interconnected
roles of transcription and the RNA transcript has proven a more thorny problem.
Some experimental tools may be too intractable or imprecise to effectively isolate
one lncRNA feature from the other and can produce muddled results. For example,
recent work has demonstrated that antisense oligonucleotides (ASOs), often a
preferred choice for RNA depletion in lncRNA studies (especially for nuclearenriched transcripts), can cause premature transcription termination and
therefore do not constitute a loss-of-function (LOF) model specific to the RNA
molecule (Lee and Mendell, 2020). Given such shortcomings in current
technologies, necessity dictates that we continue to develop diverse and innovative
experimental tools and approaches with lncRNA biology in mind.
Cis-activating lncRNAs can be especially difficult to functionally dissect, as
their transcription alone may be responsible for their ascribed regulatory outputs.
Indeed, the transcription of protein-coding genes, like lncRNAs, has been shown
to activate the expression of neighboring loci (Engreitz et al., 2016), perhaps
because active transcription increases interactions mediated by cis-regulatory
elements, thus supporting promoter-enhancer contacts (Gu et al., 2018). These
observations may point to a widespread mechanism of transcription-facilitated
cis-activation that is not specific to lncRNAs. Interestingly, many cis-activating
lncRNAs are transcribed from enhancers and regulate neighboring genes by
modulating enhancer availability through the act of their transcription or
recruitment of the Mediator complex (Isoda et al., 2017; Lai et al., 2013). Yet, the
role of other enhancer RNAs (eRNAs), such as the RNAs produced from p5311

bound enhancer regions (p53BERs), is less clear, and may depend only on DNA
elements to elicit gene expression changes (Melo et al., 2013). Other lncRNAs are
not transcribed from enhancers per se, but may have enhancer elements associated
with their loci. LincRNA-p21, for example, has been proposed to activate the
transcription of its neighboring gene p21 through cis-regulatory DNA elements
(Groff et al., 2016), despite other studies demonstrating a role for the RNA
molecule (Dimitrova et al., 2014; Huarte et al., 2010). Controversies such as these
highlight a need for robust characterization of cis-acting lncRNAs and clear
identification of the elements of lncRNA loci required for their function(s).
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Figure 1. Cis- and trans- acting mechanisms of action by lncRNAs. Long noncoding RNAs
(lncRNAs) can function in either cis or trans. Cis-acting lncRNAs are nuclear-enriched and can
regulate neighboring protein-coding genes (PCGs) through DNA elements in the lncRNA locus, the
act of transcription, or the RNA transcript. Functions of the lncRNA transcript (blue) are mediated
through interactions with target genes (red), RNA binding proteins (green and purple), or other
RNAs (orange). Trans-acting lncRNAs can reside in the nucleus and regulate target genes
expressed from different chromosomes in a similar manner, or can reside in the cytoplasm and
engage in RNA-RNA and RNA-protein interactions to influence various cellular processes.
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In contrast to cis-acting lncRNAs, trans-acting lncRNAs can travel far
from their site of transcription, and either regulate genes elsewhere in the nucleus
or are exported to the cytoplasm, enabling a range of other activities (Figure 1)
(reviewed in (Statello et al., 2020)). A notable example of a nuclear-enriched
trans-acting lncRNA is HOTAIR (HOX Transcript Antisense RNA), expressed
antisense to the HOXC gene cluster and proposed to epigenetically repress the
distally located HOXD cluster via PRC2 recruitment (Rinn et al., 2007). However,
this trans-acting mechanism has been called into question by a study noting
nonspecific interactions between PRC2 and RNA (Davidovich et al., 2013).
Additionally, the function of Hotair in the mouse has come under scrutiny after
conflicting results were obtained using the same locus deletion model. One group
documented homeotic transformations in response to Hotair loss (Li et al., 2013),
while another group found no developmental defects whatsoever, and therefore
concluded Hotair was dispensable for mouse development (Amandio et al., 2016).
Despite these inconsistencies, there is functional evidence for HOTAIR
overexpression in supporting breast cancer metastasis, highlighting a need for
improved mechanistic elucidation (Gupta et al., 2010).
Firre (Functional intergenic RNA repeat element), in contrast to other
trans-acting nuclear-enriched lncRNAs, resides close to its site of transcription on
the X-chromosome, but engages in various trans-chromosomal contacts in order
to spatially concentrate distal genomic elements (Hacisuleyman et al., 2014).
While the function of Firre was not initially clear, recent studies have proposed
roles in hematopoiesis and XCI, potentially involving both trans- and cisregulatory activities (Fang et al., 2020; Lewandowski et al., 2019). This unique
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example illustrates that lncRNA location is not always a proxy for its function and
that localization patterns in cis and trans may leave space for nuanced and
unexpected mechanisms of action.
Examples of trans-acting lncRNAs that function in the cytoplasm include
NORAD (Noncoding RNA Activated by DNA Damage), which binds PUMILIO
proteins to support genomic stability (Lee et al., 2016); LAST (LncRNA-Assisted
Stabilization of Transcripts), which stabilizes the mRNA encoding Cyclin D1
(CCND1) to promote cellular proliferation (Cao et al., 2017); and SAMMSON
(Survival Associated Mitochondrial Melanoma Specific Oncogenic Noncoding
RNA), which associates with the mitochondrial regulator p32 to increase its
localization and function in mitochondrial homeostasis (Leucci et al., 2016).
On the whole, cis-acting lncRNA mechanisms appear to be more prevalent
than trans-acting. This idea is supported by enrichment of the majority of lncRNAs
in the chromatin fraction, the low copy number of some lncRNAs, and the
conservation of lncRNA genomic organization (or synteny) despite poor sequence
conservation, all of which favor local cis-regulatory lncRNA modes of action
(reviewed in (Gil and Ulitsky, 2020)). These observations in no way preclude
abundant trans-acting lncRNA mechanisms, and indeed some lncRNAs have been
suggested to regulate in both cis and trans. For example, in this work I describe a
cis-acting role for an isoform of the lncRNA Pvt1 in negatively regulating the
expression of a neighboring protein-coding gene (see Chapters 2-5). However,
various trans-regulatory mechanisms for Pvt1 have been previously described,
including a role in protein stabilization (Tseng et al., 2014), and one in which a
circular form of Pvt1 (circPVT1) acts as a miRNA decoy (Panda et al., 2017).
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Moreover, there is disagreement even with respect to the cis-activity of Pvt1, and
whether it depends on the RNA or DNA elements in the locus (Cho et al., 2018).
Such distinct regulatory functions described for Pvt1 and other lncRNAs may be
cell-type specific and in keeping with observed differences in localization patterns.
Another exciting possibility is that they reflect bona fide isoform-specific functions
that become important in different cellular contexts, underscoring a need for
further exploration.

Long noncoding RNAs in cancer
The work in this section has been published as part of the following invited
review: Olivero, C., and Dimitrova, N. Identification and characterization of
functional long noncoding RNAs in cancer. (2020). The FASEB Journal 34,
15630-15646.
Introduction
Cancer is a disease of aberrant cell growth arising from a complex genetic
landscape of inherited and sporadic mutations and environmental factors.
Historically, cancer research has prioritized examining alterations to proteincoding genes in molecular pathways influencing the hallmarks of cancer (Hanahan
and Weinberg, 2000, 2011). While these analyses have provided extensive insights
into key players in tumorigenesis, protein-coding sequences account for only 2%
of the genome (International Human Genome Sequencing, 2004). Both the
pervasive transcription of the human genome (Djebali et al., 2012) and the
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presence of cancer- associated mutations in noncoding regions (Freedman et al.,
2011) have suggested a potential wealth of unexplored cancer targets. Notably, the
heterogeneous class of long noncoding RNAs (lncRNAs) occupies a significant
space within the noncoding transcriptome, with recent estimates suggesting the
existence of over 100,000 human lncRNA transcripts (Bertone et al., 2004;
Carninci et al., 2005; Consortium, 2012; Kapranov et al., 2007).
LncRNAs are operationally defined as RNA molecules exceeding 200
nucleotides in length that lack protein-coding potential (Mercer et al., 2009; Rinn
and Chang, 2012). Able to dynamically fold into intricate secondary structures
(Qian et al., 2019) to interact with DNA, proteins and other RNAs, lncRNAs are
diverse in their structure, localization, and pattern of expression, enabling them to
regulate the flow of cellular information at many levels (Wang and Chang, 2011).
Frequently the targets of transcriptional programs, lncRNAs influence many
fundamental cellular processes including cell division, genome maintenance, and
pluripotency (Lee et al., 2016; Loewer et al., 2010; Yap et al., 2010).
As lncRNAs are expressed with exquisite cell-type and disease-state
specificity, they are ideally positioned to act as biomarkers for a number of
pathologies, including different cancers (Derrien et al., 2012; Iyer et al., 2015; Yan
et al., 2015). Identifying lncRNA expression changes, or their association with
recurrent copy number variations (CNVs) or cancer susceptibility single nucleotide
polymorphisms (SNPs) have the potential to become useful tools in cancer
diagnosis and treatment planning. Beyond their diagnostic and prognostic utility,
over the past decade, individual lncRNAs have been mechanistically and
functionally dissected, revealing critical roles in cancer-related pathways at the
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cellular and organismal level. These studies have pointed to lncRNAs as operators
within proto-oncogenic and tumor suppressive networks, suggesting that lncRNAs
themselves may play active roles in promoting or limiting tumor development
(Huarte, 2015; Prensner and Chinnaiyan, 2011; Wapinski and Chang, 2011).
Despite growing data supporting the involvement of lncRNAs in
tumorigenesis, it is often difficult to surmise whether changes in individual
lncRNAs are bona fide drivers of human cancer development and whether
targeting altered lncRNAs in patients would be expected to produce therapeutic
benefit. Here, we present an overview of how functional lncRNAs in cancer are
identified. We highlight promising therapeutic targets based on patient data and
on experimental evidence from in vitro and in vivo cancer models. We also discuss
important discrepancies to suggest a best-practice roadmap for further
characterization of the roles of lncRNAs in cancer.

Identification of cancer-associated lncRNAs
Mining global human cancer genomic and transcriptomic data
Integrating genomic and transcriptomic data from diverse human cancers
has provided a starting point for the identification of lncRNAs with functional roles
in cancer. In particular, recurrent genetic alterations have implicated many genes
involved in oncogenesis, and the capacity to identify such genes has expanded in
the last several years due to rapid advances in sequencing technologies. These
studies have uncovered that many recurrent somatic copy number variations
(SCNVs) map to noncoding regions (Beroukhim et al., 2010). Notably, analysis of
5000 human tumor samples across 13 cancer types from The Cancer Genome Atlas
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(TCGA) revealed that, on average, as many as one quarter of all lncRNAs manifest
frequent cancer-related copy number gains or losses (Yan et al., 2015). A more
recent study probed the copy number of over 10,000 lncRNAs in 80 cancer cell
lines across 11 cancer types, identifying 136 lncRNAs involved in focal SCNVs
(Volders et al., 2018). Importantly, 76 of these lncRNAs lacked copy number
changes in flanking protein-coding genes, suggesting potential lncRNA-driven
genomic alterations in cancer. Cancer risk SNPs in noncoding loci can also point
to a potential role for specific lncRNAs in tumorigenesis. One study identified
nearly 4000 lncRNAs overlapping disease-associated SNPs, while another
estimated that roughly 12% of all cancer-associated SNPs mapped within 5 Kb of
lncRNA loci (compared to 55% mapping near protein-coding genes) (Iyer et al.,
2015; Yan et al., 2015).
Apart from harboring genomic alterations, lncRNAs have also been found
to exhibit differential expression patterns in tumor samples compared to normal
tissues. A comprehensive meta-analysis of over 7000 gene expression datasets,
including a range of normal and cancer samples, identified as many as 60,000
lncRNAs with altered expression (Iyer et al., 2015). Notably, many previously
unannotated lncRNAs were found in disease-associated regions and the expression
of roughly 8000 lncRNAs clustered with specific cancer or cell lineages, suggesting
the potential for lncRNAs to execute cancer-specific functions (Iyer et al., 2015).
Along similar lines, an analysis of seven cancer types revealed that, on average,
26% of expressed lncRNAs were significantly deregulated in at least one cancer
type (15% upregulated and 11% downregulated) with 60% of these altered lncRNAs
demonstrating cancer specificity (Yan et al., 2015). In addition, a recent study of
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lncRNA-associated epigenetic alterations across 20 different cancers identified
over 2000 lncRNAs either epigenetically activated or silenced in at least one cancer
type (Wang et al., 2018). Altogether, these studies led to the consensus that, as a
class, lncRNAs are subject to frequent genetic and epigenetic alterations in cancer.

LncRNA loci with recurrent SCNVs in cancer
In addition to global patterns of lncRNA deregulation in cancer, several
individual lncRNAs have been identified based on frequent large-scale genomic
alterations. One of the first cancer-associated lncRNAs was identified in murine
lymphomas due to the frequent translocations and viral insertions involving the
as-yet uncharacterized Pvt1 (Plasmacytoma Variant Translocation 1) lncRNA
(Cory et al., 1985; Graham et al., 1985), located approximately 72 Kb downstream
of the MYC (Myelocytomatosis) proto-oncogene. Later studies extended these
results to human cancer and demonstrated a correlation between PVT1 genomic
amplification and poor prognosis in acute myeloid leukemia and in breast and
ovarian cancers, among others (reviewed in (Colombo et al., 2015)). Significantly,
PVT1 amplification is observed frequently in a range of cancer types including in
33% of ovarian cancers, 20% of esophageal cancers, 13% of invasive breast
carcinomas and 7% of lung adenocarcinomas based on TCGA data (Hoadley et al.,
2018). Moreover, PVT1 alterations are associated with a significant reduction in
overall and disease-free survival (Cerami et al., 2012; Gao et al., 2013; Hoadley et
al., 2018).
Another prominent example of a lncRNA initially characterized by genomic
alterations is FAL1 (Focally Amplified LncRNA 1, also known as FALEC) located
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on chromosome 1q21 (Hu et al., 2014a). FAL1 copy number gains have been
observed across many cancer types, including in approximately 10% of liver
cancers, invasive breast carcinomas and lung adenocarcinomas according to TCGA
data (Hoadley et al., 2018). FAL1 amplification and overexpression are associated
with late stage tumors and with decreased survival of patients with ovarian cancer
(Hoadley et al., 2018; Hu et al., 2014a). Similarly, the lncRNA SAMMSON
(Survival Associated Mitochondrial Melanoma Specific Oncogenic Noncoding
RNA) was identified in a region of focal amplification on chromosome 3p13-14 in
10% of melanomas (Leucci et al., 2016). High SAMMSON copy number and
expression levels are correlated with a reduction in disease-free survival of
melanoma patients and associated with resistance to MAPK (Mitogen Activated
Protein Kinase) inhibitors (Cerami et al., 2012; Gao et al., 2013; Hoadley et al.,
2018; Leucci et al., 2016).
The locus of the lncRNA LOC285194 on chromosome 3q, on the other hand,
is subject to recurrent monoallelic deletions in as many as 80% of osteosarcomas,
often followed by loss of heterozygosity (LOH) (Pasic et al., 2010). Loss of
LOC285194 is associated with decreased survival in osteosarcoma patients (Pasic
et al., 2010). The focal deletion of PRAL (p53 Regulation-Associated LncRNA) on
chromosome 17p in hepatocellular carcinoma has also been associated with
reduced survival (Zhou et al., 2016). Similarly, recurrent loss of the 9p21 locus,
where the lncRNA ANRIL (Antisense Noncoding RNA in the INK4 Locus) resides,
is observed in over 50% of glioblastomas, more than 40% of mesotheliomas, and
roughly 30% of bladder cancers (Hoadley et al., 2018). Interestingly, a 403 Kb
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germline deletion encompassing the ANRIL locus is associated with a strong
hereditary predisposition to melanoma development (Pasmant et al., 2007).
Many regions of recurrent SCNVs, however, harbor both lncRNAs and
protein-coding genes. Therefore, determining the specific contribution of the
lncRNA has been challenging. For example, the presence of multiple overlapping
transcripts in the ANRIL locus, including the p15INK4B (CDKN2B), p16INK4A
(CDKN2A), and p19ARF tumor suppressors, has confounded the role of ANRIL
(Yap et al., 2010). Analogously, PVT1 is co-amplified with MYC and the PVT1 gene
body contains DNA regulatory elements, which promote MYC expression (Fulco et
al., 2016). Likewise, SAMMSON is expressed near MITF (Microphthalmia
Associated Transcription Factor), a key factor in melanocyte differentiation,
whereas the commonly amplified genomic region in which FAL1 resides contains
the proto-oncogene MCL1 (Myeloid Cell Leukemia Sequence 1). Finally, the
LOC285194-associated region of deletion also harbors the tumor suppressor
LSAMP (Limbic System-Associated Membrane Protein). Given the complex
chromatin architecture and transcriptional profiles in these loci, further studies
are needed to deconvolve the specific roles of the lncRNAs and to determine
whether lncRNAs act in cooperation with or independently of their neighboring
protein-coding genes.

LncRNA loci with cancer-associated SNPs
The link between inherited germline variants in lncRNA loci and cancer
predisposition or prognosis has been probed extensively in large-scale genome-
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wide associated studies (GWAS). These studies have identified a plethora of
lncRNA-linked SNPs associated with altered cancer risk or patient prognosis.
As an example, the 2 Mb region mapping to 8q24 has emerged as a major
hotspot for over a hundred SNPs strongly associated with multiple diseases,
including cancers of the breast, colon, ovaries, prostate, and bladder (Easton and
Eeles, 2008; Ghoussaini et al., 2008; Grisanzio and Freedman, 2010; Huppi et al.,
2012). Many of these SNPs are significantly correlated with cancer development
and highly predictive of poor patient outcome (Bertucci et al., 2012; Garcia-Closas
et al., 2008; Haiman et al., 2007; Yeager et al., 2007; Zhang et al., 2012b). While
MYC is the dominant oncogene in the locus, many of the cancer risk SNPs are
linked to the expression of lncRNAs in the surrounding region, including PVT1
(Meyer et al., 2011), CCAT1 (Colon Cancer Associated Transcript 1, also known as
CARLo-5) (Zhao et al., 2016), CCAT2 (Colon Cancer Associated Transcript 2) (Ling
et al., 2013), PCAT1 (Prostate Cancer Associated Transcript 1) (Guo et al., 2016),
PCAT19 (Prostate Associated Transcript 19) (Hua et al., 2018), and PRNCR1
(Prostate Cancer Associated Noncoding RNA 1) (Huang et al., 2018b). The ANRIL
locus is another example of a hotspot harboring more than 10 cancer risk SNPs,
some of which are correlated with ANRIL expression (Cunnington et al., 2010;
Khorshidi et al., 2017). Other lncRNAs linked to cancer SNPs include HOTAIR
(HOX Transcript Antisense RNA) (Botti et al., 2018), HOTTIP (HOXA Distal
Transcript Antisense RNA) (Huang et al., 2018b), MALAT1 (Metastasis-Associated
Lung Adenocarcinoma Transcript 1) (Huang et al., 2018b), HULC (Highly
Upregulated in Liver Cancer) (Huang et al., 2018b), MEG3 (Maternally Expressed
3) (Dong et al., 2020), H19 (Hashemi et al., 2019), GAS5 (Growth Arrest Specific
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5) (Dong et al., 2020), and PTENP1 (Phosphatase And Tensin Homolog
Pseudogene 1) (Ge et al., 2017).
Mechanistic investigations of SNPs associated with lncRNAs have
suggested that the risk variants may, in some cases, affect regulatory DNA
sequences, thereby resulting in altered lncRNA expression. For example, the
PCAT1-linked risk variant rs7463708 was found to increase the activity of a distal
enhancer, resulting in increased PCAT1 expression (Guo et al., 2016), whereas the
PCAT19-linked SNP rs11672691 was proposed to perturb transcription factor
binding sites, resulting in the increased expression of a pro-metastatic PCAT19
isoform (Gao et al., 2018; Hua et al., 2018). Finally, a high-risk neuroblastoma
associated SNP rs693940 on chromosome 6p22 was found to contribute to
differential

CpG

methylation

and

decreased

expression

of

NBAT-1

(Neuroblastoma Associated Transcript-1, also known as CASC14), a lncRNA with
tumor suppressor properties (Pandey et al., 2014). Apart from these intriguing
examples, however, the majority of lncRNA-associated SNPs lack experimental
support that would robustly link the cancer-susceptibility variants with
deregulation of lncRNA levels or function, and have thus had limited impact on the
identification and characterization of functional lncRNAs in cancer.

LncRNAs differentially expressed in cancer
Global gene expression analyses of normal and cancer samples have also led
to the identification of numerous differentially expressed lncRNAs hypothesized
to contribute to disease development. Some of the initial analyses revealed
frequent upregulation of lncRNAs, such as the imprinted lncRNA H19 in Wilms’
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tumors and lung cancer (Hibi et al., 1996; Kondo et al., 1995; Rainier et al., 1993),
the prostate cancer-specific lncRNA PCGEM1 (Prostate Cancer Gene Expression
Marker 1) (Srikantan et al., 2000), the lung metastasis-promoting lncRNA
MALAT1 (Ji et al., 2003) and the hepatocellular carcinoma overexpressed lncRNA
HULC (Panzitt et al., 2007).
The differential expression of some of these lncRNAs has been associated
with clinical outcomes. For example, altered H19 expression correlates with poor
clinical outcomes across various cancer types including breast cancer, non-small
cell lung cancer and acute myeloid leukemia (Shima et al., 2018; Zhang et al.,
2018b; Zhou et al., 2017). On the other hand, increased expression of PCGEM1 in
normal prostate tissue is a prostate cancer risk factor (Petrovics et al., 2004;
Srikantan et al., 2000). At the same time, a large body of literature has cemented
the strong correlation between high MALAT1 expression levels and poor patient
prognosis across over 20 cancer types (Amodio et al., 2018; Zhang et al., 2015).
Finally, high expression of HULC is associated with poor overall survival and
distant metastases (Chen et al., 2017).
Notably, integrated analysis of gene expression and methylation datasets
has also led to the identification of differentially expressed lncRNAs arising from
cancer-associated epigenetic changes, including AFAP1-AS1 (AFAP1 Antisense
RNA 1) and EPIC1 (Epigenetically Induced LncRNA1), both identified as
hypomethylated and overexpressed in Barrett's esophagus and esophageal
adenocarcinoma, and breast cancer, respectively (Wang et al., 2018; Wu et al.,
2013).
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Gene expression profiling in cohorts of cancer patients have further fueled
the discovery of lncRNAs associated with specific cancer types. Transcriptome
sequencing across a cohort of prostate cancer patients identified PCAT-1 amongst
121 unannotated prostate cancer-associated ncRNA (noncoding RNA) transcripts
(PCATs) (Prensner et al., 2011). Similarly, comprehensive lncRNA profiling in
colorectal carcinoma led to the identification of CCAT1 (Kim et al., 2014b; Nissan
et al., 2012), CCAT2 (Ling et al., 2013) and other CCAT family members (Kim et
al., 2015b), whereas the lncRNA GAPLINC (Gastric Adenocarcinoma Predictive
Long Intergenic Noncoding RNA) stood out as aberrantly overexpressed in gastric
tumors (Hu et al., 2014b). A different set of analyses led to the identification of
stage-specific lncRNAs, such as the lncRNA CRNDE (Colorectal Neoplasia
Differentially Expressed) (Graham et al., 2011), a marker of early stages of
colorectal cancer development, although the protein-coding capacity of CRDNE
remains an open question (Szafron et al., 2015). Transcriptome profiling of breast
cancer subtypes, on the other hand, highlighted sets of lncRNAs which are either
differentially expressed in tumor samples compared to normal tissues or uniquely
enriched in specific stages or subtypes of breast cancer. Examples include MALAT1
(Arun et al., 2016; Jadaliha et al., 2016), HOTAIR (Gupta et al., 2010), and BCAR4
(Breast Cancer Anti- Estrogen Resistance 4) (Meijer et al., 2006; Xing et al., 2014).
In parallel, mouse models of cancer were recently employed for the identification
of 30 murine MaTARs (Mammary Tumor Associated RNAs), many of which were
found to have human counterparts (hMaTARs) with potential clinical significance
determined based on differential expression and correlation with cancer subtype
and/or hormone receptor status (Diermeier et al., 2016). Interestingly, many of
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these examples of cancer-specific lncRNAs were later found to show differential
expression across multiple cancer types, hinting at universal roles in cancer
pathogenesis.

LncRNAs in cancer pathways
In addition to profiling tumor samples, many researchers have undertaken
diverse functional approaches to identify novel lncRNAs, including dissecting
tumor suppressive and pro-oncogenic transcriptional networks, analyzing various
cancer-related cellular states and processes, and performing genome-wide
functional screens.
Analysis of the p53 (also known as Trp53) transcriptional network, in
particular, has revealed a wealth of lncRNAs with potential tumor suppressor
functions. By comparing gene expression profiles and p53 binding patterns in the
absence and in the presence of genotoxic or oncogenic stress, known to activate the
p53 pathway, as well as in p53-proficient and -deficient cells, researchers have
identified multiple direct lncRNA targets of p53. These included lincRNA-p21
(Huarte et al., 2010); PANDAR (Promoter Of CDKN1A Antisense DNA Damage
Activated RNA, also known as PANDA) (Hung et al., 2011); p53BERs (p53-Bound
Enhancer Regions) (Melo et al., 2013); Pint (P53 Induced Transcript) (Marin-Bejar
et al., 2013); LED (LncRNA Activator of Enhancer Domains) (Leveille et al., 2015);
PR-lncRNAs (p53-Regulated lncRNAs) (Sanchez et al., 2014; Younger et al., 2015);
DINO (Damage Induced Noncoding) (Schmitt et al., 2016); lncPRESS1 (LncRNA
P53 Regulated And ESC Associated 1) (Jain et al., 2016); NEAT1 (Nuclear Enriched
Abundant Transcript 1) (Adriaens et al., 2016; Blume et al., 2015; Mello et al.,
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2017); PURPL (P53 Upregulated Regulator Of P53 Levels) (Li et al., 2017); PINCR
(P53-Induced Noncoding RNA) (Chaudhary et al., 2017); GUARDIN (Hu et al.,
2018); and an isoform of Pvt1, Pvt1b (Olivero et al., 2020). Functional
characterizations have suggested that many of these lncRNAs contribute to p53
tumor suppressor activities.
Other lncRNAs have been identified downstream of oncogenic signaling
networks, giving insight into their potential functions. For example, Orilnc1
(Oncogenic RAS-Induced lncRNA 1) was identified as a target of oncogenic RAS
signaling with a proposed role in promoting cell growth (Zhang et al., 2017).
LncRNA-OIS1 (Oncogene- Induced Senescence 1) was found to modulate
senescence induced by activation of oncogenic RAS (Li et al., 2018), whereas
BANCR (BRAF-Activated Non-Protein Coding RNA) was identified as a transcript
induced upon expression of oncogenic BRAFV600E (Flockhart et al., 2012).
Analogously, investigation of estrogen receptor (ER) signaling targets identified 33
ER agitation-related (ERAR) lncRNAs and suggested potential roles in ER-positive
breast cancer (Wu et al., 2016). A similar study was performed to examine lncRNAs
regulated by androgen receptor (AR) signaling, which identified ARLNC1 (ARRegulated Long Noncoding RNA 1) as both a downstream target and upstream
effector of AR signaling during prostate cancer progression (Zhang et al., 2018c).
MYC-regulated lncRNAs have also been identified, including a set of MYCLos
(MYC-regulated lncRNAs) (Kim et al., 2015b); LAST (LncRNA-Assisted
Stabilization of Transcripts) (Cao et al., 2017); DANCR (Differentiation
Antagonizing Non-Protein Coding RNA) (Lu et al., 2018), and SNHG15 (Small
Nucleolar RNA Host Gene 15) (Jiang et al., 2018).
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Alterations of cancer hallmarks that enable tumorigenesis have also been
linked to the functions of specific lncRNAs (reviewed in (Gutschner and
Diederichs, 2012)). Examples include lncRNA gadd7 (growth-arrested DNA
damage-inducible gene 7) with a proposed role in suppressing cell cycle
progression (Liu et al., 2012), SPRY4-IT1 (SPRY4 Intronic Transcript 1) with a
proposed role in inhibiting apoptosis in melanoma (Khaitan et al., 2011), and
SALNR (Senescence-Associated lncRNA), proposed to regulate senescence (Wu et
al., 2015).
Finally, genome-wide functional screens for lncRNAs involved in
promoting or inhibiting specific cellular outcomes important in cancer have aimed
to identify candidates for further study. A CRISPR/Cas9-based genome editing
approach used a paired guide RNA (gRNA) strategy to target for deletion a set of
700 human lncRNAs, identifying 51 lncRNAs able to regulate cancer cell growth
(Zhu et al., 2016). Alternatively, CRISPRi (CRISPR inactivation) and CRISPRa
(CRISPR activation) screens, involving a nuclease-dead Cas9 to tether
transcriptional repressors or activators to lncRNA loci have provided effective
epigenetic loss-of-function and gain-of-function approaches to query on a genomewide level the role of lncRNAs in processes such as cellular proliferation or
therapeutic resistance (Bester et al., 2018; Joung et al., 2017; Liu et al., 2017; Liu
et al., 2020).

Functional characterization of lncRNAs in cancer
Common approaches and limitations
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For the hundred or so lncRNAs identified in the approaches described
above, the pressing question has become how to accurately distinguish functional
lncRNAs from lncRNAs that are subject to passenger genetic and epigenetic
alterations in cancer. RNA interference (RNAi)-mediated downregulation of
lncRNAs has been a common approach for functional characterization. In parallel,
antisense oligonucleotides (ASOs) have provided a convenient and efficient lossof-function alternative. While RNAi is most effective for lncRNAs exported to the
cytoplasm, ASOs lend broader efficacy by triggering RNase H-mediated cotranscriptional RNA cleavage and degradation, in some cases accompanied by
transcriptional repression (Lai et al., 2020; Lee and Mendell, 2020). Frequently,
RNAi and ASO approaches have been performed in parallel with exogenous
lncRNA overexpression. Regrettably, few studies have complemented RNAi or
ASO loss-of-function experiments with knockdown-resistant lncRNA rescue
mutants, missing an important opportunity to both demonstrate specificity and
establish a system to investigate the sequence basis for lncRNA function. CRISPRbased epigenetic inhibition (CRISPRi) and activation (CRISPRa) have also been
employed as successful loss-of-function and gain-of-function approaches,
respectively.
Genetically engineered mouse models (GEMMs) of lncRNAs and CRISPRbased editing of lncRNA loci in cell lines have also brought important insights. In
contrast to protein-coding genes, where genetic approaches aim to perturb the
open reading frame (ORF) and therefore, the functional output of the transcript,
methods to target lncRNAs have been, by necessity, more diverse and creative
(reviewed in (Bassett et al., 2014)). Some loss-of-function studies have undertaken
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deletion of the entire gene body, the promoter region, or narrower functional
regions, while others have employed introduction of a premature polyadenylation
signal (PAS) or polyadenylation cassette (STOP) to terminate transcription.
Conversely, gain-of-function studies in animal models have involved the
introduction of a transgenic lncRNA sequence or amplification of an entire lncRNA
locus.
Strikingly, for many lncRNAs, observed phenotypes have varied with the
use of alternative approaches. For example, initial RNAi knockdown of the p53regulated lncRNA, lincRNA-p21, suggested that it acts globally to modulate the
expression of multiple p53 target genes, whereas subsequent genetic deletion of its
promoter in the mouse revealed a more restricted role in promoting the expression
of the neighboring p21/CDKN1a gene (Dimitrova et al., 2014; Huarte et al., 2010).
Further investigation involving a locus deletion genetic approach, however, raised
doubts about whether the lncRNA plays any functional role at all (Groff et al.,
2016). The metastasis-promoting lncRNA HOTAIR has provided additional
examples of the complexity in developing lncRNA models. While ectopic
expression of HOTAIR in breast cancer cells induced global gene expression
changes and increased metastases in a xenograft mouse model, supporting an
oncogenic function (Gupta et al., 2010), loss-of-function models, including RNAimediated knockdown, a 4 Kb gene body deletion, and a 140 Kb locus deletion have
led to significant discrepancies (Amandio et al., 2016; Li et al., 2013; Rinn et al.,
2007; Schorderet and Duboule, 2011). The differences between alternative models
have highlighted the need to use multiple independent and complementary
approaches to investigate the functional roles of lncRNAs in cancer biology.
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Multi-pronged approaches to lncRNA characterization
In this section, we focus on a small set of lncRNAs for which work from
multiple groups or involving an array of in vitro and in vivo approaches has
revealed exciting functional insights and provided starting points for further
exploration of their contributions to tumor development.

MALAT1
MALAT1 remains one of the most studied cancer-associated lncRNAs, with
proposed roles in influencing nuclear speckles (Hutchinson et al., 2007), premRNA splicing (Tripathi et al., 2010), and epigenetically regulating gene
transcription (West et al., 2014). While initial studies pointed to a pro-metastatic
function (Ji et al., 2003), further characterization resulted in discrepancies (Figure
2). Three different loss-of-function GEMMs, including an insertion of a LacZ
reporter and polyadenylation cassette 69 nucleotides downstream of the Malat1
transcription start site, a 3 Kb deletion of the 5’ end and promoter region of Malat1,
and a conditional deletion of 7 Kb encompassing the entire Malat1 gene body,
revealed that Malat1 is dispensable for organismal development and viability
(Eissmann et al., 2012; Nakagawa et al., 2012; Zhang et al., 2012a). Strikingly, none
of the mouse models showed effects on global gene expression, nuclear speckle
formation, or alternative pre-mRNA splicing. This opposed previous findings
using RNAi to downregulate MALAT1 levels in cancer cell lines in vitro (Tripathi
et al., 2010; West et al., 2014), perhaps suggesting a cancer-specific function.
Furthermore, different in vivo models have yielded conflicting results about the
function of MALAT1 in cancer. On the one hand, crossing the promoter deletion
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model (Zhang et al., 2012a) to the MMTV-PyMT (mouse mammary tumor viruspolyomavirus middle T antigen) mouse model of breast cancer resulted in reduced
metastases to the lung, without affecting primary tumor burden, an effect largely
recapitulated by ASO-depletion of Malat1 in vivo (Arun et al., 2016). This prometastatic function was also observed in a mouse xenograft model of lung cancer
where MALAT1 knockout human lung tumor cells formed fewer tumor nodules
(Gutschner et al., 2013). In this model, targeting MALAT1 with ASOs after tumor
implantation prevented metastasis formation, pointing to MALAT1 as a viable
therapeutic target (Gutschner et al., 2013). On the other hand, crossing the Malat1
premature termination model (Nakagawa et al., 2012) to the MMTV-PyMT breast
cancer model led to a significant increase in the number and area of metastatic
nodules in the lungs (Kim et al., 2018). This surprising tumor suppressive effect
could be rescued with a Malat1 transgene expressed from the Rosa26 locus (Kim
et al., 2018). A similar effect was observed in vitro in human breast cancer cells,
with expression of MALAT1 from an exogenous construct rescuing the increased
metastatic ability conferred by MALAT1 knockout in clonal cell populations (Kim
et al., 2018). The debate surrounding the precise contribution of MALAT1 to cancer
development is ongoing. It is unclear whether the phenotypic differences arising
from MALAT1 loss might be due to differences in experimental setup, such as
mouse strain or knockout approach, or reflect the complex biology of MALAT1.
Altogether, investigations of MALAT1 using in vitro and in vivo approaches have
highlighted the biological and technical complexities associated with studying the
functional roles of lncRNAs in cancer (Arun and Spector, 2019; Sun and Ma, 2019).
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Figure 2. Identification and functional characterization of MALAT1. MALAT1 was
identified as upregulated in metastatic (M) LUAD (lung adenocarcinoma) compared to nonmetastatic (NM) tissue. Functional characterization of MALAT1 has utilized various loss-offunction (LOF) and gain-of-function (GOF) models including polyadenylation cassette insertion
(Malat1STOP, (Nakagawa et al., 2012)), promoter deletion (Malat1 D3, (Zhang et al., 2012a)), and
locus deletion (Malat1 D7, (Eissmann et al., 2012)) genetically engineered mouse models (GEMMs),
as well as transcript degradation with RNAi and ASO, and transgenic overexpression. Crossing
Malat1 D3 or Malat1STOP GEMMs to the MMTV-PyMT BC (breast cancer) mouse model has
resulted in either oncogenic (red box, (Arun et al., 2016)) or tumor suppressor (green box, (Kim et
al., 2018)) models for Malat1 function, due to observed decreases and increases in lung metastases,
respectively.
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NEAT1
Similarly to MALAT1, several studies have examined the role of NEAT1
during cancer development, leading to opposing views (Figure 3). Initial studies
suggested that NEAT1 levels were elevated in a variety of human cancers relative
to normal tissues and correlated with worse prognosis, suggesting a pro-oncogenic
role for NEAT1 ((Chakravarty et al., 2014) and reviewed in (Yang et al., 2017)).
This conclusion was supported by a study of Neat1 knockout mice subjected to
chemical induction of skin squamous cell carcinoma with the carcinogen DMBA
and the pro- inflammatory agent TPA (Adriaens et al., 2016; Nassar et al., 2015).
While Neat1-deficient animals displayed no obvious phenotypes in the absence of
stress (Nakagawa et al., 2011), loss of Neat1 conferred resistance to chemicallyinduced squamous cell carcinoma (Adriaens et al., 2016). Interestingly, studies
have also suggested that NEAT1 may be a target of the p53 pathway and, therefore,
may have tumor suppressive activities in some contexts (Blume et al., 2015;
Idogawa et al., 2017). Indeed, tumor suppressive functions of Neat1 were unveiled
in primary mouse embryonic fibroblasts (MEFs), where Neat1 knockout led to
increased colony formation in an E1A; HrasG12V transformation experiment, as
well as in an autochthonous mouse model of pancreatic cancer, where Neat1
deficiency increased the occurrence of premalignant lesions, known as pancreatic
intraepithelial neoplasias (PanINs) (Mello et al., 2017). Interestingly, Malat1 and
Neat1 are neighboring genes and studies have suggested that genomic deletion of
either lncRNA may impact the epigenetic organization and transcriptional profiles
of the entire locus, raising questions about the specificity of each approach
(Nakagawa et al., 2012).
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Figure 3. Identification and functional characterization of NEAT1. NEAT1 was initially
identified as being upregulated in prostate cancer (PCa) compared to normal (N) tissue, suggesting
a potential oncogenic function (top, red box). Later, it was also identified as a p53 target with p53
binding to a conserved p53 Response Element (p53RE) in the NEAT1 promoter, as well as a
paraspeckle component induced by cellular stress, suggesting a potential tumor suppressor
function (top, green box). Functional characterization of NEAT1 has utilized various loss-offunction (LOF) and gain-of-function (GOF) models including a polyadenylation cassette insertion
genetically engineered mouse model (GEMM) (Nakagawa et al., 2011), transcript degradation with
RNAi or ASO, and exogenous overexpression. The Neat1STOP GEMM has been shown to either
decrease (Adriaens et al., 2016) or increase (Mello et al., 2017) tumor growth following chemical
induction of SCC (squamous cell carcinoma) or when crossed to a PDAC (pancreatic ductal
adenocarcinoma) GEMM, respectively, suggesting either oncogenic (bottom, red box) or tumor
suppressor (bottom, green box) models for Neat1 function in cancer.
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PVT1
As one of the lncRNAs strongly associated with advanced disease and poor
patient prognosis, PVT1 has been the subject of extensive investigation (Figure 4).
In keeping with the finding that PVT1 is frequently co- amplified with the MYC
proto-oncogene, Myc-Pvt1 co-amplification in a mouse model of breast cancer was
found to be more tumorigenic than Myc amplification alone (Tseng et al., 2014).
This study suggested that PVT1 acts in trans to promote MYC protein stability,
based on evidence that a 300 Kb genomic deletion of the PVT1 locus in a human
colorectal carcinoma cell line resulted in decreased MYC protein levels (Tseng et
al., 2014). However, later studies found evidence for MYC enhancers within the
region of deletion, raising questions about the role of the PVT1 locus and its
associated RNA in MYC regulation (Fulco et al., 2016). Subsequent studies
confirmed the presence of DNA regulatory elements in the locus but challenged the
understanding of PVT1 as a strictly pro-oncogenic lncRNA (Cho et al., 2018; Porter
et al., 2017). On the one hand, deletion of a ~600 bp region containing a p53
binding site and mapping to the 5’ end of PVT1 led to defects in p53-mediated MYC
repression, although the contribution of PVT1 to the p53 response was unclear
(Porter et al., 2017). On the other hand, CRISPRi-based inhibition of PVT1 in
breast cancer cell lines revealed a role for the PVT1 promoter as a DNA tumor
suppressor boundary element that limits MYC promoter accessibility to enhancers
within the PVT1 gene body, resulting in restricted MYC expression (Cho et al.,
2018). In this setting, the PVT1 RNA appeared to be dispensable (Cho et al., 2018).
In contrast, our group identified a stress-induced, p53- dependent isoform of Pvt1,
Pvt1b, which is both necessary and sufficient to repress Myc transcription (Olivero
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et al., 2020). These findings were recapitulated in vitro using a genetic loss-offunction approach to mutate the p53 binding site required for Pvt1b expression
(Olivero et al., 2020). Importantly, mutagenesis of the Pvt1-associated p53 binding
site at the time of tumor initiation in an autochthonous mouse model of lung
cancer led to larger tumors and indicated a key role for Pvt1b in restraining tumor
growth downstream of p53 (Olivero et al., 2020). In the future, it would be
interesting to deconvolve the oncogenic and tumor suppressive elements in the
PVT1 locus and to differentiate between DNA elements and RNA isoforms with
potentially distinct functions.
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Figure 4. Identification and functional characterization of PVT1. PVT1 was identified in
murine lymphomas following the observation of translocations, viral insertions, and amplifications
involving the Pvt1 locus. Functional characterization of PVT1 has utilized various loss-of- function
(LOF) and gain-of-function (GOF) models including amplification genetically engineered mouse
models (GEMMs) (Myc/Pvt1AMP, MycAMP, (Tseng et al., 2014)), locus deletion (PVT1 ), tumorspecific mutagenesis of the Pvt1-associated p53 Response Element (p53RE) (p53RE, (Olivero et al.,
2020)), transcript degradation with RNAi and ASO, and CRISPR-mediated epigenetic activation
and inhibition (CRISPRa/i). The increased tumor growth observed in a Myc/Pvt1 co-amplification
GEMM (Myc/Pvt1AMP) compared to Myc amplification alone (MycAMP) when crossed to the
MMTV-Neu BC (breast cancer) GEMM suggests an oncogenic function for Pvt1 (red box, (Tseng et
al., 2014)). However, the increased tumor growth in Pvt1-associated p53RE mutagenized lung
tumors following Cre-mediated tumor initiation in a Kras-driven lung adenocarcinoma (LUAD)
GEMM suggests a tumor suppressor function (green box, (Olivero et al., 2020)).
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XIST
With a critical role in X chromosome inactivation and dosage compensation
that has been investigated for decades (reviewed in (Brockdorff et al., 2020;
Sahakyan et al., 2018)), the potential role of XIST (X Inactive Specific Transcript)
in tumorigenesis has intrigued researchers. Historically, it has been observed that
altered chromosome copy numbers and inappropriate dosage compensation are
frequently associated with human cancer. Notably, men with Klinefelter syndrome
characterized by an extra X chromosome have an increased risk of many
malignancies including breast cancer and non-Hodgkin lymphoma (Swerdlow et
al., 2005), and loss of X chromosome inactivation has been observed in breast
cancer cell lines (Sirchia et al., 2005) and testicular germ cell tumors (Kawakami
et al., 2003). In support of these correlative observations, a conditional Xist
deletion model in mouse blood cell lineages led to aggressive myeloproliferative
neoplasm and myelodysplastic syndrome with complete penetrance, likely as the
result of widespread gene expression changes (Yildirim et al., 2013). The tumor
suppressive role of XIST was recapitulated in RNAi and overexpression studies in
breast cancer cell lines as well as by crossing the Xist knockout to the MMTV-PyMT
mouse model of breast cancer (Xing et al., 2018). Further studies should determine
the prevalence of XIST and X inactivation perturbations in human cancer and
investigate the possibility of targeting this pathway as a therapeutic strategy.

ANRIL
High ANRIL expression in tumor tissues has been linked to aggressive
pathological features and poor overall survival (reviewed in (Kong et al., 2018)).
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In initial studies, targeted deletion of a 70 Kb region in the Anril locus, which
harbors multiple cancer and coronary artery disease associated SNPs, led to viable
progeny but showed increased mortality during development and as adults (Visel
et al., 2010). Primary cultures of smooth muscle cells, isolated from mutant mice,
exhibited excessive proliferation and diminished senescence, cellular phenotypes
consistent both with accelerated coronary disease pathogenesis and increased
cancer risk. Mechanistic investigation revealed that the effects were mediated in
cis through the reduced expression of Cdkn2a and Cdkn2b and led to the
conclusion that the risk region contained key regulatory elements. Subsequent
investigation using exogenous overexpression of ANRIL in primary human
fibroblasts suggested that the lncRNA may be responsible for CDKN2A/2B
repression through the locus-specific recruitment of the repressive PRC1 complex
(Yap et al., 2010). Unfortunately, little progress has been made over the past
decade in determining whether ANRIL transcription or transcript accumulation is
required for its cis-regulatory function, in part due to the limited conservation of
ANRIL sequence and exonic structure between human and mouse.

Promising lncRNA candidates warranting further investigation
In this section we examine exciting, albeit limited, initial studies of lncRNAs
with putative cancer functions, the validation of which could benefit from the
development of alternative approaches and further characterization.
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SAMMSON
To investigate the role of SAMMSON as a lineage addiction oncogene in
melanoma, researchers employed ASO-mediated knockdown and exogenous
overexpression as loss-of-function and gain-of-function tools (Leucci et al., 2016).
They observed that SAMMSON amplification and increased expression led to
altered mitochondrial metabolism and homeostasis. In turn, this caused increased
melanoma cell viability and clonogenic potential and resulted in sensitization of
melanoma cells to MAPK targeting therapeutics in vitro and in patient-derived
xenograft (PDX) models in vivo. Further mechanistic studies clarified the role of
SAMMSON in balancing mitochondrial translation rates (Vendramin et al., 2018).
The generation of genetic models of SAMMSON may reveal further insights into
its role in melanoma development.

NKILA
NKILA (NF-κB interacting long noncoding RNA) was identified as both a
target and negative modulator of the NF-κB signaling pathway, with low NKILA
levels observed in metastatic breast cancer cell lines and correlated with decreased
disease-free survival in a cohort of breast cancer patients (Liu et al., 2015).
Mechanistically, a series of deletion mutants demonstrated that NKILA interacts
directly and stably with the NF-κB:IκB complex in the cytoplasm to prevent IκB
phosphorylation and suppress activation of the NF-κB pathway, suggesting a
tumor suppressive role for NKILA in limiting inflammatory processes in cancer
(Liu et al., 2015). A different study from the same group showed that RNAi
downregulation of NKILA in cytotoxic T cells (CTLs) led to increased tumor
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infiltration and reduced tumor volume in a breast cancer PDX mouse model,
implicating NKILA as a potential target in the field of cancer immunotherapy
(Huang et al., 2018a).

LncGata6
LncGata6 (LncRNA GATA6) was identified as a divergent transcript
expressed from the promoter of Gata6, which is specifically enriched in a subset of
intestinal stem cells (Zhu et al., 2018). Deletion of exons 2-4 of lncGata6 in the
mouse did not affect Gata6 levels but resulted in decreased intestinal regeneration
due to decreased proliferative capacity of intestinal stem cells (Zhu et al., 2018).
Consistent with the key role of stem cells in intestinal tumorigenesis, genetic and
ASO-mediated depletion of lncGata6/lncGATA6 were found to impair tumor
growth in the APCmin mouse model of intestinal adenoma and in a PDX model
(Zhu et al., 2018). Future studies should focus on elucidating the mechanism by
which lncGATA6 is upregulated in colorectal cancer and on determining the extent
to which it contributes to aberrant Wnt signaling, a known colorectal cancer driver.

DINO
The p53 target lncRNA DINO binds to and stabilizes p53 in a positive
feedback loop, enhancing the activation of p53 target genes (Schmitt et al., 2016).
Importantly, RNAi knockdown of DINO in human fibroblasts and a deletion of the
Dino promoter in MEFs led to impaired cell cycle arrest following genotoxic stress
(Schmitt et al., 2016). Interestingly, ectopic expression of DINO in HPV-positive
cervical cancer cells, which suppress p53 stabilization and express DINO at low
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levels, led to reactivation of dormant p53, resulting in sensitization of the cancer
cells to chemotherapeutic agents and vulnerability to metabolic stress (Sharma
and Munger, 2020). To date, however, evidence that DINO acts as a tumor
suppressor in human cancer is limited.

LINC-PINT
Like DINO, linc-Pint was also identified as a p53 target (Marin-Bejar et al.,
2013). A knockout mouse generated by replacing the linc-Pint locus with a LacZ
reporter cassette yielded smaller pups, suggesting a role for linc-Pint in early
development (Sauvageau et al., 2013). Characterization of LINC-PINT function in
cancer suggested a role in limiting cell invasion, with LINC-PINT overexpression
leading to decreased liver metastases in a mouse model (Marin-Bejar et al., 2017).
In a transwell migration and invasion assay, invasiveness increased following
treatment with LINC-PINT -targeting ASOs or following CRISPR-mediated
deletion of a highly conserved LINC-PINT sequence element (Marin-Bejar et al.,
2017). Analysis of the previously generated linc-Pint knockout mouse (Sauvageau
et al., 2013) in a cancer background could help support these results. However, the
potential role of the LINC-PINT RNA may be confounded by the identification of
a peptide with a function in suppressing cell proliferation encoded by a circular
form of LINC-PINT (Zhang et al., 2018a).

THOR
While examples of alternative organismal models for lncRNA function in
cancer are limited, in part due to low evolutionary conservation of lncRNAs,
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investigation of the highly conserved lncRNA THOR (Testis-associated Highly
conserved Oncogenic long noncoding RNA) in human and zebrafish cancer models
has implicated this lncRNA in promoting melanoma development (Figure 5)
(Hosono et al., 2017). THOR expression is normally restricted to the testis, but has
been found aberrantly overexpressed in multiple cancer types, including lung
adenocarcinoma, lung squamous carcinoma, and melanoma (Hosono et al., 2017).
Knockdown of THOR via RNAi and ASOs in lung adenocarcinoma and melanoma
cell lines led to decreased proliferation and reduced colony formation (Hosono et
al., 2017). These findings were corroborated in two independently derived lung
adenocarcinoma cell lines harboring approximately 3 Kb CRISPR-mediated
deletions within the THOR gene body. Conversely, THOR overexpression gave the
opposite phenotype, leading to increased proliferative capacity and anchorageindependent growth. Importantly, ectopic expression of human THOR in zebrafish
cooperated with oncogenic NRAS and p53 loss to promote melanoma
development, whereas knockout of THOR in zebrafish embryos delayed mutant
NRAS-induced melanoma formation (Hosono et al., 2017). Further studies may
reveal the potential of using THOR expression as a biomarker or targeting THOR
as a therapeutic strategy.
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Figure 5. Identification and functional characterization of THOR. THOR was identified
as a testis-specific ultra-conserved lncRNA aberrantly expressed in cancer tissues (Hosono et al.,
2017). Hosono and colleagues generated several in vitro and in vivo loss-of-function (LOF) and
gain-of-function (GOF) models to functionally characterize THOR. LOF models included transcript
degradation with RNAi and ASO, and THOR partial locus deletion (THOR-/-) in both human cells
injected in severe combined immunodeficiency disease (SCID) mice and in a genetically engineered
zebrafish model (THOR-/-) embryonically injected with NRAS to induce melanoma. GOF models
included THOR overexpression (OE) in vitro and OE of human THOR (hTHOR) in p53-deficient
zebrafish (p53-/-) embryonically injected with NRAS to induce melanoma. Overexpression of
THOR plays an oncogenic role (red box) in cancer by binding to IGF2BP1 and increasing the
stability of its mRNA targets to promote cancer progression.
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Future Perspectives
Identification of lncRNAs that are genetically or epigenetically perturbed in
cancer has risen sharply over the past decade. The precipitous increase in the
number of cancer-associated lncRNAs has been accompanied by a growing
excitement that many lncRNAs may act as novel drivers of cancer development.
Yet, lagging understanding of how lncRNAs function in physiologic and pathologic
contexts has limited our insights into the roles of lncRNAs in tumorigenesis. The
current literature points to many lncRNAs acting as both oncogenes and tumor
suppressors. While these seemingly contradictory findings may stem from
differences in experimental models, they may also be reflective of complex and
context-dependent lncRNA biology, analogous to the dual oncogenic and tumor
suppressor roles played by cancer-associated protein-coding genes (Shen et al.,
2018). Future studies should prioritize the identification and validation of true
dual functions from technical inconsistencies.
LncRNAs make attractive drug targets, particularly in diseases where
protein candidates are not amenable to pharmacological inhibition (Dang et al.,
2017). Both siRNA- and ASO-mediated lncRNA degradation as well as locked
nucleic acid (LNA)-mediated interference with lncRNA function have emerged as
clinic-ready approaches (Arun et al., 2018; Lieberman, 2018). The successful
deployment of these approaches in cancer, however, is predicated upon robust
functional characterization. In the future, it would be essential to develop in vitro
and in vivo models that closely recapitulate the recurrent genetic or epigenetic
changes of lncRNAs observed in human cancer. In parallel, experiments that
uncover the functional elements of perturbed lncRNA loci will inform whether
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motives or structural features of the lncRNA molecules, the act of their
transcription, or underlying DNA elements mediate their roles in disease
development. These questions will be best answered through the integration of
diverse and complementary approaches and by corroboration from multiple
independent studies.

The p53 and Myc duet in cancer
Transcription networks coordinate the expression of a variety of genes in
response to cellular inputs. As such, transcription factors and their downstream
gene expression programs are frequently deregulated in cancer, with many the
target of alterations that promote tumor growth (reviewed in (Bradner et al.,
2017)). Two significant transcription networks in cancer are regulated by the p53
tumor suppressor and the Myc proto-oncogene, respectively. As a consequence of
their central roles in controlling cellular growth and survival, albeit activated by
very different cellular impulses, both networks are often subject to protumorigenic genetic and epigenetic modifications (Dang, 2012; Kastenhuber and
Lowe, 2017).
The human TP53 gene, which encodes the p53 tumor suppressor protein, is
mutated in as many as 50% of all human cancers, with p53 loss often predictive of
advanced tumor grade and poor overall survival (Kandoth et al., 2013; Olivier et
al., 2010). Germline TP53 mutations, the defining characteristic of Li Fraumeni
Syndrome, dramatically increase the risk of developing a range of tumor types
(Olivier et al., 2010). Similarly, mice with germline loss of one or both copies of
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p53 (Trp53-/- or Trp53+/-) are prone to spontaneous tumorigenesis, with
complete p53 loss often resulting in neoplasm development within the first year of
life (Donehower et al., 1992; Jacks et al., 1994). Apart from mutations which inhibit
p53 directly, mutations that disturb critical p53 effector genes are also common,
and can be equally as disruptive to p53 network function. For example, transgenic
mice that overexpress Mdm2 (Mouse double minute 2), a negative regulator of p53,
and mice lacking Arf (Alternate reading frame of Cdkn2a), a positive regulator of
p53, are both similarly prone to spontaneous tumorigenesis (Jones et al., 1998;
Kamijo et al., 1999).
On the other hand, cancer-driving mutations affecting the Myc network are
often characterized not by alterations to Myc coding sequences, but by alterations
that increase Myc expression or activity. Upregulation of MYC in avian leukosis
virus (ALV)-induced lymphomas via retroviral insertion upstream of the MYC
promoter is well-documented (Hayward et al., 1981; Payne et al., 1982).
Furthermore, an analysis of somatic copy number alterations (SCNAs) in human
cancer revealed MYC alterations as one of the most prominent (Beroukhim et al.,
2010). The MYC locus often participates in chromosomal rearrangements, and is
a frequent translocation partner of the immunoglobulin heavy chain locus (Taub
et al., 1982), a fusion that increases MYC expression and is modeled in the Eµ–
Myc mouse model of B-cell lymphoma (Adams et al., 1985). Focal genomic
amplifications of the MYC locus in the form of homogeneously staining regions
and double minutes are also common (Alitalo et al., 1983; Collins and Groudine,
1982). Notably, several studies have illustrated MYC oncogene addiction, with
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suppression of MYC sufficient to cause tumor regression (reviewed in (Dang,
2012)), suggesting its importance for viability in MYC-driven cancers.
The observation that loss-of-function and gain-of-function mutations in
TP53 and MYC, respectively, have such pervasive effects on cancer pathology
points to critical roles for these transcription networks in maintaining normal
cellular growth and homeostasis.

The p53 tumor suppressor pathway
Under normal conditions, p53 is constitutively produced and degraded,
enabling rapid action to be taken against cellular assaults (Kastenhuber and Lowe,
2017). In response to a variety of cellular stressors, such as doxorubicin-induced
DNA damage or the expression of an activated oncogene, p53 is stabilized via
repression of MDM2 activity and p53 post-translational modifications, thus
enabling its tetrameric binding to canonical p53 response elements (p53REs) and
the induction of the p53 transcriptional program (Figure 6) (Beckerman and
Prives, 2010; Kastenhuber and Lowe, 2017). The ability of p53 to bind specific DNA
sequences is critical to its function. Genes directly induced by p53 share the
presence of a conserved p53RE, usually in their promoter or first intron
(Beckerman and Prives, 2010), composed of two 10 bp motifs separated by a
stretch of nucleotides between 10-13 bp in length (el-Deiry et al., 1992). There is
some evidence of gene repression downstream of p53 (Allen et al., 2014), but its
contribution to the p53 response remains unclear. Significantly, p53 stabilization
strongly correlates with reduced MYC levels, suggesting that p53 may actively
suppress positive regulators of the cell cycle rather than simply promoting the
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expression of negative regulators of cell growth (Ho et al., 2005; Porter et al.,
2017).
Through the activation of its transcription program, p53 drives a variety of
cellular outcomes, the most prominent of which are transient cell cycle arrest
(Brugarolas et al., 1995), senescence (Ferbeyre et al., 2002), and apoptosis (Lowe
et al., 1994). Moreover, several studies have suggested that canonical p53
responses and full p53 transcriptional activation may be dispensable for tumor
suppression, suggesting that some non-canonical p53-driven responses may play
equally important roles in cellular homeostasis (Jiang et al., 2011; Li et al., 2012).
The targets of p53 are diverse and include coding and noncoding genes with
functions in a range of cellular processes such as cell cycle regulation,
pluripotency, metabolism, and inflammation (reviewed in (Kastenhuber and
Lowe, 2017)). Notably, the characterization of numerous lncRNA targets of p53 in
recent years suggests the growing importance of this class of noncoding transcripts
in the p53 response to stress (as discussed previously in this chapter). What
dictates selection of a particular cellular outcome in response to p53 activation is
unclear, although evidence suggests it may depend on cell type and stressor
(Attardi et al., 2004; Paris et al., 2008). Despite these gaps in knowledge, it is clear
that p53 is critical in preventing the outgrowth of aberrantly proliferating cell
populations that might otherwise initiate cancer development.
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Figure 6. The p53 tumor suppressor pathway. The tumor suppressor protein p53 is a
transcription factor that is stabilized by cellular stress (i.e. DNA damage, oncogene activation,
hypoxia, etc) and binds p53 Response Elements (p53REs) to upregulate various coding and
noncoding target genes. The induction of the p53 transcription program drives cellular outcomes
(i.e. cell cycle arrest, senescence, and apoptosis) that limit cell growth.
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The proto-oncogenic Myc network
Myc responds to pro-growth stimuli by orchestrating the induction of cell
cycle genes to promote cell division. It does so most commonly through
heterodimerization with its partner Max (Myc-associated factor X) and
cooperative binding to E-box (CACGTG) sequences in the promoters of target
genes (Amati et al., 1993; Blackwell et al., 1990). While Myc half-life is short, Max
is more stable, pointing to both Myc expression and protein synthesis as rate
limiting steps in cellular proliferation (Amati et al., 1993).
Researchers have long sought to define a universal set of Myc target genes,
but precise characterization of the Myc transcription network has remained
elusive. Analysis of serum-stimulated fibroblasts revealed nearly 300 genes
induced in a Myc-dependent manner (Perna et al., 2012), consistent with an
understanding of Myc as driving a selective gene expression program (Sabo et al.,
2014; Walz et al., 2014). However, several studies have advocated a less
discriminatory role for Myc function, suggesting that Myc acts not necessarily as a
sequence-specific transcription factor, but as a global amplifier of genes expressed
from open chromatin (Lin et al., 2012; Rahl et al., 2010). These differing
viewpoints stem, in part, from normalization tactics used in RNA-sequencing
experiments to identify Myc target genes. Specifically, there has been
disagreement over how to contend with the proposed ability of Myc to increase
global transcription as a potential confounding factor in standard normalization
practices. Some have argued that normalization based on cell equivalents
overcomes biases introduced by Myc-induced surges in total RNA content, but in
practice accuracy may require multiple analyses (Kress et al., 2015). Of note, Myc
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roles in gene repression have also been suggested, such as its proposed function in
influencing the cellular response to DNA damage by downregulating the CDK
inhibitor p21 to promote apoptosis, perhaps indicating feedback between the p53
and Myc transcription programs (Seoane et al., 2002).
Ambiguities concerning Myc regulation and function in cancer also persist.
Expressed from the 8q24 locus, MYC is impacted by a range of cis-acting DNA
elements (Fulco et al., 2016). An abundance of lncRNAs in the MYC locus have also
been identified, with some proposed to have cancer-specific functions in MYC
regulation (Ling et al., 2013; Xiang et al., 2014). How these lncRNAs and other
enhancer and repressor elements adjacent to the MYC locus drive MYC expression
in different cancer types is still an open question. While elevated Myc levels are
known to promote aberrant cell growth under circumstances favorable to
tumorigenesis, its dysregulation has also been associated with an increased
propensity for cells to undergo programmed cell death (Zindy et al., 1998).
Interestingly, some have speculated about a Myc expression threshold cells cannot
surpass without triggering apoptosis (Murphy et al., 2008). This has been
proposed as especially critical in early cancer development when cells retain
functional tumor suppressor pathways, suggesting that lower levels of Myc
dysregulation may be optimal for initial cancer cell survival.

Project framework: p53, Myc, and the missing lncRNA
This chapter links together disparate elements of lncRNA biology and
cancer biology in broad strokes. A key question raised at the intersection of these
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fields is whether, and to what extent, lncRNA aberrations in cancer can constitute
true drivers of tumorigenesis. There is abundant evidence for genetic and
epigenetic alterations of lncRNAs in cancer and their presence in pathways
essential to cancer growth and development is well-documented. However,
ultimately only a small fraction of cancer-related lncRNAs have been shown to
have significant, and functionally consistent, physiological impacts when they are
manipulated in vivo (discussed in detail previously in this chapter). As such, the
functional impacts of individual lncRNAs, and indeed lncRNAs as a class, on
cancer pathogenesis are incompletely understood.
An additional, and ultimately related, question highlighted here concerns
the elusive threads connecting the p53 and Myc transcription networks. Given the
significant, albeit often contradictory, influences of the tumor suppressor p53 and
the proto-oncogene Myc on cell growth, and by extension, cancer development,
one might expect a need for cells to coordinate their activities in order to avoid the
transmission of opposing cellular impulses (Figure 7). As alluded to previously,
p53 activation results in repression of Myc as a mechanism for temporarily
curtailing cellular proliferation in stressed cells (discussed more in Chapter 2).
This phenomenon has long been of interest to cancer biologists, but remained
poorly understood despite decades spent studying Myc regulation. We find that
this cellular fail-safe is primarily facilitated by the lncRNA isoform Pvt1b, the
subject of this work. Considering the heterogeneity of lncRNAs in form and
function, they make apt candidates for enacting specific local regulation
downstream of broadly active transcription factors. However, the lncRNA field has
been plagued by challenges in ascertaining lncRNA functional roles, particularly
55

under tumorigenic conditions; many controversies center on lncRNAs with both
ascribed pro- and anti- oncogenic capabilities rooted in evidence from conflicting
model systems.
Here I describe Pvt1b as an emissary connecting two extensive gene
expression programs, a potential archetype for lncRNA function, which may exist
in other cellular processes and pathways. Incorporating lessons in experimental
design derived from lncRNA literature and guided by an understanding of the roles
of p53 and Myc in cancer, I employ a range of orthogonal approaches to assess the
function and biological significance of Pvt1b under physiologic and tumorigenic
conditions. I first identify and characterize Pvt1b, presenting evidence for its role
in repressing Myc transcription downstream of p53 activation (see Chapter 2). I
further investigate the functional elements of the Pvt1b transcript (see Chapter
3) and pursue a potential mechanism of action involving Pvt1b-guided histone
deacetylation at the Myc promoter (see Chapter 4). Finally, I provide a
foundation for future dissection of Pvt1 function in vivo through my role in
generating three genetically engineered Pvt1 mouse models, the incisive
combination of which should help illuminate features of the Pvt1 locus required
for its activities (see Chapter 5). Rationales for specific experiments are discussed
in detail in Chapters 2-5.
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Figure 7. The p53 and Myc transcription networks in cancer. In response to mitogenic
stimuli, MYC (red) dimerizes with its partner MAX (yellow) to upregulate target genes that promote
cellular proliferation. In contrast, p53 (green) responds to cellular stress, binding as a tetramer to
induce genes that suppress cellular growth. In cancer, MYC is frequently the target of gain-offunction (GOF) mutations, while p53 is frequently the target of loss-of-function (LOF) mutations.
MYC levels have been observed to decrease following p53 activation, and various mechanisms, both
direct and indirect, have been proposed to explain this phenomenon.
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Chapter 2:
p53 activates the long noncoding RNA Pvt1b to inhibit Myc and
suppress tumorigenesis

The work described in this chapter has been published as follows: Olivero, C.E.,
Martinez-Terroba, E., Zimmer, J., Liao, C., Tesfaye, E., Hooshdaran, N.,
Schofield, J.A., Bendor, J., Fang, D., Simon, M.D., et al. (2020). p53 Activates the
Long Noncoding RNA Pvt1b to Inhibit Myc and Suppress Tumorigenesis. Mol Cell
77, 761-774 e768. Co-author contributions that have also been included in this
thesis are specified in figure legends and/or text.

Introduction
The p53 (also known as TP53) network is a central tumor suppressive
mechanism in mammalian cells that is inactivated in the vast majority of human
cancers (Vousden and Prives, 2009). In response to cellular stress induced by DNA
damage or oncogenic signaling, p53 transcriptionally activates target genes to limit
cellular proliferation or to permanently eliminate damaged cells (Vousden and
Prives, 2009). Transcriptional activation by p53 relies on its binding to conserved
p53 response elements (p53REs) in the promoters of target genes (Levine and
Oren, 2009). p53 has also been implicated in the repression of cell cycle regulators
(Engeland, 2018). One of the prominent targets of p53 repression is the
Myelocytomasis (Myc) oncogene (Ho et al., 2005; Levy et al., 1993; Sachdeva et al.,
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2009), a global transcriptional amplifier that responds to mitogenic signals to
promote cellular proliferation (Lin et al., 2012). Multiple models for how p53
negatively affects Myc levels have been proposed, including p53 binding to the Myc
promoter to suppress histone acetylation, binding to a distal regulatory element to
alter nucleosome positioning in the Myc promoter, or activating repressive Myctargeting microRNAs (Ho et al., 2005; Porter et al., 2017; Sachdeva et al., 2009).
However, the mechanism of p53-mediated Myc downregulation and its
contribution to tumor suppression in vivo have remained unclear.
Long noncoding RNAs (lncRNAs) can modulate gene expression locally by
accumulating near their sites of transcription (Kopp and Mendell, 2018). In dosage
compensation, Xist and other lncRNAs expressed from the X-chromosome
specifically repress genes across the entire X-chromosome through the
recruitment of epigenetic regulators (Lee, 2012). Other cis-regulatory lncRNAs act
in a more limited, locus-specific manner, such as the p53 target lincRNA-p21
proposed to promote the levels of its neighbor p21 (also known as Cdkn1a) by
recruiting activating factors (Dimitrova et al., 2014). While studies of locus-specific
cis-regulatory lncRNAs have revealed important roles in diverse biological
processes (Dimitrova et al., 2014; Elling et al., 2018; Kotzin et al., 2016),
characterization of the RNA molecule is often confounded by potential functional
roles of DNA regulatory sequences in the lncRNA locus (Bassett et al., 2014;
Engreitz et al., 2016; Groff et al., 2016). Defining the RNA-mediated regulation
provides important opportunities for RNA-based therapeutics that can alter
hardwired molecular interactions to change cellular responses.
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Plasmacytoma variant 1 (Pvt1), a lncRNA expressed 50 Kb downstream of
Myc, is altered in a large fraction of human cancers. Frequent translocations and
viral integrations in the Pvt1 locus in lymphomas suggest important roles for Pvt1
in cancer progression (Cory et al., 1985; Graham and Adams, 1986; Graham et al.,
1985). In addition, co-amplification of Myc and Pvt1 across multiple cancer types
correlates with poor cancer patient prognosis, suggesting cooperation between the
two genes during tumorigenesis (Cui et al., 2016; Tseng and Bagchi, 2015; Zeng et
al., 2017). This pro-oncogenic cooperation between Myc and Pvt1 was recently
confounded by the identification of a p53-binding site in the Pvt1 locus and by the
description of the Pvt1 promoter as a transcriptional repressor of Myc (Cho et al.,
2018; Porter et al., 2017). These studies suggested undefined roles for Pvt1 in
cancer progression and a potential crosstalk between the tumor suppressor p53
pathway and the oncogenic Myc network.
In this study, I characterized Pvt1b, a p53-induced isoform of the lncRNA
Pvt1, and determined its contribution to Myc regulation and the p53 response to
stress. I show that production of the Pvt1b RNA downstream of p53 represses Myc
transcription and suppresses cellular proliferation during stress and in the early
stages of tumorigenesis. The model presented here illuminates a role for the
lncRNA isoform Pvt1b as a locus-specific transcriptional regulator that serves to
enact selective gene repression downstream of the broad p53 transcriptional
activation network.
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Results
p53 suppresses Myc under conditions of genotoxic and oncogenic
stress
To gain insight into the mechanism by which p53 causes suppression of
Myc, I used multiple independent approaches to model the p53-dependent
response to stress. To model the cellular response to genotoxic stress, I utilized
wild-type (WT) mouse embryonic fibroblasts (MEFs) treated with the genotoxic
agent Doxorubicin (Doxo) (Figure 8A). I observed that activation of the p53
transcriptional program following Doxo treatment for 24 hours resulted in 3-fold
induction of the p53 target p21 and a concomitant reduction in Myc RNA and
protein levels by 34±6% (p=0.008, Figure 8B) and 44±15% (p=0.0051, Figure 8C),
respectively, consistent with previous findings (Ho et al., 2005; Porter et al., 2017).
I also found that p53 activation by oncogenic stress, modeled by Tamoxifen (Tam)CreER-dependent restoration of endogenous p53 expression in a murine lung
adenocarcinoma cell line (K-rasLA2-G12D/+; p53LSL/LSL; Rosa26-CreERT2+, KPR)
(Figure 8D) (Feldser et al., 2010), similarly led to a 70-fold activation of p21, a
34±7% repression of Myc RNA (p=0.0020, Figure 8E) and a 37±10% decrease in
Myc protein (p=0.0028, Figure 8F). Myc repression by 39±5% was also observed
in intestinal epithelium cells isolated from mice exposed to 6 Grays (Gy) of wholebody irradiation, which leads to a well-characterized p53-mediated response to
genotoxic stress in vivo (p=0.0007, Figures 8G and 8H) (Clarke et al., 1994).
Altogether, these results suggested that Myc repression is a general event
downstream of p53 transcriptional activation.
In an effort to elucidate the mechanism by which p53 activation results in
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Myc repression, Nadya Dimitrova examined whether p53 associates with the Myc
locus. She observed that both in Doxo-treated MEFs and Tam-treated KPR cells,
stress-dependent Myc repression was accompanied by binding of p53 to a distal
p53RE, located 50 Kb downstream of Myc, which has previously been implicated
in limiting Myc expression (Figure 8I)(Porter et al., 2017).
Consistent with p53 dependency, the changes in Myc RNA and protein
levels were present in p53-proficient, but not p53-deficient MEFs (Figures 8J and
8K). Additionally, the decrease in Myc RNA levels was detectable as early as 4
hours following p53 activation and was coincident with the decrease in Myc protein
levels, suggesting direct transcriptional modulation by p53 (Figures 8L and 8M).
Inhibition of protein translation with Cycloheximide (Chx) revealed that Myc
protein stability was not significantly affected by the presence of stress, suggesting
that the decrease in Myc levels was not primarily due to post-translational
regulation (Figure 8N).
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Figure 8. p53 suppresses Myc in response to genotoxic and oncogenic stress. (A)
Schematic of the model system for studying p53-mediated response to genotoxic stress in WT MEFs
untreated or treated with Doxo for 24 h. Activation of p53 by passaging or by genotoxic stress is
represented by light and dark red nuclei, respectively. (B) p21 and Myc RNA levels in cells from
(A). Data show mean ± SEM (n=4, biological replicates), *p<0.05, **p<0.01, paired t test. (C) Left
Representative image and quantification of Myc protein levels from cells in (A). Hsp90 as a loading
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control. Right Bargraph of Myc protein levels showing mean±SEM (n=5, biological replicates),
**p<0.01, paired t test. (D) Schematic of the model system for studying p53-mediated response to
oncogenic stress in KPR cells untreated or treated with Tam for 24 h. Activation of p53 by oncogenic
stress is represented by red nucleus. (E) p21 and Myc RNA levels in cells from (D). Data show mean
± SEM (n=6, biological replicates), ***p<0.001, paired t test. (F) Left Representative image and
quantification of Myc protein levels from cells in (D). Hsp90 as a loading control. Right Bargraph
of Myc protein levels showing mean±SEM (n=5, biological replicates), **p<0.01, paired t test. (G)
Schematic of the model system for studying p53-mediated response in vivo in intestinal epithelial
cells isolated from WT mice at 6 h post 6 Gy whole-body irradiation. Samples provided by Nadya
Dimitrova. (H) p21 and Myc RNA levels from mice in (G). Data show mean ± SEM (n=3, biological
replicates) **p<0.01, ***p<0.001, unpaired t test. (I) Enrichment of p53 binding at the Pvt1associated p53RE by ChIP-qPCR in Left Doxo-treated MEFs and Right Tam-treated KPR cells. Data
show mean ± SEM (MEFs: n=4; KPR: n=3, biological replicates) *p<0.05, **p<0.01, paired t test.
P53 ChIP performed by Nadya Dimitrova. (J) Myc RNA levels in p53-deficient or p53-proficient
MEFs, untreated or treated with Doxo for 24 h. Data show mean ± SEM (n=3, biological replicates),
ns = not significant, *p<0.05, paired t test. (K) Left Representative image and quantification of
Myc protein levels from cells in (J). Hsp90 as a loading control. Right Bargraph of Myc protein
levels showing mean ± SEM (n=3, biological replicates), ns = not significant, *p<0.05, paired t test.
(L) Myc RNA levels in WT MEFs, untreated or treated with Doxo for the indicated times. Data
show mean ± SEM (n=4, biological replicates), ***p<0.001, paired t test. (M) Left Representative
image and quantification of Myc protein levels from cells in (L). Hsp90 as a loading control. Right
Bargraph of Myc protein levels showing mean ± SEM (n=4, biological replicates), **p<0.01,
***p<0.001, paired t test. (N) Left Representative image and quantification of Myc protein levels
following treatment with cycloheximide (Chx) for indicated times in WT MEFs, untreated or treated
with Doxo for 8 h. Right Myc protein half-life (n=3, biological replicates), ns = not significant,
paired t test.
Contributions from N. Dimitrova in (G) and (I) are described above.

Myc repression correlates with activation of a p53-dependent Pvt1
isoform, Pvt1b
I was intrigued that the distal p53RE was located within the gene body of
the lncRNA Pvt1 (Figure 9A), which has previously been implicated as a p53 target
(Barsotti et al., 2012). Considering lncRNAs can act in cis to regulate the
transcription of neighboring genes, I examined whether Pvt1 played a role in
restricting Myc expression during stress. I noted significant stress-dependent
induction of an isoform of Pvt1, termed Pvt1b, initiated at a transcription start site
located immediately downstream of the p53RE. I observed a 3.1±0.2-fold
induction of Pvt1b in Doxo-treated MEFs (Figure 9B) and a 38±6-fold induction
of Pvt1b in Tam-treated KPR cells (Figure 9C). Pvt1a, an isoform of Pvt1 initiated
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at exon 1a, was induced to a lesser extent in Doxo-treated MEFs (Figure 9B) and
was not significantly induced by Tam in KPR cells (Figure 9C). Copy number
calculations suggested that Pvt1b was induced from 20 to 210 copes per cell, while
Pvt1a was expressed at 300-400 copies per cell (Figure 10A). Notably, activation
of Pvt1b was coincident with Myc repression and occurred as early as 4 hours
following Doxo treatment in MEFs (Figure 10B) or 6 hours following Tam
treatment in KPR cells (Figure 10C), consistent with direct transcriptional
regulation by p53. Similarly, Doxo-treated human fibroblasts exhibited a 2-fold
decrease in MYC levels and an 8-fold increase of human PVT1B (Figure 10D).
These findings indicated that the downregulation of Myc and the activation of a
p53-dependent, stress-specific Pvt1 variant are conserved between mouse and
human.
To further characterize the transcripts produced from the Pvt1 locus, I
performed RT-PCR with forward primers located in either exon 1a or 1b and a
reverse primer in exon 5. I found evidence for extensive alternative splicing and
confirmed that variants containing exon 1b were induced by p53, while exon 1acontaining variants were constitutively expressed (Figures 9D and 9E). Despite the
splicing heterogeneity, sequencing of nascent RNA revealed that stress-induced
Pvt1b differed from constitutively expressed Pvt1a solely by the use of exon 1b
versus exon 1a, and exhibited comparable splicing patterns to downstream exons
(Figure 9F). I concluded that p53 activation during genotoxic and oncogenic stress
initiated transcription in the Pvt1 locus from exon 1b, leading to the production of
the p53-dependent isoform, Pvt1b, while Pvt1a represented a largely constitutively
expressed isoform.
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Figure 9. p53-dependent induction of the Pvt1 isoform, Pvt1b. (A) Schematic of the
mouse Myc-Pvt1 locus, highlighting exons 1a and 1b of Pvt1 and the location of the p53RE (green
*). (B, C) Isoform-specific and total Pvt1 RNA levels detected with primers located in indicated
exons in (B) WT MEFs and (C) KPR cells, treated as indicated. Data show mean ± SEM (n=3,
biological replicates), *p<0.05, **p<0.01, ***p<0.001, paired t test. (D, E) RT-PCR detection of
Pvt1a isoforms (a, blue), amplified with primers from exon 1a to exon 5, and Pvt1b isoforms (b,
orange), amplified with primers from exon 1b to exon 5, in RNA isolated from (D) MEFs and (E)
KPR cells, ladder (L). (F) Genome browser tracks and Sashimi plots from TimeLapse-seq data in
KPR cells, treated as indicated. Average number of splice junctions from 2 biological replicates from
exon 1a to exon 2 (blue) and from exon 1b to exon 2 (orange) are indicated. Processing of samples
for TimeLapse-seq and data analysis performed by Jeremy Schofield and Josh Zimmer.
Contributions from J. Schofield and J. Zimmer in (F) are described above.
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Figure 10. p53 activates the lncRNA isoform Pvt1b. (A) Copy number calculations of Pvt1a,
Pvt1b, and Myc by qRT-PCR analysis of KPR cells untreated or 24 h post-treatment with Tam. (B,
C) qRT-PCR analysis of Pvt1b levels in (B) MEFs treated with Doxo for the indicated times and (C)
KPR cells treated with Tam for the indicated times. The observed induction of Pvt1b as early as 46 hours post stress suggests direct transcriptional activation by p53. (D) Top Schematic of the
human PVT1 locus, highlighting exon 1a (blue), exon 1b (orange), the conserved p53RE (green star)
and showing the location of qPCR primers (red arrows), Bottom qRT-PCR analysis of relative
PVT1A, PVT1B, and MYC RNA levels in normal human fibroblasts untreated or treated with Doxo
for 24 h. Data show the mean ± SEM of 3 technical replicates from a representative example of two
biological replicates. Human fibroblast samples provided by Nadya Dimitrova.
Contributions from N. Dimitrova in (D) are described above.
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Stress-induced Myc repression occurs in the absence of promoterenhancer contact reorganization
Previous work had shown that CRISPR-mediated transcriptional regulation
of the Pvt1 promoter in p53-deficient cancer cells causes reorganization of the
chromatin architecture in the locus and impacts the access of Myc to downstream
enhancers (Cho et al., 2018). To test whether the stress-responsive, p53-dependent
induction of Pvt1b was associated with changes of these chromatin contacts, I
performed Chromosome Conformation Capture (3C) in MEFs and KPR cells.
Using an anchor in the Myc promoter, I confirmed that the Myc promoter accessed
multiple upstream and downstream enhancers, including previously described
Pvt1 intragenic enhancers (Figures 11A and 11B) (Cho et al., 2018). However, I did
not detect significant changes in the chromatin looping between the Myc promoter
and Myc-associated enhancers during the p53-mediated stress response (Figures
11A and 11B). These results argue against a model where p53-dependent activation
of Pvt1b leads to reorganization of the three-dimensional architecture of the locus.
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Figure 11. p53 activation does not substantially alter chromatin architecture of the
Myc-Pvt1 locus. (A-B) 3C analysis of BamHI-digested DNA from (A) WT MEFs, untreated or
treated for 24 h with Doxo and (B) KPR cells, untreated or treated for 24 h with Tam. Interaction
frequency with an anchor in the Myc promoter (A1, green arrow) is plotted relative to genomic
location. A unidirectional forward primer strategy was used to probe chromatin interactions within
the Myc- Pvt1 locus and primers were designed to query previously described enhancer regions
interacting with the Myc promoter (Cho et al., Cell 2018), published H3K4me1 peaks (Meyer et al.,
JBC 2016), and control regions. Top Interaction frequency plots depicting the strongest
interactions between the Myc promoter and upstream and downstream enhancers. Note that the
chromatin architecture is largely unchanged by the presence of stress. Bottom Interaction
frequency plot depicting weaker interactions between the Myc promoter and upstream and
downstream enhancers. Note the change of scale and that the three strongest peaks, depicted in the
Top panels, are excluded in the Bottom panels to allow visualization of smaller peaks. Note that
there is a pre-existing chromatin looping interaction between the Myc and Pvt1 promoters, which
exhibits a mild increase following Doxo treatment in (A) WT MEFs but is not significantly changed
in (B) Tam-treated compared to untreated KPR cells. Data represent (A) n=3 biological replicates
or (B) representative plot from n=2 biological replicates, ns = not significant, *p<0.05, paired ttest.
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Accumulation of Pvt1b in the chromatin surrounding the Pvt1-Myc
locus
To gain insight into the potential regulatory function of Pvt1b, I performed
single-molecule RNA Fluorescence in situ Hybridization (smRNA-FISH), which
allows visualization of individual RNA molecules by utilizing multiple
fluorescently-labeled probes per transcript. I designed four independent probesets
to detect Pvt1 transcripts. Pvt1a- and Pvt1b-specific probesets (named Pvt1a
(ex.1a) and Pvt1b (ex.1b)) were designed against the first exon of each isoform.
While isoform-specific, the two probesets were not expected to detect single RNA
molecules due to the low number of probes per transcript. The probeset Pvt1
(ex.1a-10) was designed to detect both full-length Pvt1a and full-length Pvt1b at
single-molecule resolution, while the Pvt1 (introns) probeset was specific to
unspliced Pvt1 molecules. Finally, I designed a probeset to detect Myc intronic
regions (Myc (intron)) and mark the site of Myc transcription. I observed that
Pvt1a and Pvt1b exhibited a primarily 2- or 4-dot nuclear pattern in Etoposide
(Etop)-treated MEFs, reflective of G1 or S/G2 stages of the cell cycle, respectively
(Figures 12A and 13A). Pvt1a and Pvt1b formed larger clouds in Tam-treated KPR
cells (Figures 12B and 13B), which have amplified the locus, as shown by DNA
Fluorescence in situ Hybridization (DNA-FISH) (Figure 13C). By co-staining either
Pvt1a or Pvt1b with total Pvt1, I concluded that both isoforms exhibited an
identical localization pattern (Figures 12A, 12B, 13A and 13B). Notably, Pvt1a- and
Pvt1b-containing foci co-localized with signals specific to the introns of nascent
Myc (Figures 12C and 12D) as well as with nascent Pvt1 transcripts (Figures 12E
and 12F). These results led me to conclude that, following transcription, Pvt1a and
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Pvt1b are retained on the chromatin surrounding the Pvt1-Myc locus. Subcellular
fractionation analysis confirmed enrichment of both Pvt1 variants in the
chromatin fraction (Figure 12G).
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Figure 12. Accumulation of Pvt1 isoforms in the chromatin surrounding the Pvt1-Myc
locus. (A-F) smRNA-FISH with indicated probes in (A, C, E) WT MEFs, untreated or treated with
Etop for 24 h and in (B, D, F) KPR cells untreated or treated with Tam for 24 h. DNA, DAPI. Note:
Pvt1b is detectable in untreated, p53-proficient MEFs likely due to activation of the p53 pathway
by passaging in primary cells but is undetectable in untreated, p53-deficient KPR cells. (G) Pvt1a
and Pvt1b RNA levels in Doxo-treated WT MEFs following subcellular fractionation (representative
from n=2 biological replicates). Rn7s1 and Kcnq1ot1 used as controls for the cytoplasmic and
chromatin fractions, respectively. Subcellular fractionation and analysis performed by Ephrath
Tesfaye.
Contributions from E. Tesfaye in (G) are described above.
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Figure 13. Co-localization of Pvt1a and total Pvt1 by smRNA-FISH. (A-B) smRNA-FISH
with probes designed against indicated regions in (A) WT MEFs, untreated or treated with Etop for
24 h and in (B) KPR cells untreated or treated with Tam for 24 h. The following probesets are
shown: Pvt1a (ex.1a, red) detecting Pvt1a isoform with 11 probes spanning exon 1a and Pvt1 (ex.1a10, green) detecting total Pvt1 with 48 probes spanning exons 1a-10. Note: The Pvt1a probeset does
not detect at the single molecule level. (C) DNA-FISH with probes generated using a Bacterial
Artificial Chromosome (BAC) of the Myc locus (Myc BAC, red) or a control region in chromosome
6 (Chr 6 BAC, green) in untreated WT MEFs and KPR cells, highlighting increased copy number of
the Myc locus in KPR cells. DNA-FISH performed by Dorthy Fang.
Contributions from D. Fang in (C) are described above.
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Pvt1b RNA represses Myc levels in cis
Based on the stress-dependent expression of Pvt1b and its local chromatin
accumulation, I hypothesized that Pvt1b could be involved in Myc repression
through an RNA-dependent mechanism. To directly test this hypothesis, I
designed three independent antisense oligonucleotides (ASOs) specific to exon 1b
(Figure 14A). I used a non-targeting ASO (CON) as a negative control. As ASOs
lead to co-transcriptional RNA cleavage and degradation, ASO1, 2, and 3
significantly downregulated both Pvt1a and Pvt1b (Figure 14B).
Next, I examined how Pvt1-targeting ASOs affected Myc expression levels.
In untreated MEFs, Myc RNA and protein levels were not significantly altered in
ASO compared to CON samples, indicating that knockdown of Pvt1 isoforms did
not affect Myc regulation in the absence of stress, consistent with previous findings
(Figures 14C, 14D and 15A) (Cho et al., 2018). As expected, upon treatment with
Doxo, CON MEFs experienced a significant decrease in Myc RNA (Figure 14C) and
protein levels (Figures 14D and 15A). On the other hand, I found that Pvt1targeting ASOs completely rescued stress-induced downregulation of Myc RNA
and protein (Figures 14C, 14D and 15A). These findings revealed that
transcriptional activation of Pvt1b by p53 is required for Myc repression during
stress. As a control, the absence of Myc downregulation was not due to altered
association of p53 with the Pvt1b-associated p53RE (Figure 15B).
To test the sufficiency of Pvt1b in suppressing Myc, Elena Martínez-Terroba
employed the CRISPR-SAM (Synergistic Activation Mediator) system to activate
the expression of endogenous Pvt1b in p53-deficient cells (Dahlman et al., 2015).
CRISPR-SAM combines nuclease-proficient Cas9 with 15-nucleotide ʻdead RNAsʼ
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(dRNAs), which are competent for Cas9 recruitment but do not support Cas9
nuclease activity. In CRISPR-SAM, the dRNA scaffold is extended by two MS2
binding loops (dRNA-MS2), which serve to recruit the MS2-binding protein (MBP)
fused to the transcriptional activator domains of p65 and HSF1, allowing CRISPR
activation (CRISPRa) of target genes (Dahlman et al., 2015). Martínez-Terroba
designed A1 and A2 dRNA-MS2 targeting the promoters of Pvt1a and Pvt1b,
respectively (Figure 14E). Compared to a non-targeting control (C), CRISPRa using
A1 led to 1.6-fold induction of Pvt1a, without altering Pvt1b levels, while A2
resulted in a 20-fold activation of Pvt1b with no significant induction of Pvt1a
(Figure 14F). Next, she examined the effect of activation of endogenous Pvt1a and
Pvt1b on Myc levels. In support of the model, she found that CRISPRa of Pvt1b,
but not Pvt1a, was sufficient to significantly repress Myc RNA in p53-deficient cells
compared to control dRNA-expressing cells (p=0.023, Figure 14G). Activation of
Pvt1b did not further downregulate Myc levels following p53 restoration,
indicating that Pvt1b acted downstream of p53 (Figure 14G). On the other hand,
activation of Pvt1b was not sufficient to suppress Myc protein levels, opening the
possibility for Pvt1b-independent input at the post-transcriptional level (Figures
15C and 14H).
To distinguish between activity in cis versus in trans, I tested whether
exogenous overexpression of Pvt1a and Pvt1b by transfection of cDNA constructs
containing exons 1a-10 (1a) or 1b-10 (1b) affected Myc expression (Figure 14I). I
observed a 6.5-fold overexpression of Pvt1a as well as a 23-fold overexpression of
Pvt1b, which were comparable to CRISPRa-induced overexpression (Figure 14J).
However, I found that exogenously delivered Pvt1a or Pvt1b did not significantly
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affect Myc RNA or protein levels, arguing against an effect in trans (Figures 14K,
14L and 15D). Altogether, these data supported a previously unappreciated role for
Pvt1b, but not Pvt1a, in the repression of Myc in cis.
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Figure 14. Production of Pvt1b RNA suppresses Myc expression in cis. (A) Schematic
of ASO design. * denotes p53RE. (B) Isoform-specific and total Pvt1 RNA levels in WT MEFs
transfected with indicated control (CON) or Pvt1-targeting ASOs and harvested 24 h post Doxo
treatment. Data are normalized to CON and show mean ± SEM (n=3, biological replicates). (C)
Myc RNA levels in cells from (B), untreated or treated with Doxo for 24 h. Data are normalized to
CON-Doxo and show mean ± SEM (n=3, biological replicates), ***p<0.001, ns = not significant,
paired t test. (D) Quantification of Myc protein levels in cells from (B). Data are normalized to
CON-Doxo and show mean ± SEM (n=3, biological replicates), *p<0.05, ns = not significant, paired
t test. (E) Schematic of CRISPRa dRNA design. * denotes p53RE. CRISPRa cell lines generated by
Elena Martínez-Terroba. (F) Pvt1a and Pvt1b RNA levels following Pvt1a (A1) or Pvt1b (A2)
transcriptional activation in KPR cells, untreated or treated with Tam for 24 hours. Data are
normalized to control dRNA (C) and show mean ± SEM (n=5, biological replicates), ns = not
significant, *p<0.05, paired t test. Data collection and analysis performed by Elena MartínezTerroba. (G) Myc RNA levels from experiment in (F). Data collection and analysis performed by
Elena Martínez-Terroba. (H) Quantification of Myc protein levels in cells from (F). Data show
mean ± SEM (n=3, biological replicates), ns = not significant, paired t test. Protein samples
provided by Elena Martínez-Terroba. (I) Schematic of Pvt1a and Pvt1b overexpression constructs.
(J) Isoform-specific and total Pvt1 RNA levels in WT MEFs transiently overexpressing full length
Pvt1a (1a) or Pvt1b (1b). Data are normalized to empty vector (EV) and show mean ± SEM (n=3,
biological replicates), ns = not significant, paired t-test. (K) Myc RNA levels from experiment in
(J). (L) Quantification of Myc protein levels in cells from (J). Data show mean ± SEM (n=3,
biological replicates), ns = not significant, paired t test.
Contributions from E. Martínez-Terroba in (E), (F), (G) and (H) are described above.
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Figure 15. Effects of Pvt1b manipulation in cis and in trans on Myc protein levels. (A)
Representative immunoblot analysis of Myc protein levels in whole-cell extracts isolated from ASO
knockdown experiments in Fig. 4D. Hsp90 as a loading control. (B) ChIP-qPCR analysis showing
the enrichment of p53 binding at p53RE relative to input in CON- and ASO1- treated WT MEFs
following 8 h Doxo treatment. Data represented mean ± - SEM of biological replicates, ns = not
significant, paired t-test. P53 ChIP performed by Nadya Dimitrova. (C) Representative
immunoblot analysis of Myc protein levels in whole-cell extracts isolated from CRISPRa
experiments in Fig. 4H. Hsp90 as a loading control. Protein samples provided by Elena MartínezTerroba. (D) Representative immunoblot analysis of Myc protein levels in whole-cell extracts
isolated from exogenous overexpression experiments in Fig. 4L. Hsp90 as a loading control.
Contributions from N. Dimitrova in (B) and E. Martínez-Terroba in (C) are described above.
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Genetic

inhibition

of

Pvt1b

reverses

stress-induced

Myc

downregulation
To investigate the functional contribution of Pvt1b to the p53 tumor
suppressor pathway, I developed a genetic approach to specifically inhibit Pvt1b
expression by mutating the p53RE required for its expression. I targeted Cas9 to
the Pvt1b p53RE by designing a guide RNA (DRE) adjacent to the GGG protospacer
adjacent motif (PAM) site located in the central region of the p53 consensus
binding motif (Figure 16A). A non-targeting gRNA (Con) was used as a negative
control. I generated control (Con) and mutant (DRE) KPR population, MEF
population, and KPR clonal cell lines, which contain numerous or clone-specific
CRISPR/Cas9-induced mutations of the Pvt1b-associated p53RE. I confirmed
mutagenesis of the p53RE by Sanger sequencing (Figures 16A, 17A and 17B) and
ChIP showed that DRE mutagenesis reduced p53 binding by 15-fold (Figure 16B).
Importantly, by qRT-PCR, Pvt1b levels were significantly suppressed in DRE cells
compared to controls (Figures 16C, 17C, 17D and 17G), and, by smRNA-FISH, I
observed loss of Pvt1b-specific signal in Tam-treated DRE KPR cells compared to
Tam-treated controls (Figures 16D and 16E). These observations led to the
conclusion that mutagenesis of the Pvt1b-associated p53RE leads to efficient
abrogation of stress-dependent Pvt1b activation.
Next, I queried whether DRE mutagenesis led to isoform-specific inhibition.
By qRT-PCR and smRNA-FISH, I found that Pvt1a RNA levels and localization
pattern were not significantly altered in DRE KPR population and clonal cell lines
compared to controls, indicating that mutation of the p53RE led to specific
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inhibition of Pvt1b in KPR cells (Figures 16C, 16D, 17C and 17D). On the other
hand, mutagenesis of the p53RE in MEFs led to a significant reduction of Pvt1a
(Figure 17G), consistent with our findings that Pvt1a expression has a p53dependent component in this cell type (Figure 9B).
Finally, I examined by qRT-PCR and immunoblotting the effects of the DRE
mutation and the resulting loss of Pvt1b expression on Myc levels during the
cellular response to stress. In Con KPR population, KPR clonal, and MEF lines,
exposure to oncogenic or genotoxic stress led to the expected significant decrease
in Myc RNA (Figures 16F, 17E, 17F and 17H) and protein levels (Figures 16G, 16H,
17I and 17J). In contrast, exposure to stress in DRE KPR population, KPR clonal,
and MEF lines did not lead to a significant decrease in Myc RNA levels compared
to unstressed cells, consistent with the ASO data (Figures 16F, 17E, 17F and 17H).
These results provided an independent, genetic confirmation that Pvt1b regulates
Myc RNA levels downstream of p53.
Interestingly, while Myc protein levels were significantly elevated in DRE
KPR+Tam and DRE MEF+Doxo lines compared to Con KPR+Tam and Con
MEF+Doxo lines, respectively, the rescue was not complete (Figures 16G, 16H, 17I
and 17J), consistent with the possibility of Pvt1b-independent regulatory input at
the post-transcriptional level (Figure 14H).
Of note, mutagenesis of the Pvt1b-associated p53RE did not impact the
long-range chromatin interactions in the locus, consistent with chromatin
architecture not playing a significant role in p53-mediated Myc repression (Figure
18A).
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Figure 16. Genetic inhibition of Pvt1b leads to increased Myc levels. (A) Top Schematic
of p53RE mutagenesis, indicating the PAM site (red box) and Cas9 cleavage site (red arrow).
Bottom Mutant alleles, determined by Sanger sequencing. (B) ChIP-qPCR analysis of p53
enrichment at Pvt1b-associated p53RE in indicated cells and treatments. Data show mean ± SEM
(n=3, biological replicates) *p<0.05, paired t test. P53 ChIP performed by Nadya Dimitrova. (C)
Pvt1a and Pvt1b RNA levels in indicated cells and treatments. Data show mean ± SEM (n=3,
biological replicates), **p<0.01, ns = not significant, paired t test. (D, E) smRNA-FISH of Pvt1b
(ex.1b, red) co-localized with (D) total Pvt1 (ex1a-10, green) or (E) nascent Myc (intron, green) in
indicated cells and treatments. DNA, DAPI. (F) Myc RNA levels in indicated cells and treatments.
Data show mean ± SEM (n=3, biological replicates), *p<0.05, ***p<0.001, ns = not significant,
paired t test. (G) Representative image and quantification of Myc protein levels in indicated cells
and treatments. Hsp90 as a loading control. (H) Quantification of Myc protein levels from
experiments in (G). Data show mean ± SEM (n=6, biological replicates), *p<0.05, ***p<0.001,
paired t test.
Contributions from N. Dimitrova in (B) are described above.
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Figure 17. Genetic inhibition of Pvt1b rescues stress-dependent Myc repression in
KPR clonal and MEF cell lines. (A-F) Analysis of (A, C, E) clone D and (B, D, F) clone E,
isolated from KPR cells infected with a gRNA targeting the Pvt1b p53RE (ΔRE). As a control, KPR
clones expressing Con gRNA were analyzed. (A, B) Sanger sequencing of the region containing the
Pvt1b-associated p53RE. (C, D) qRT-PCR analysis of relative Pvt1a and Pvt1b RNA levels in
indicated samples. (E, F) qRT-PCR of the ratio (+Tam/-Tam) of Myc expression in indicated
clones. Bars show the mean ± SEM of n=3 biological replicates, ***p<0.001, paired t-test. (G-J)
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Analysis of MEF population cell lines, infected with a gRNA targeting the Pvt1b p53RE (ΔRE) or a
non-targeting control (Con) and harvested untreated or 8-24 h post Doxo treatment. (G) qRT-PCR
analysis of relative Pvt1a and Pvt1b RNA levels in indicated samples. Data represent mean ± SEM
of n=3 biological replicates, **p<0.01, ***p<0.001, paired t- test. (H) qRT-PCR analysis of relative
Myc RNA levels in indicated samples. Data represented as mean±SEM of n=3 biological replicates,
ns = not significant, ***p<0.001, paired t- test. (I) Immunoblot analysis of Myc protein levels in
whole-cell extracts from indicated cells. Hsp90 as a loading control. (J) Quantification of Myc
protein levels from cells in (I). Data represent mean ± SEM of n=7 biological replicates, *p<0.05,
**p<0.01, ***p<0.001, paired t- test.
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Figure 18. Effects of genetic inhibition of Pvt1b on the chromatin architecture of the
Myc-Pvt1 locus and Myc transcription. (A) 3C analysis in KPR cells, infected with Pvt1b
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p53RE-targeting (ΔRE) or Control (Con) gRNAs and treated for 24 h with Tam. Interaction
frequency relative to an anchor in the Myc promoter (A1, green arrow) is plotted from three
technical replicates from a representative experiment of two biological replicates, as described in
Figure S2. (B) MA plots from TT-TimeLapse-seq data depicting log2 fold change in nascent RNA
(n >11,000 for each condition) in (A) untreated or (B) Tam-treated KPR cells. Myc and total Pvt1
are indicated (purple dots). Processing of samples for TT-TimeLapse-seq and data analysis
performed by Jeremy Schofield, Josh Zimmer and Matt Simon.
Contributions from J. Schofield, J. Zimmer, and M. Simon in (B) are described above.
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By analyzing the effects of the DRE mutation on gene expression in total
RNA from untreated and Doxo-treated DRE and Con MEFs in collaboration with
Nima Hooshdaran and Jesse Zamudio, I confirmed that Myc is a target of Pvt1b
regulation in response to stress (Figure 19A). Next, to test whether Pvt1b acted at
the transcriptional or post-transcriptional level, my collaborators Josh Zimmer,
Jeremy Schofield and Matt Simon sequenced nascent RNA from untreated and
Tam-treated DRE and Con KPR cells (Schofield et al., 2018). They found that
nascent Myc transcripts were significantly upregulated in DRE+Tam compared to
Con+Tam KPR cells, indicative of transcriptional regulation (Figures 19B and
19C). These data revealed that Pvt1b production promotes transcriptional
suppression of Myc.
Next, Hooshdaran and Zamudio queried how the changes in Myc RNA
levels affected the Myc transcriptional program by examining the consequence of
Pvt1b loss on a curated set of 196 Myc target genes (Gene Set Enrichment Analysis,
HALLMARK_MYC_TARGETS_V1 (Liberzon et al., 2015)). They plotted the
cumulative frequency distribution of the fold change of Myc target genes in DRE
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cells relative to Con cells in the presence of stress (logFC [DRE/Con+stress]).
Compared to a randomly generated set of control genes expressed at comparable
levels, they found a significant increase in the levels of Myc targets in MEFs and
KPR cells (Figures 19D and 19E). They concluded that Myc derepression by DRE
mutagenesis leads to a small but significant increase in the transcriptional activity
of Myc.
Considering Myc target genes include factors that promote cellular growth,
I compared the proliferation of mutant cells compared to controls. It has
previously been shown that Tam-mediated p53 restoration in KPR cells leads to a
permanent cell cycle arrest, called senescence (Feldser et al., 2010). While loss of
Pvt1b expression did not overcome senescence, it led to a significant increase in
cellular proliferation and colony formation compared to control cells (Figures 19F
and 19G). As a control, the DRE mutation did not impact Myc levels and
proliferation in p53-deficient cells, ruling out off target effects (Figures 18B and
19F). These data suggested that Pvt1b mediates specific aspects of p53 function to
suppress the proliferative potential of cells in vitro.
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Figure 19. Pvt1b suppresses Myc transcription and proliferative function. (A, B)
Butterfly plot depicting the fold change (logFC) in gene expression of indicated samples relative to
statistical significance (-log10(p-value), MEF: n=3; KPR: n=2, biological replicates). Gene
expression profiling was performed by (A) RNAseq of polyA-selected RNA isolated from Con or
ΔRE gRNA-expressing MEFs, untreated or treated with Doxo for 24 hours or (B) TimeLapse-seq of
ribosomal cDNA-depleted s4U-labeled RNA isolated from Con or ΔRE gRNA-expressing KPR cells,
untreated or treated with Tam for 16 hours. Total Pvt1 (blue) and Myc (red) are labeled. Library
preparation performed by Nadya Dimitrova. Data analysis performed by Nima Hooshdaran and
Jesse Zamudio. (C) Top Genome browser tracks depicting the Myc-Pvt1 locus and Bottom Detail
of the Myc locus from TT-TimeLapse-seq. Processing of samples for TT-TimeLapse-seq and data
analysis performed by Jeremy Schofield, Josh Zimmer and Matt Simon. (D, E) Cumulative
frequency distribution plot of differential expression for a set of curated Myc target genes and a
matched set of control genes from analyses in (A, B). Library preparation performed by Nadya
Dimitrova. Data analysis performed by Nima Hooshdaran and Jesse Zamudio. (F) Population
doublings in Con or ΔRE gRNA-expressing KPR cells, untreated or treated with Tam over indicated
timecourse. Data show mean ± SEM (n=3, biological replicates), **p<0.01, unpaired t test. (G)
Representative images of colony formation assay of Tam-treated KPR cells, infected with Con or
ΔRE gRNAs. Numbers show mean ± SEM (n=3, biological replicates), **p<0.01, unpaired t test.

Contributions from N. Hooshdaran and J. Zamudio in (A), (B), (D) and (E), and from J. Schofield,
J. Zimmer, and M. Simon in (C) are described above.
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Tumor-specific inhibition of Pvt1b promotes tumor growth in vivo
Inactivation of p53 in the K-rasLSL-G12D/+(K) autochthonous mouse model of
lung cancer has been shown to increase tumor burden and promote tumor
progression from benign to aggressive disease (DuPage et al., 2009; Jackson et al.,
2005; Jackson et al., 2001). To elucidate whether Pvt1b mediated some aspects of
p53 function, Nadya Dimitrova and Clara Liao performed tumor-specific
mutagenesis of the Pvt1b-associated p53RE (Figure 20A). Dimitrova built a
bifunctional lentiviral construct (U6-gRNA PGK-Cre, UGPC) for co-expression of
the DRE gRNA (UGPC-DRE) and Cre recombinase, required for Cas9 targeting and
tumor initiation, respectively (DuPage et al., 2009). Expression of Cas9 in a tumorspecific manner was achieved by crossing the K model to Rosa26-Cas9LSL (C) mice
to generate KC animals (Platt et al., 2014). As a negative control, they used a nontargeting control (UGPC-Con). As a positive control, they used a previously
described gRNA that targets the open reading frame of p53 (UGPC-p53KO) (Xue
et al., 2014). Sanger sequencing confirmed successful mutagenesis of the Pvt1bassociated p53RE in UGPC-DRE-infected animals (Figure 20B).
They next examined hematoxylin and eosin (H&E) sections of lungs from
mice infected with UGPC-Con, -p53KO and -DRE virus and sacrificed at 16 weeks
post tumor initiation. In the K model, progression of atypical adenomatous
hyperplasia (AAH, grade 1) and lung adenoma (grade 2) to adenocarcinoma (grade
3) and invasive adenocarcinoma (grade 4) is promoted by loss of p53 function
(Jackson et al., 2005). Indeed, histopathological analysis revealed that all of the
tumors (53/53 tumors) in UGPC-Con-infected animals manifested grade 1 features
(Figures 20C and 20D). In contrast, 70% of UGPC-p53KO-expressing tumors
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(39/56 tumors) were marked by atypical nuclei, desmoplasia, and transition to a
poorly differentiated phenotype and were classified as grade 2 or 3 (Figures 20C
and 20D) (DuPage et al., 2009). Based on these data, they estimated that a large
portion of the tumors underwent successful CRISPR/Cas9 editing in vivo. Editing
of the Pvt1b-associated p53RE resulted in tumors with histopathological features
comparable to controls and only 3% of tumors (2/67 tumors) in UGPC-DREinfected animals were classified grade 2 or 3, suggesting that tumor progression
was not accelerated by Pvt1b inhibition (Figures 20C and 20D). They concluded
that Pvt1b does not likely mediate the ability of p53 to restrain tumor progression
from benign hyperplasia to advanced disease.
On the other hand, quantification of the tumor area relative to the total lung
area revealed that the tumor burden in UGPC-DRE-infected animals (21±4%) was
significantly increased compared to the burden of control mice (12±2%)
(p=0.0040, Figure 20E). Notably, the tumor burden in p53RE-edited mice was
comparable to the tumor burden in UGPC-p53KO-infected mice (26±3%) (Figure
20E). These findings suggested that Pvt1b mediated in large part the growthrestrictive functions downstream of p53, particularly during the pre-malignant
stages of the disease. As a control for potential off-target effects of Cas9 expression
and CRISPR editing, Ephrath Tesfaye used two independent sgRNAs (sg1 and sg2)
to target the p53RE in intron 1 of an unrelated lncRNA, Gm26542, for which we
had evidence for direct p53 regulation (Figures 21A, 21B and 21C). In contrast to
Pvt1b, inhibition of Gm26542 did not affect proliferation in Tam-treated KPR cells
in vitro (Figure 21D) and did not significantly alter the tumor burden in KC mice
in vivo (Figure 21E).
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The increase in tumor burden in UGPC-DRE-infected animals compared to
UGPC-Con mice was not due to decreased apoptosis as there was no evidence for
Cleaved Caspase 3 (CC3) immunohistochemistry (IHC) staining in lung sections.
Instead, the increase in tumor burden could be attributed to enhanced
proliferation, as manifested by the significantly greater number of phosphorylated
histone H3 (pHH3)-positive mitotic cells in Pvt1b-deficient tumors from UGPCDRE-infected animals compared to tumors from UGPC-Con-infected mice
(p=0.0026, Figures 20F and 20G).
Finally, to investigate whether Pvt1b acted downstream or independent of
p53, Dimitrova and Liao performed an epistasis experiment. They generated
cohorts of either KC or K-rasLSL-G12D/+; p53FL/FL; Rosa26-Cas9LSL/LSL (KPC)
animals, which have genetically engineered Cre-inducible loss-of-function alleles
of p53. They analyzed tumor burden at 12 weeks post tumor initiation with UGPCCon or -DRE virus. Consistent with their findings above, they observed a significant
increase in the tumor burden of UGPC-DRE-infected mice compared to UGPCCon-infected KC animals (p=0.0035, Figure 20H). In contrast, they found that the
tumor burden was not significantly different between UGPC-DRE and UGPC-Coninfected KPC animals (Figure 20H). Moreover, there was no statistically significant
difference between the tumor burden of KC mice infected with UGPC-DRE and
KPC mice infected with UGPC-Con (Figure 20H). Altogether, these results
revealed that Pvt1b and p53 enhance the expansion of pre-malignant tumors
through a common pathway.
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Figure 20. Tumor-specific editing in a lung cancer model reveals a role for Pvt1b in
suppressing tumor growth, but not progression. (A) Schematic of tumor-specific gene
editing in KC and KPC lung cancer mouse models. (B) Mutant ΔRE alleles, determined by Sanger
sequencing of bulk DNA isolated from tumor-bearing lungs. (C) H&E staining of lung sections of
KC mice infected with indicated gRNAs and analyzed at 16 weeks post tumor initiation (pti). Scale
bars as indicated. (D) Quantification of tumor grade in mice described in (C). The number of
tumors analyzed from n=5 mice is indicated for each group. (E) Quantification of tumor burden in
mice described in (C). Dots represent individual animals and bargraph shows mean ± SEM (n=7
mice), ***p<0.001, **p<0.01, ns = not significant, unpaired t test. (F) Representative images of
immunohistochemistry for the mitotic marker pHH3 in lung sections from (C). Scale bars as
indicated. (G) Quantification of images in (F). Data show mean ± SEM of n=13-15 tumors from
n=5 mice, **p<0.01, Mann-Whitney test. (H) Quantification of tumor burden in KC and KPC mice
infected with indicated gRNAs and analyzed at 12 weeks pti. Dots represent individual animals and
bargraph shows mean ± SEM (KC: n=6 mice, KPC: n=3 mice), *p<0.05, ns=not significant,
unpaired t-test. All in vivo experiments and data analysis performed by Nadya Dimitrova and Clara
Liao.
Contributions from N. Dimitrova and C. Liao in (A-H) are described above.
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Figure 21. Mutagenesis of Gm26542-associated p53RE does not affect proliferation
in vitro, tumor growth in vivo. (A) Schematic of the mouse Gm26542 lncRNA locus depicting
the sequence of the p53RE located in intron 1, and the PAM sites (PAM #1 and PAM #2) utilized by
guide RNAs sg1 and sg2, respectively. Schematic provided by Ephrath Tesfaye. (B) Sanger
sequencing of the region containing the Gm26542-associated p53RE in KPR cells infected with sg1
or sg2. Data collection and analysis performed by Ephrath Tesfaye. (C) qRT-PCR analysis of
relative RNA levels of the Gm26542 lncRNA in Con-, sg1- and sg2- infected KPR cell populations
showing the p53-dependent induction of Gm26542 at 24 hours post Tam treatment and the
abrogation of this induction by p53RE mutagenesis. Data collection and analysis performed by
Ephrath Tesfaye. (D) Growth analysis showing population doublings in Con, sg1, or sg2 gRNAexpressing KPR cells, untreated or treated with Tam. Data show mean ± SEM of n=3 biological
replicates, ns= not significant, unpaired t-test. Cell lines provided by Ephrath Tesfaye. (E)
Quantification of tumor burden as tumor area relative to total lung area in KC mice infected with
indicated gRNAs and analyzed at 16 weeks post tumor initiation (pti) as described in Fig. 20. Data
show tumor burden of individual mice and mean±SD, ns = not significant, unpaired t-test. In vivo
experiments and data analysis performed by Nadya Dimitrova.
Contributions from E. Tesfaye in (A-D) and N. Dimitrova in (E) are described above.
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Discussion
This study provides new mechanistic insights into the function of the
lncRNA Pvt1 in the context of the p53 tumor suppressor pathway. I identify a
conserved isoform of Pvt1, Pvt1b, which is directly activated by p53 in response to
genotoxic and oncogenic stress. My data reveal that production of Pvt1b functions
as a p53-dependent mechanism that is wired into the Myc-Pvt1 locus to directly
and swiftly down-regulate Myc transcription during stress (Figure 22). This
appears to be the primary mechanism underlying stress-induced Myc reduction at
the transcriptional level, although these data are also consistent with Pvt1bindependent regulation at the post-transcriptional level.
Functionally, I observed that Pvt1b activation leads to restricted Myc levels
and transcriptional activity and suppressed cellular proliferation. Furthermore,
use of an autochthonous mouse model of lung cancer demonstrated that Pvt1b acts
downstream of p53 during the early stages of cancer development to limit tumor
growth. Strikingly, in this respect, epistasis analysis suggested that Pvt1b acts as
the primary mediator of p53. On the other hand, I found that Pvt1b is not involved
in other aspects of p53 function, such as promoting senescence or limiting tumor
progression to advanced disease. Altogether, these analyses define the specific
contributions of Pvt1b downstream of p53, pointing to growth limiting and tumor
suppressive functions of Pvt1b in the context of cancer. These conclusions contrast
the common classification of Pvt1 as an oncogene, which is based on extensive
correlative evidence linking Pvt1 aberrations with increased invasive capacities of
cancer cells and poor patient survival (Guan et al., 2007; Guo et al., 2018; Kong et
al., 2015; Riquelme et al., 2014; Tseng et al., 2014; Zeng et al., 2017; Zhang et al.,
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2019; Zhao et al., 2018; Zheng et al., 2016; Zhu et al., 2017). On the other hand,
these data are consistent with recent reports of tumor suppressive elements in the
Pvt1 locus (Barsotti et al., 2012; Cho et al., 2018; Porter et al., 2017).
My findings shed light on a subset of genomic aberrations reported across a
variety of malignancies, which represent translocations between the first exon of
Pvt1a fused to various 3’ gene partners (Iwakawa et al., 2013; Kim et al., 2014a;
Nagoshi et al., 2012; Northcott et al., 2012). Such rearrangements would be
expected to separate the Myc locus from Pvt1b, providing cells with a proliferative
advantage due to the inability of p53 to suppress Myc levels during early stages of
tumor development. On the other hand, the proposed tumor suppressive role of
Pvt1b is at odds with the common amplification of the Pvt1 locus in cancer (Guan
et al., 2007; Riquelme et al., 2014). I propose that amplification of other elements,
such as the Pvt1a transcript or Pvt1-associated Myc enhancers may be the drivers
of oncogenic activities in this setting, as proposed by others (Cho et al., 2018; Tseng
et al., 2014). Alternatively, these alterations might be occurring following p53
inactivation, which would preclude Pvt1b expression.
Mechanistically, I provide direct evidence for a role of Pvt1b RNA
production in Myc regulation. Antisense-mediated depletion experiments reveal
that Pvt1b is required for stress-induced Myc inhibition, whereas epigenetic
activation from the endogenous locus shows that Pvt1b is sufficient to repress Myc
in the absence of stress or a functional p53 pathway. While ASO-based knockdown
and CRISPR-guided epigenetic experiments cannot formally differentiate between
the mature Pvt1b molecules or the production of nascent Pvt1b transcripts as the
mediator of Myc repression, these data support an RNA-based mechanism.
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This conclusion differs from the recent finding that the Pvt1a promoter
suppresses Myc levels in an RNA-independent manner (Cho et al., 2018). The
discrepancy can potentially be explained by the previous focus on the constitutive
Pvt1 isoform, by the use of p53-deficient cell lines, or by the use of ineffective ASOs
(Cho et al., 2018). Alternatively, I propose that the two tumor suppressive activities
in the Pvt1 locus, one p53- and RNA-dependent and the other p53- and RNAindependent, may co-exist and operate in distinct cellular contexts. My findings
also do not contradict studies that have implicated Pvt1a or circular Pvt1 isoforms
as oncogenes via diverse mechanisms, such as oncoprotein stabilization or
competition for miRNA binding (Tseng et al., 2014; Xu et al., 2017; Zhao et al.,
2018). Indeed, the complexity of the Pvt1 locus highlights the need for further
rigorous dissection of the various alternative start site- and splice-variants.
It is important to note that Pvt1b mediates a repressive event downstream
of p53, which is a well-characterized transcriptional activator. Considered in the
context of the previously characterized p53-dependent cis-regulatory lincRNA-p21
(Dimitrova et al., 2014), it appears that transcription factors use lncRNAs to either
enhance their inherent activity or to allow reverse regulation within local circuits.
LncRNAs which accumulate at their sites of transcription, such as Pvt1b, are poised
to act as modulators of gene expression in a locus-specific manner. Indeed, Pvt1b
activation leads to Myc repression within four hours of exposure to genotoxic
stress, which is comparable to the kinetics of activation of p53 target genes. I
propose that production and/or chromatin accumulation of p53-induced Pvt1b
transcripts act in cis during the cellular response to stress to rapidly influence the
transcriptional environment at the Myc promoter. Thus, locus-specific
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transcriptional regulation by lncRNAs may provide additional tools within a
transcriptional program that allow dynamic and swift responses to cellular
challenges. As the mechanisms of more p53-dependent lncRNAs are revealed, we
can gain new insight into how regulatory RNAs contribute to the cellular responses
to stress mediated by p53. Although future work will determine the functional
elements of Pvt1b transcripts, the widespread importance of this regulatory circuit
in normal and transformed cells in vitro and in vivo suggests the possibility of
controlling Myc levels in cancer by modulating Pvt1b activity.
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Figure 22. LncRNA Pvt1b mediates crosstalk between the Myc and p53
transcriptional networks. Top Under conditions of cellular stress, p53 (green) directly activates
lncRNA Pvt1b (orange) to indirectly repress Myc (red), inhibiting cellular proliferation and tumor
growth. Bottom p53-mediated induction of Pvt1b following cellular stress leads to local repression
of Myc transcription, with smRNA-FISH inset showing Pvt1b accumulation at the Myc-Pvt1 locus.
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Chapter 3:
Investigating the functional elements of the Pvt1b transcript

Introduction
The elements of lncRNAs required to perform specific functions can
comprise a range of characteristics encoded in the transcripts themselves,
including sequence and/or structural motifs (see Chapter 1). The sequence of a
lncRNA may enable its association with specific RNA binding proteins (RBPs) or
may fold into unique hairpins or more complex structures that otherwise confer
function (reviewed in (Zampetaki et al., 2018)). Given that Pvt1b differs from
Pvt1a primarily based on whether transcript initiation is from exon 1b or exon 1a,
respectively, I reasoned that the function of Pvt1b may depend explicitly on the
exon 1b sequence or any structures therein. In this chapter, I investigate the
importance of Pvt1 exon 1b for p53-dependent Myc repression by attempting to
either alter Pvt1b-specific sequences or disrupt their production. In doing so, I
provide insight into the potential mechanism by which Pvt1b downregulates Myc
under conditions of cellular stress.

Results
Investigating the function of the Pvt1 exon 1b sequence in p53dependent Myc repression
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To determine if Pvt1 exon 1b harbors any sequence and/or structural motifs
required for Pvt1b function, I developed a genetic approach to test the functionality
of regions within exon 1b whose disruption could rescue p53-induced Myc
repression. To accomplish this, I employed a strategy to generate numerous
CRISPR/Cas9-induced mutations throughout the 191 bp exon 1b sequence (Figure
23A). After analyzing available PAM sites, I selected 11 high specificity guide RNAs,
excluding those with low specificity scores (Concordet and Haeussler, 2018) and
those targeting similar areas of the exon 1b sequence (Figure 23B). I generated 11
mutant (gALT1-11) KPR population and PR MEF population cell lines (refer to
Chapter 2, Figure 8 for descriptions of KPR and PR MEF cell lines), each of which
contain heterogeneous mutations in the guide RNA-specific region targeted by
Cas9 (Figure 23B). A guide RNA targeting dTomato (gTOM) was used as a negative
control, while the guide RNA targeting the Pvt1b-associated p53RE (gRE, see
Chapter 2, Figure 16) was used as a positive control due to its previously
documented ability to rescue stress-induced Myc downregulation (see Chapter 2,
Figure 16). I confirmed mutagenesis by each guide RNA (gALT1-11) by Sanger
sequencing and Tracking of Indels by DEcomposition (TIDE) analysis (Brinkman
et al., 2014), observing estimated mutagenesis efficiencies ranging from 37.2 –
94.4% (Figure 23C). Importantly, by qRT-PCR, Pvt1b levels were significantly
suppressed in gRE cells compared to controls (Figures 23C and 23E), consistent
with previous results (see Chapter 2, Figure 16). These observations led us to
conclude that I had successfully mutagenized sequences in Pvt1 exon 1b.
Infection with gALT1-11 resulted in fluctuations in Pvt1b expression levels
in both KPR and PR MEF cell lines, variations which appeared guide RNA100

independent, with some guide RNAs yielding differing Pvt1b levels depending on
cell line (Figures 23C and 23E). Considering that the qRT-PCR Pvt1b forward
primer overlaps the exon 1b regions targeted by gALT8 and gALT9, I anticipated
Pvt1b levels in these cell lines might be unusually low, although any
underestimation of Pvt1b expression appeared to be minimal (Figures 23C and
23E). Importantly, any reductions in Pvt1b expression resulting from infection
with gALT1-11 did not approach the extent of Pvt1b inhibition observed following
infection with gRE (Figures 23C and 23E).
Finally, I used qRT-PCR to assess whether mutations within the Pvt1 exon
1b sequence had any effect on Myc levels during the cellular response to stress. In
negative control KPR population and PR MEF population cell lines infected with
gTOM, exposure to oncogenic or genotoxic stress led to an expected decrease in
Myc RNA (Figures 23D and 23F). Importantly, positive control KPR population
and PR MEF population cell lines infected with gRE experienced a rescue in stressdependent Myc downregulation (Figures 23D and 23F), consistent with previous
findings (see Chapter 2, Figure 16). Next, I found that exposure to stress in
gALT1-11 KPR population and PR MEF population cell lines did not result in any
notable increases in Myc levels approaching the rescue observed in gRE cell lines.
Taken together, these results suggested mutagenesis of sequences throughout Pvt1
exon 1b was insufficient to rescue p53-dependent Myc repression.
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Figure 23. Probing the role of the Pvt1 ex1b sequence in p53-dependent Myc
repression. (A) Schematic of the 5’ end of the Pvt1 locus showing transcript initiation sites for
Pvt1a (blue) and Pvt1b (orange) at exon 1a and exon 1b, respectively. Guide RNAs to mutate the
exon 1b sequence (gALT1-11) shown in red, with red 5’ ends of Pvt1b transcripts indicating
mutagenesis. Location of Pvt1b-associated p53RE indicated by green asterisk. (B) Left, Pvt1 exon
1b sequence, with PAM sites (red) utilized by guide RNAs gALT1-11 indicated sequentially. Right,
percent mutagenesis efficiency yielded by each guide RNA (gRNA) as estimated by Tracking of
Indels by DEcomposition (TIDE) analysis in KPR cells as described in (Brinkman et al., 2014). N/A
= data not available. (C) Pvt1b RNA levels in KPR cells infected with indicated guide RNAs,
untreated or treated with tamoxifen (TAM) for 24 h. Data show mean ± SEM (n=3, technical
replicates, confirmed in independent biological replicates). (D) Myc RNA levels in same cells as
(C). Data are normalized to untreated within each cell line and show mean ± SEM (n=2, biological
replicates). (E) Pvt1b RNA levels in PR MEFs infected with indicated guide RNAs, untreated or
treated with tamoxifen (TAM) for 48 h and doxorubicin (DOXO) for 24 h. Data show mean ± SEM
(n=3, technical replicates, confirmed in independent biological replicates). (F) Myc RNA levels in
the same cells as (E). Data are normalized to untreated within each cell line and show mean ± SEM
(n=2, biological replicates).
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Investigating the function of spliced Pvt1b in p53-dependent Myc
repression
To determine if the spliced Pvt1b transcript is required for p53-dependent
Myc repression, I developed a genetic approach to abrogate splicing between Pvt1
exon 1b and its downstream exon 2 and thereby decrease processing of nascent
Pvt1b transcripts. I designed a guide RNA (gdeltaSS) to target Cas9 close to the 3’
end of Pvt1 exon 1b (Figure 24A) with the goal of mutagenizing the AG|GU
sequence spanning the exon|intron junction, which comprises a key sequence
element of the splice donor site (Mount, 1982). I generated KPR population and
PR MEF population cell lines (refer to Chapter 2, Figure 8 for descriptions of KPR
and PR MEF cell lines) containing numerous mutations at the 3’ end of Pvt1 exon
1b. As above, a guide RNA targeting dTomato (gTOM) was used as a negative
control, while the guide RNA targeting the Pvt1b-associated p53RE (gRE, see
Chapter 2, Figure 16) was used as a positive control due to its previously
documented ability to rescue stress-induced Myc downregulation. I confirmed
mutagenesis of the exon|intron junction by Sanger sequencing and Tracking of
Indels by DEcomposition (TIDE) analysis (Brinkman et al., 2014) in KPR cells and
PR MEFs, observing 92.8% and 90.5% estimated efficiencies, respectively (Figure
24B and Figure 24C). However, I observed low frequencies of deletions larger than
5 nucleotides (Figure 24B and Figure 24C), and given the location of the Cas9 cut
site 4-5 nucleotides away from the exon|intron junction, it is possible that a low
percentage of mutations directly affected the AG|GU splice site.
To determine the efficacy of this approach in inhibiting the production of
spliced Pvt1b, I analyzed the expression of Pvt1 transcripts in gdeltaSS-infected
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population cell lines. While exon 1b 3’ end mutagenesis did not affect Pvt1a
expression, it resulted in a significant 34% decrease in spliced Pvt1b in tamoxifentreated KPR cells relative to control (Figure 24D) and a similar, albeit
nonsignificant, decrease in spliced Pvt1b in PR MEFs treated with tamoxifen and
doxorubicin (Figure 24F). Importantly, infection with gRE inhibited Pvt1b
expression in both KPR cells (Figure 24D) and PR MEFs (Figure 24F), consistent
with previous results (see Chapter 2, Figure 16). To determine if the observed
reduction in spliced Pvt1b was due to abrogated splicing and not simply decreased
expression, I analyzed nascent Pvt1b RNA levels using a qRT-PCR primer set
spanning the Pvt1 exon 1b|intron junction. Concurrent with a decrease in spliced
Pvt1b, gdeltaSS-infected KPR and PR MEF cells exhibited increases in nascent
Pvt1b compared to controls, suggesting a defect in pre-mRNA processing (Figures
24D and 24F). Collectively, these data suggested partial inhibition of the splicing
event linking Pvt1 exon 1b and exon 2.
To assess whether the processing of nascent Pvt1b into spliced Pvt1b, and
the resulting Pvt1 ex 1b – exon 2 sequence is required for stress-dependent Myc
repression, I analyzed Myc RNA levels in response to oncogenic or genotoxic
stress. In negative control KPR population and PR MEF population cell lines
infected with gTOM, exposure to oncogenic or genotoxic stress led to an expected
decrease in Myc RNA (Figures 24E and 24G). Importantly, positive control KPR
population and PR MEF population cell lines infected with gRE experienced a
rescue in stress-dependent Myc downregulation (Figures 24E and 24G), consistent
with previous findings (see Chapter 2, Figure 16). However, mutagenesis of the
3’ end of exon 1b did not increase Myc levels following cellular stress to the extent
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observed in gRE-infected cells (Figures 24E and 24G). Given that Pvt1b-associated
p53RE mutagenesis resulted in near total loss of Pvt1b expression and yielded a
~30% rescue of Myc levels, I would expect to observe a fraction of that rescue in
Myc expression with a loss of spliced Pvt1b reaching only as high as 34% in
gdeltaSS cells (Figures 24D and 24F). As such, these data and the importance of
spliced Pvt1b in p53-dependent Myc repression are largely inconclusive, but could
be further resolved with the isolation of gdeltaSS clones with biallelic
modifications.
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Figure 24. Probing the role of spliced Pvt1b in p53-dependent Myc repression. (A)
Schematic of the 5’ end of the Pvt1b transcript, indicating splicing between exon 1b and exon 2 and
its disruption due to CRISPR-induced mutagenesis of the splice site at the 3’ end of exon 1b. Region
targeted by guide RNA (gdeltaSS) shown in red. (B, C) Mutagenesis efficiency of gdeltaSS
estimated by Tracking of Indels by DEcomposition (TIDE) analysis in KPR cells (B) and PR MEFs
(C) as described in (Brinkman et al., 2014). (D) Pvt1a, spliced Pvt1b, and nascent Pvt1b RNA levels
in KPR cells infected with indicated guide RNAs, untreated or treated with tamoxifen (TAM) for 24
h. Data show mean ± SEM (n=3, biological replicates); ns = not significant; **p < 0.01, ***p < 0.001
and ****p < 0.0001, unpaired t test. (E) Myc RNA levels from cells in (D). Data show mean ± SEM
(n=3, biological replicates); ns = not significant; ***p < 0.001, unpaired t test. (F) Pvt1a, spliced
Pvt1b, and nascent Pvt1b RNA levels in PR MEFs infected with indicated guide RNAs, untreated or
treated with tamoxifen (TAM) for 48 h and doxorubicin (DOXO) for 24 h. Data show mean ± SEM
(n=3, biological replicates); ns = not significant; **p < 0.01, unpaired t test. (G) Myc RNA levels
from cells in (F). Data show mean ± SEM (n=3, biological replicates); ns = not significant; unpaired
t test.
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Discussion
The research presented in this chapter attempts to address whether Pvt1b
sequence and/or structural specificity is necessary for its stress-dependent
function in repressing Myc expression. Neither mutagenesis of sequences
throughout Pvt1 exon 1b, nor abrogation of Pvt1b splicing was sufficient to rescue
p53-induced Myc downregulation to the extent observed following Pvt1b
inhibition via mutagenesis of the p53 binding site required for its expression.
While the experiments outlined in this chapter were ultimately unsuccessful in
identifying discrete elements of the Pvt1b transcript required for its function, these
data do not conclusively disprove the existence of such sequence and/or structural
motifs.
The analysis of cell populations with mutation heterogeneity, while useful
in rapidly assessing the broad importance of numerous sequence elements at once,
may not be sensitive enough to pinpoint essential sequences. There are several
possible outcomes of such cell population-based mutagenesis experiments that
may muddle our interpretation: (1) mutagenesis efficiency is not high enough or,
depending on the types of indels produced by a particular guide RNA, yields
mutations that preserve rather than disrupt critical motifs, (2) the guide RNAs
chosen do not target close enough to key sequences to effectively alter them, and
(3) any useful mutations that might inhibit RNA function in isolation are easily
obscured by other, less impactful, mutations. In short, it is possible that these
approaches are not precise enough to yield interpretable results. For example, the
decrease in spliced Pvt1b observed in gdeltaSS KPR and PR cell lines is
significantly less than the decrease in Pvt1b levels following p53RE mutagenesis
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and may not have been sufficient to rescue Myc levels. Therefore, it is possible a
more robust abrogation of splicing would nullify Myc repression and recapitulate
the results observed with Pvt1b transcriptional inhibition. One method for
overcoming some of these pitfalls involves the isolation of clonal cell lines and
comprehensive analysis of individual mutations. This approach can be fruitful but
may result in clone-specific behaviors unrelated to the mutation in question.
Choosing the appropriate cell model in which to perform such cell
population-based mutagenesis experiments poses an additional challenge. KPR
cells, while a robust model for p53-dependent Myc repression under conditions of
oncogenic stress, harbor multiple copies of the Myc-Pvt1 locus in the form of
extrachromosomal DNA circles (see Chapter 2, Figure 13). This leads to a
landscape of numerous distinct Cas9-induced Pvt1 mutations existing in a single
cell, the effects of which on the expression of individual Myc alleles may vary and
produce an average that does not reflect complex heterogeneity between loci.
However, my experiments in PR MEFs, which do not exhibit the same extensive
Myc-Pvt1 amplifications, support and provide an independent confirmation of our
data in KPR cells. In summary, while this set of genetic queries did not successfully
discover a sequence-based and/or structural mechanism for Pvt1b function, they
do not preclude the existence of such a mechanism and alternative approaches are
needed to better understand the functional elements of the Pvt1b transcript.
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Chapter 4:
Investigating the mechanism of Pvt1b-mediated Myc repression

Introduction
Previous studies have investigated the role of histone deacetylases (HDACs)
in p53-dependent Myc repression (Harms and Chen, 2007; Ho et al., 2005).
Notably, Ho et al. observed decreased histone H4 acetylation marks at the Myc
promoter following p53 activation and further posited a mechanism for p53induced Myc downregulation involving mSin3a, a corepressor that associates with
HDAC1 (Ho et al., 2005). However, the function of HDACs in regulating Myc
expression is unclear, with different studies investigating the effect of HDAC
inhibitors on Myc levels reporting conflicting results (Majumdar et al., 2012;
Sasakawa et al., 2003; Xu et al., 2005; Yu et al., 2020).
The function of lncRNAs in gene regulation via epigenetic modification is
well-documented (reviewed in (Statello et al., 2020)). A significant example of an
HDAC-dependent mechanism of lncRNA-mediated gene regulation is the function
of XIST in cis-repression of the X-chromosome via SHARP/HDAC3 (McHugh et
al., 2015). One of a family of transcriptional repressors, SHARP (also known as
Spen) interacts with SMRT (Ariyoshi and Schwabe, 2003), a component of the
nuclear corepressor complex with a known role in HDAC3-mediated chromatin
deacetylation (You et al., 2013). A direct interaction between XIST and SHARP is
required to recruit SMRT and HDAC3, enabling transcriptional silencing of the X-
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chromosome via histone deacetylation and RNA Pol II exclusion (Chu et al., 2015;
McHugh et al., 2015; Moindrot et al., 2015; Monfort et al., 2015). Recent evidence
from the Guttman (unpublished) and Chang (Carter et al., 2020) labs notes an
association between SHARP/Spen and exon 2 of human and mouse Pvt1. In
preliminary RAP-MS experiments performed by Giuseppe Militello in our lab, we
also detected evidence for SHARP/Spen binding the Pvt1 RNA in KPR cells (data
not shown). This may suggest a mechanism of cis-repression by Pvt1b similar to
that employed by XIST during X-chromosome inactivation (XCI), involving
histone deacetylation via HDAC3 recruited by SHARP/Spen (McHugh et al., 2015).
In this chapter, I present preliminary evidence supporting a role for Pvt1b in stressdependent Myc repression via histone deacetylation at the Myc promoter.

Results
Histone deacetylation may be required for stress-dependent Myc
repression
To confirm previous findings (Ho et al., 2005) and determine whether
histone acetylation marks at the Myc promoter change in response to cellular
stress, I performed H3K27ac ChIP in KPR cells following treatment with or without
tamoxifen. Concurrent with a decrease in Myc expression, I observed
commensurate decreases in H3K27ac marks upstream of the Myc transcriptional
start site following exposure to oncogenic stress (Figure 25A). To gain insight into
whether Pvt1b is required for histone deacetylation at the Myc promoter following
p53 activation, I performed H3K27ac ChIP in KPR cells infected with gRE to
mutagenize the Pvt1b-associated p53RE and inhibit Pvt1b expression (see
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Chapter 2). In contrast to the results observed in wildtype cells (Figure 25A),
H3K27ac marks did not decrease in response to oncogenic stress in cells in which
Pvt1b expression was inhibited (Figure 25B). These results, while preliminary and
in need of repetition, suggest a potential HDAC-based mechanism underpinning
Pvt1b function.
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Figure 25. Histone deacetylation may be required for stress-dependent Myc
repression. (A) Left, Myc RNA levels in KPR cells, untreated or treated with tamoxifen (TAM)
for 24 h. Right, ChIP-qPCR analysis of H3K27ac enrichment at the Myc promoter in the same cells.
Data show mean ± SEM (n=3, technical replicates of one biological replicate); ns = not significant;
*p < 0.05, paired t test. (B) ChIP-qPCR analysis of H3K27ac enrichment at the Myc promoter in
KPR cells infected with a guide RNA targeting the Pvt1b-associated p53RE (gRE), untreated or
treated with tamoxifen (TAM) for 24 h. Data show mean ± SEM (n=3, technical replicates of one
biological replicate); ns = not significant; paired t test. (C,D) qRT-PCR of the ratio (+stress/stress) of Pvt1b and Myc expression levels in KPR cells (C) and PR MEFs (D) treated with or without
the HDAC3 inhibitor RGFP966 for 6 h (C) or 4 h (D). KPR cells were treated with 24 h tamoxifen
(C) and PR MEFs were treated with 48 h tamoxifen and 24 h doxorubicin (D) to induce cellular
stress. Data in (C) show mean ± SEM (n=3, technical replicates of one biological replicate); *p <
0.05, paired t test. Data in (D) show mean ± SEM (n=3, biological replicates); ns = not significant;
paired t test. NT = no treatment. (E,F) qRT-PCR of the ratio (+stress/-stress) of Pvt1b and Myc
expression levels in KPR cells (E) and PR MEFs (F) treated with or without the pan-HDAC
inhibitors TSA or SAHA for 4 h. Treatment with cellular stress and fold induction of Pvt1b
performed as in (C,D). Data show mean ± SEM (n=3, biological replicates); ns = not significant; *p
< 0.05, paired t test. NT = no treatment. Data collection and analysis performed by Giuseppe
Militello.
Contributions from G. Militello in (E) and (F) are described above.
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stress-dependent

Myc

repression
To query whether HDACs play a role in p53-dependent Myc repression
more directly, I sought to determine whether the inhibition of one or more HDACs
could rescue stress-induced Myc downregulation. Given the importance of HDAC3
in XIST-mediated XCI, we treated KPR cells and PR MEFs with the HDAC3
inhibitor RGFP966 in the presence and absence of stress. HDACs, including
HDAC3, have a well-documented role in repressing the p53 pathway (Ito et al.,
2002; Monte et al., 2006; Narita et al., 2010), and treatment with RGFP966 caused
a minor decrease in Pvt1b compared to untreated controls (Figures 25C and 25D).
While Myc levels decreased in response to both oncogenic and genotoxic stress in
control samples, we observed a partial, albeit nonsignificant, rescue of Myc levels
with HDAC3 inhibition (Figures 25C and 25D). These results indicated that
HDAC3 may play a role in p53-induced Myc repression, but do not completely
explain the observed decreases in Myc expression.
To determine whether additional HDACs might be important for Myc
downregulation under conditions of cellular stress, Giuseppe Militello performed
experiments

utilizing

pan-HDAC

inhibitors

trichostatin

A

(TSA)

and

suberoylanilide hydroxamic acid (SAHA), which inhibit class I and class II HDACs,
including HDAC3 (Xu et al., 2007). While SAHA did not have significant effects on
Pvt1b expression relative to controls, TSA treatment caused robust downregulation
of Pvt1b, perhaps indicating systemic effects on the p53 network (Figures 25E and
25F). While Myc RNA levels displayed an expected decrease in the presence of
stress, he observed a significant increase in Myc RNA in KPR cells treated with
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either TSA or SAHA, amounting to a near-full rescue of Myc expression (Figure
25E). Similarly, he observed robust, albeit nonsignificant, increases in Myc
expression in stressed PR MEFs following treatment with pan-HDAC inhibitors
(Figure 25F). Taken together, these data point to an HDAC-dependent mechanism
for Pvt1b-mediated Myc repression.

Discussion
The results presented in this chapter comprise a broad investigation of the
hypothesis that Pvt1b represses Myc transcription by facilitating histone
deacetylation at the Myc promoter in response to cellular stress. These preliminary
data thus far point to a mechanism of p53-dependent Myc repression via histone
deacetylation, which may require Pvt1b expression. That H3K27ac marks did not
decrease at the Myc promoter in cells in which Pvt1b expression was inhibited, in
contrast to wildtype cells, suggests the specific importance of Pvt1b in histone
deacetylation. Significantly, preliminary findings from an epistasis experiment
involving HDAC inhibition in cells lacking Pvt1b implicate HDACs as functioning
in the same pathway as Pvt1b (data not shown), providing further support for
Pvt1b modulating Myc expression via HDACs. However, additional mechanistic
studies are needed to establish the link between Pvt1b, HDACs, and Myc
repression more definitively. While HDAC3 inhibition prompted a partial rescue
of Myc downregulation under conditions of oncogenic or genotoxic stress, the
more prominent Myc rescue observed following pan-HDAC inhibition suggests the
potential involvement of additional HDACs. In the future, it will be necessary to
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determine which class I/II HDACs inhibited by TSA and SAHA are responsible for
the stress-dependent decrease in Myc expression.
While my results certainly point to a role for histone deacetylation in stressspecific Myc regulation, any potential involvement of SHARP/Spen in keeping
with the mechanism of XIST-mediated XCI still needs to be investigated (Chu et
al., 2015; McHugh et al., 2015; Moindrot et al., 2015; Monfort et al., 2015). I have
designed a strategy for generating a CRISPR-mediated Spen knockout model,
which will be useful for assessing any requirement for SHARP/Spen in p53dependent Myc regulation. Thoroughly validating any putative interaction
between Pvt1b and Spen (Carter et al., 2020) via RNA immunoprecipitation (RIP)
or crosslinking and immunoprecipitation (CLIP) studies will also be important for
elucidating the mechanism of Pvt1b-mediated Myc repression. LncRNAs often
engage epigenetic regulators to elicit repression (reviewed in (Statello et al.,
2020)), and the data presented here currently support this paradigm. Future work
in our lab will focus on both further defining the functional elements of the Pvt1b
isoform and elucidating the role of HDACs in the p53-Pvt1b-Myc regulatory axis.
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Chapter 5:
Generation of Pvt1 genetically engineered mouse models

Introduction
Historically, the study of lncRNAs in cancer has benefitted from the use of
GEMMs to probe lncRNA function in vivo (see Chapter 1). Perturbation of
lncRNA function via genetic or epigenetic modifications to the endogenous locus
can help overcome many issues with the study of lncRNAs in in vitro model
systems (see Chapter 1) and can solidify our understanding of lncRNA function
at the organismal level. Considering the power of in vivo models in resolving
lncRNA function(s), I sought to deploy a suite of molecular tools that would enable
elucidation of the function(s) of Pvt1 isoforms under both physiologic and
tumorigenic conditions.
First, I took advantage of a well-characterized synthetic polyadenylation
signal (PAS) to elicit premature transcription termination (Levitt et al., 1989), a
robust genetic tool that has been used previously to clarify mechanisms of local
gene regulation enacted by lncRNAs (Engreitz et al., 2016). The short 49 bp
sequence, when transcribed as part of the Pvt1 locus, should cause efficient 3’
cleavage and polyadenylation of nascent Pvt1 transcripts (Figure 26A) (Levitt et
al., 1989). In addition to stimulating 3’ end-processing machinery via transcription
of a A(A/U)UAAA hexamer followed by a GU-rich tract 30 bp downstream
(Millevoi and Vagner, 2010), PAS insertion may also suppress Pvt1 transcription
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initiation due to the tight connection between the splicing and transcriptional
processes (Engreitz et al., 2016).
I chose to insert the synthetic PAS within Pvt1 exon 1b, just downstream of
the Pvt1b transcription start site (TSS), in order to abrogate production of the full
length Pvt1b transcript (Pvt1b-PAS, Figures 26A and 26C). Due to the efficiency
with which polyadenylation occurs and the location of Pvt1 exon 1b downstream
from exon 1a, I expected that a PAS insertion within exon 1b would also abrogate
the production of nascent Pvt1a transcripts, effectively acting as a LOF model for
both Pvt1a and Pvt1b. Therefore, to distinguish between any potentially divergent
functions ascribed to Pvt1a and Pvt1b isoforms, I designed a separate LOF model
specific to Pvt1a (Pvt1a-PAS) by inserting a PAS into Pvt1 exon 1a, just
downstream of the Pvt1a TSS (Figures 26A and 26C). This model should result in
specific abrogation of Pvt1a transcription, without negatively affecting Pvt1b, thus
providing both a control for any experiments using the Pvt1b-PAS model and an
important tool for elucidating Pvt1a function independent of Pvt1b.
To complement the Pvt1a-PAS and Pvt1b-PAS GEMMs, I designed an
additional Pvt1 GEMM using a novel ribozyme-based tool developed in our lab to
elicit co-transcriptional cleavage and subsequent transcript degradation (Winkler
et al., in preparation). This strategy relies on the 74 bp-length self-cleaving
ribozyme Twister, initially identified and characterized by the Breaker lab at Yale
(Figure 26B) (Roth et al., 2014). In in vitro studies, Twister undergoes efficient
self-cleavage under simulated physiologic conditions, approaching rates as high as
~1000 min-1 (Roth et al., 2014). Twister’s small size and ability to rapidly selfcleave via site-specific phosphodiester scission (Jimenez et al., 2015) make it an
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ideal candidate for a lncRNA LOF tool. Previous studies have demonstrated
success using ribozymes to inhibit ncRNA accumulation in yeast and mouse cells
(Camblong et al., 2009; Tuck and Buhler, 2021; Tuck et al., 2018) and unpublished
results from our lab indicate that Twister robustly destabilizes transcript
aggregation in vivo when inserted into the LincRNA-p21 locus (Winkler et al., in
preparation).
I chose to insert the Twister sequence into Pvt1 exon 1b in order to abrogate
accumulation of both Pvt1a and Pvt1b transcripts, similar to the Pvt1b-PAS model
(Pvt1b-TWI, Figure 26C). Inserting Twister into the same location as the PAS in
the Pvt1b-PAS model enables direct comparison between the effects of premature
polyadenylation and Twister-mediated transcript cleavage on neighboring Myc
expression. While PAS-mediated transcript cleavage and polyadenylation leaves a
downstream nascent cleavage product with a terminal 5’ phosphate group, a ready
substrate for degradation by the 5’ end surveillance factor XRN2 (West et al.,
2004), the downstream fragment resulting from Twister self-cleavage instead
possesses a 5’ hydroxyl group (Roth et al., 2014), which is unlikely to engage
XRN2-mediated transcriptional termination (Doamekpor et al., 2020; Jinek et al.,
2011; Mathy et al., 2007; West et al., 2004). Indeed, unpublished results from our
lab suggest that Twister-mediated RNA cleavage enables some level of
transcription to proceed through the locus (Winkler et al., in preparation), in
contrast to the rapid drop-off in transcription resulting from PAS insertion, usually
within 2 Kb (Core et al., 2008). Considering that local gene regulation by lncRNAs
may depend on the RNA transcript or the process of transcription through the
locus alone (Engreitz et al., 2016), the Pvt1b-TWI model will provide further
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insight into the elements of the Pvt1 transcript required for its function(s).
Whether the Pvt1b-PAS and Pvt1b-TWI models successfully abrogate both Pvt1a
and Pvt1b levels will need to be empirically determined, as the increased distance
between either the polyadenylation sequence or the Twister ribozyme and the
Pvt1a TSS may result in reduced efficiency of these LOF tools (Engreitz et al., 2016;
Tuck and Buhler, 2021; Tuck et al., 2018).
In this chapter, I describe the successful generation of the Pvt1a-PAS,
Pvt1b-PAS and Pvt1b-TWI alleles in the mouse and provide evidence for their
germline transmission. These GEMMs set the stage for further extensive
characterization of the contributions of Pvt1a and Pvt1b isoforms to organismal
development and normal homeostasis, the cellular response to stress, and
tumorigenesis.
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Figure 26. Schematic of Pvt1 GEMMs. (A) Illustration of premature RNA cleavage and
polyadenylation induced by insertion of a 49 bp synthetic polyadenylation signal (PAS) into an
endogenous gene. Inhibitory line indicates transcriptional suppression. (B) Illustration of cotranscriptional RNA degradation induced by insertion of the 74 bp self-cleaving Twister ribozyme
(TWI) into an endogenous gene. Inhibitory line indicates transcriptional suppression. The
structure of the Twister ribozyme is shown (adapted from Roth et al. 2014). (C) Top, schematic of
the Myc-Pvt1 locus. Bottom, schematics of the Pvt1a-PAS, Pvt1b-PAS and Pvt1b-TWI alleles, as
present in their associated genetically engineered mouse models (GEMMs).
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Results
Design and generation of in vivo Pvt1a-PAS, Pvt1b-PAS and Pvt1b-TWI
alleles
Pvt1a-PAS, Pvt1b-PAS and Pvt1-TWI mice were generated in collaboration
with Adam Williams and Rick Maser at the Jackson Laboratory for Genomic
Medicine (JAX). We chose candidate guide RNAs based on predicted specificity
scores (Concordet and Haeussler, 2018) and the criteria that Cas9 cleavage and
subsequent insertion of either PAS or TWI occur <100 bp from Pvt1a and Pvt1b
TSSs to increase the likelihood of efficient premature transcript termination or cotranscriptional transcript degradation, respectively. The final two guide RNAs, one
targeting Pvt1 exon 1a (gEx1a) and one targeting Pvt1 exon 1b (gEx1b), were
selected based on cleavage efficiency estimates from in vitro analyses performed
at JAX (Figure 27A; data not shown). Homology directed repair (HDR) templates
were subsequently designed with either the 49 bp PAS or the 74 bp TWI sequence
inserted at the expected Cas9 cleavage site with appropriate length homology arms
on either side of the altered DNA. Single-stranded oligo donors (ssODNs) were
constructed complementary to the non-target strand to increase repair efficiency
(Richardson et al., 2016).
Briefly, mouse embryos were electroporated with guide RNA:Cas9
ribonucleoprotein (RNP) complexes and the appropriate homology directed repair
(HDR) templates to generate Pvt1a-PAS, Pvt1b-PAS and Pvt1b-TWI alleles. These
embryos were surgically implanted into pseudo-pregnant mice and we received the
resulting litters from JAX including at least five potential founder mice for each
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allele with successful knock-ins based on initial genotyping performed by JAX
(data not shown).
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Figure 27. Pvt1-PAS, Pvt1b-PAS, and Pvt1b-TWI genotyping. (A) Schematic of the mouse
Pvt1 locus highlighting in vivo CRISPR/Cas9 editing strategy, including guide RNAs used to edit
Pvt1 exon 1a (gEx1a) and exon 1b (gEx1B), respectively. Red lines indicate location of genotyping
primers. (B-D) Gel images of genotyping results from potential (B) Pvt1a-PAS, (C) Pvt1b-PAS, and
(D) Pvt1b-TWI founder mice. Allele combinations of each mouse indicated. PAS = Polyadenylation
sequence; TWI = Twister ribozyme; KI = Knock-in; WT = Wildtype. Genotyping performed by
Nadya Dimitrova. (E) Gel images of genotyping results from F1 mice, generated by backcrossing
Pvt1 mutant (mut) founder mice to wildtype (wt) mice to produce heterozygotes. Genotyping
results from F1 heterozygous mice with germline transmission of Pvt1a-PAS, Pvt1b-PAS, and
Pvt1b-TWI alleles are shown. PAS = Polyadenylation sequence; TWI = Twister ribozyme; WT =
Wildtype. Matings and genotyping performed by Nadya Dimitrova.
Contributions from N. Dimitrova in (B-E) are described above.
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Germline transmission of Pvt1a-PAS, Pvt1b-PAS, and Pvt1b-TWI
alleles
As founder mice are subject to mosaicism, it is necessary to deconvolve the
altered Pvt1 alleles and establish germline transmission of successful knock-ins.
First, the presence of Pvt1a-PAS, Pvt1b-PAS and Pvt1b-TWI alleles in potential
founder mice was confirmed by genotyping of DNA extracted from mouse tail
clippings (Figures 27A-D). In multiple independent founders, increases in band
size compared to wildtype mice were observed, indicating varying degrees of
successful PAS and TWI knock-ins (Figures 27B-D). All five potential Pvt1a-PAS
founders appeared homozygous for PAS knock-in, six potential Pvt1b-PAS
founders appeared heterozygous for PAS knock-in, and analysis of potential Pvt1bTWI founders revealed one homozygous and four heterozygous for TWI knock-in
(Figures 27B-D).
To establish germline transmission, founder mice were crossed to wildtype
C57BL/6J mice. Heterozygous mice constitute generation F1 (filial 1) and are
poised to be utilized in future experiments, as they, unlike the founder mice, do not
suffer from the challenges associated with mosaicism. Crossing two F1
heterozygous mice together will produce a litter of wildtype mice and mice
heterozygous or homozygous for the altered allele, enabling further analyses.
Therefore, the establishment of germline transmission for all Pvt1a-PAS, Pvt1bPAS, and Pvt1b-TWI alleles and production of F1 mice heterozygous for these
altered alleles paves the way for downstream analyses (Figure 27E).
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Discussion
In summary, this chapter describes the design and generation of the Pvt1aPAS, Pvt1b-PAS and Pvt1b-TWI mouse models, the combination of which will
allow us to better understand and define the functional elements of the Pvt1 locus
and its associated isoforms. Future experiments will focus on characterizing the
effects of these mutant alleles on both Pvt1 transcription and transcript stability,
and on neighboring Myc expression. Careful analysis of the efficacy of the PAS and
TWI alleles in vivo and how they influence local regulation of Myc will allow us to
more precisely describe how Pvt1b represses Myc transcription, and whether this
requires Pvt1b RNA production alone, or additionally requires the Pvt1b RNA
transcript itself. In addition, the inclusion of a Pvt1a-specific mouse model, will
provide insight into the potentially divergent functions of the Pvt1a and Pvt1b
isoforms and whether pro- and anti-tumorigenic functions coexist in the same
locus.
Importantly, the insertion of either the synthetic polyadenylation signal or
the Twister ribozyme constitutes the addition of a short (<100 bp) sequence into
the endogenous Pvt1 locus without requiring the deletion of any DNA elements.
Previous work has demonstrated the role of DNA elements encoded in the Pvt1
locus in positively and negatively regulating Myc expression (Cho et al., 2018;
Fulco et al., 2016), suggesting the importance of minimal disruption to the
endogenous sequence in Pvt1 GEMM design considerations. Deletion of over 300
Kb of the Pvt1 locus in vivo resulted in reduced stability of the Myc protein (Tseng
et al., 2014), but raised questions about the relative functional contributions of the
Pvt1 RNA itself compared to DNA elements. In comparison, the mouse models
125

described above do not delete, and should largely avoid the disruption of, DNA
elements, providing an opportunity to assess the role of the Pvt1 RNA and its
production more directly.
In addition to helping elucidate molecular mechanism, these three GEMMs
will improve our understanding of the importance of Pvt1 at the organismal level.
For example, analysis of developmental timepoints and aging studies will shed
light on any physiologic effects observed as a result of Pvt1 loss, and may suggest
new roles in organism growth and homeostasis. While Pvt1 loss alone may not be
sufficient to predispose animals to spontaneous tumor development, crossing the
Pvt1a-PAS, Pvt1b-PAS and Pvt1b-TWI models with established cancer models will
enable investigation of the importance of Pvt1 in promoting or suppressing various
cancer types. There is much that we still do not understand about the role of Pvt1b
as a tumor suppressor, For example, previous work has demonstrated that Pvt1b
loss increases oncogenic K-ras-driven tumor growth (see Chapter 2, Figure 19).
However, it is unknown whether Pvt1b loss in combination with loss of another
tumor suppressor gene may constitute a second “hit” in the “two-hit hypothesis”
framework of cancer development (Knudson, 2001) and be sufficient to drive
tumorigenesis. Taken together, these novel GEMMs provide an unprecedented
opportunity to further our knowledge of Pvt1’s roles in development and disease
and inform our understanding of lncRNA function at the organismal level.
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Chapter 6: Summary and Perspectives

Here I have identified and characterized Pvt1b, revealing a bona fide tumor
suppressor function embedded in the Pvt1 locus and mediated by a stress-specific
lncRNA isoform. This work substantially contributes to both the fields of cancer
biology and lncRNA biology by (1) improving our understanding of the regulatory
feedback between the p53 tumor suppressor and Myc proto-oncogenic networks
and its physiological impacts on cancer initiation and development, and (2)
uncovering a novel lncRNA isoform-switching mechanism that enables swift locusspecific reverse regulation downstream of a transcriptional activator. In employing
diverse LOF and GOF tools in powerful in vitro and in vivo model systems, I
provided critical insight into how, and the extent to which, Pvt1b contributes to
tumor suppression and growth inhibition downstream of p53 activation.
I found that Pvt1b is rapidly induced by genotoxic and oncogenic stress in a
p53-dependent manner. The production of the Pvt1b RNA, 50 Kb downstream of
the Myc locus, is necessary and sufficient to repress Myc transcription in cis, with
negative functional consequences on Myc transcriptional activity and cellular
proliferation. Importantly, using a genetic LOF model specific to p53 function, I
demonstrated that Pvt1b inhibition increases Myc expression, cellular
proliferation, and tumorigenesis under conditions of cellular stress. These
observations complicate the long-standing classification of Pvt1 as an oncogenic
lncRNA, which stems from decades of evidence linking its elevated expression to
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the increased proliferative and invasive capacities of cancer cells (Cui et al., 2016)
as well as increased tumor aggressiveness and poor patient survival (Zhu et al.,
2017). In stark contrast to this body of literature, I have unearthed a novel tumor
suppressor function for this lncRNA gene, previously hidden in the vast expanse of
the complex pro-oncogenic Pvt1 locus. My work does not contradict the wealth of
evidence implicating Pvt1 as an oncogenic lncRNA, which dates back to its
discovery nearly 40 years ago (Cory et al., 1985; Graham et al., 1985). Instead, we
can now propose a more nuanced and holistic model for Pvt1 function that
incorporates both tumor suppressive and oncogenic activities as mediated by
different elements of the Pvt1 locus and its associated RNAs.
The study of cancer-associated genetic and epigenetic alterations and their
frequencies has implicated both coding and noncoding genes as potential drivers
of tumorigenesis (see Chapter 1). As such, the identification of recurrent genetic
rearrangements involving the lncRNA Pvt1 locus provided strong impetus for the
study of Pvt1 in the context of cancer (Cory et al., 1985; Graham and Adams, 1986;
Graham et al., 1985; Shtivelman et al., 1989). In keeping with co-amplifications of
the Myc-Pvt1 locus observed in tumors (Riquelme et al., 2014), co-gain of Myc and
Pvt1 was found to advance cancer progression in a mouse model of breast cancer
(Tseng et al., 2014). Importantly, gain of either Myc or Pvt1 alone had more limited
effects on tumor growth, suggesting a pro-oncogenic synergy between these two
loci, perhaps deriving from a role for the Pvt1 RNA in promoting Myc protein
stability (Tseng et al., 2014). Several additional molecular mechanisms have been
proposed to describe the tumor-promoting function of Pvt1, including its function
as a miRNA sponge (Panda et al., 2017; Zhao et al., 2018), its role in epigenetically
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repressing tumor suppressor genes via association with chromatin modifying
complexes (Kong et al., 2015), and its ability to stabilize oncoproteins (Xu et al.,
2017). Distinct from these proposed oncogenic functions, my work and the work of
others demonstrates a function for the Pvt1 locus in restricting Myc expression to
limit tumorigenesis, either through DNA elements (Cho et al., 2018; Fulco et al.,
2016) or through stress-induced production of the Pvt1b RNA, as shown here. The
discovery of both activating and repressive DNA elements in the Pvt1 locus that
regulate Myc expression calls into question previous assumptions about Pvt1
function (Fulco et al., 2016), suggesting a more nuanced picture of Pvt1 regulatory
roles.
The tumor suppressive function of Pvt1 may have operated under the radar
of cancer biologists due to the frequent inactivation of the p53 network in tumor
development. In such cases where Pvt1b is inhibited due to genetic alterations in
the Pvt1 locus or the removal of upstream activating signals, the oncogenic
activities of Pvt1 would be expected to predominate. This may explain the
acquisition of extrachromosomal DNA (ecDNA) circles harboring Myc-Pvt1 coamplifications in p53-deficient KPR cells, as well as the recent observation of a
Myc-Pvt1 ecDNA genomic rearrangement in a human colon cancer cell line, which
fused exon 1 of Pvt1 to exons 2 and 3 of Myc, disrupting normal cis-regulatory
circuits in the locus (Hung et al., 2020). Interestingly, genomic alterations in the
region surrounding the Pvt1 p53RE are common. Several studies have documented
translocations specifically involving the first exon of Pvt1 fused to a number of 3’
gene partners across a variety of malignancies (Iwakawa et al., 2013; Nagoshi et
al., 2012; Northcott et al., 2012), and various somatic mutations encompassing the
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Pvt1 promoter (Cho et al., 2018). In p53-proficient tumors, such genetic
aberrations might be expected to either separate the Myc locus from Pvt1b, likely
rendering Pvt1b incapable of repressing Myc in trans, or potentially destroy the
p53RE required for Pvt1b expression, thus providing cells with a proliferative
advantage. Future studies of Pvt1 in cancer should therefore consider whether
observed Pvt1-associated tumor-promoting effects derive from the activation of its
oncogenic features, the disruption of its tumor suppressive features, or some
combination thereof.
Pvt1 functional studies have largely been performed in cancer backgrounds.
However, surprisingly little knowledge has been amassed concerning the function
of Pvt1 under physiological conditions, with the biological relevance of some
proposed regulatory activities of Pvt1 unclear due to their inherent cancerspecificity (Cho et al., 2018). Here I have provided insight into this mystery by
demonstrating that Pvt1b is a target of the p53 gene expression program, and is
therefore linked to normal cellular homeostasis and the cellular response to stress.
Researchers long puzzled over the molecular mechanism(s) underpinning the
negative regulatory feedback observed between the p53 and Myc pathways, and
whether p53 activation played a direct or indirect role in Myc repression. Several
models to explain this phenomenon have been proposed, including histone deacetylation at the Myc promoter via direct p53 binding (Ho et al., 2005), p53
induction of Myc-targeting miRNAs (Christoffersen et al., 2010; Sachdeva et al.,
2009), and p53 binding to a distal repressor element in the Pvt1 locus to reduce
Myc levels (Porter et al., 2017). Pvt1 has been previously identified as a p53 target
gene in several studies (Allen et al., 2014; Barsotti et al., 2012), but the role of Pvt1
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within the p53 transcriptional program, if any, was virtually unexplored.
Expanding on these findings, I provided evidence that induction of Pvt1b by p53 is
the primary mediator of p53-dependent Myc repression using two distinct LOF
systems. Therefore, Pvt1b joins a class of p53-regulated lncRNAs responsible for
executing important growth-inhibitory functions within the p53-coordinated
tumor suppressor response (Dimitrova et al., 2014; Hung et al., 2011; Schmitt et
al., 2016). While p53 has been previously implicated in the indirect repression of
cell cycle genes through the p53-DREAM (p53–p21–DREAM–E2F/CHR) pathway
(reviewed in (Engeland, 2018)), to my knowledge Pvt1b is the first example of a
p53-regulated lncRNA enacting local repression of a growth-promoting gene.
Indeed, work from our lab has found that cis-acting lncRNA targets of p53 often
engage in positive co-regulatory relationships with neighboring loci, while Pvt1b is
currently the only known outlier in this trend (Tesfaye et al., In review). Taken
together, I propose a model whereby p53 induces Pvt1b to dampen proliferative
signaling during potential cancer-initiating events. As such, Pvt1b acts at the
intersection between two pervasive transcription networks, providing a crucial
avenue of communication that allows cells to prioritize tumor suppression over
continued growth under conditions of stress.
While I describe a stress-specific role for Pvt1b in restricting Myc
expression, the molecular mechanism underlying this regulatory relationship is
still a matter of open investigation. Both the localization of Pvt1b near its TSS and
the negative effect of Pvt1b induction on neighboring Myc transcription clearly
establish a cis-regulatory model for Pvt1b function. Moreover, the effects of ASOmediated depletion or endogenous activation of Pvt1b point to a role for the Pvt1b
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RNA in Myc repression, as opposed to DNA elements in the locus. Importantly,
p53 is not explicitly required for this effect, as upregulation of Pvt1b alone is
sufficient to drive Myc downregulation. ASO-mediated depletion of Pvt1b reduced
Myc levels, suggesting a role for the RNA molecule itself; however, we cannot
formally exclude a role for the act of Pvt1b transcription in mediating Myc
repression, especially in light of recent evidence that ASOs can cause premature
transcription termination (Lee and Mendell, 2020). Indeed, my Pvt1 exon 1btargeting ASOs act near the Pvt1b TSS, rendering it impossible to distinguish
between the effects mediated by the Pvt1b RNA or its production. However, my
findings concerning the role of HDACs in Myc repression via p53-dependent
deacetylation of the Myc promoter, and the potential requirement for Pvt1b in this
process, while preliminary, strongly suggest a function for the lncRNA molecule.
Modulation of epigenetic marks is a common mode by which lncRNAs regulate
gene expression, especially in cis (see Chapter 1). Therefore, we may envision
Pvt1b as acting in a similar manner to lncRNA Morrbid, regulating a neighboring
gene via association with chromatin modifying complexes to influence critical cell
survival decisions (Kotzin et al., 2016). Notably, the additional evidence that Pvt1b
binds SHARP (Carter et al., 2020), a transcriptional repressor known to function
in Xist-mediated histone deacetylation of the X-chromosome (McHugh et al.,
2015) and predicted to have Xist-like repressive activity via computational analysis
(Kirk et al., 2018), may implicate Pvt1b as engaging in a similar mechanism of
action to Xist. Future work will explore this possibility.
Our inability to identify sequences in Pvt1 exon 1b required for p53dependent Myc repression does not preclude a role for the RNA molecule, or
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indeed the existence of sequence-specific function. My attempts to mutate critical
Pvt1b sequence and/or structural motifs may not have been efficient or pervasive
enough to produce effects at the population level. On the other hand, the ~200 bp
stretch of nucleotides unique to the Pvt1b isoform may be dispensable to its
function. The existence of RNA sequence-independent lncRNA mechanisms has
been insinuated by the nonspecific interactions between RNAs and PRC2
(Davidovich et al., 2013). Indeed, some proteins can engage in dynamic and
promiscuous RNA interactions in the absence of a true RNA-binding domain due
to intrinsically disordered regions (IDRs) (Protter et al., 2018). The structural
disorder of IDRs also favors liquid-liquid phase separation (LLPS), and IDRcontaining proteins have been shown to interact with lncRNAs in the formation of
nuclear and cytoplasmic condensates (Garcia-Jove Navarro et al., 2019; Yamazaki
et al., 2018). As such, Pvt1b may associate with IDR-containing proteins or other
RBPs to repress Myc in a sequence-independent manner, although this possibility
requires further investigation.
Critically, Nadya Dimitrova and Clara Liao demonstrated a role for Pvt1b in
restricting tumor growth at the organismal level using an autochthonous mouse
model of lung cancer. In the KC mouse, tumorigenesis is driven by oncogenic Kras and is exquisitely sensitive to p53 loss. Tumor-specific Pvt1b ablation in this
background had profound consequences, producing tumors that were larger than
their Pvt1b-expressing counterparts and increasing tumor burden almost to the
extent observed with p53 loss. Epistasis analysis and the absence of increases in
tumor grade in Pvt1b-deficient tumors revealed a highly specific and powerful role
for Pvt1b downstream of p53 activation in curtailing tumor growth. In this way,
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Pvt1b acts as a critical barrier to the ability of cancer cells to proliferate unchecked,
joining the ranks of a select number of cancer-associated lncRNAs with
documented roles in tumorigenesis in vivo (Gupta et al., 2010; Gutschner et al.,
2013; Mello et al., 2017). While this LOF model does not allow for differentiation
between the effects of DNA elements in the Pvt1 locus and the Pvt1b RNA, the
Pvt1a-PAS, Pvt1b-PAS, and Pvt1b-TWI mouse models, generated in the course of
this work, should distinguish the functional elements of Pvt1 transcripts with a
higher degree of sensitivity.
An exciting implication from this work is the significant influence cis-acting
lncRNAs can exert over cellular activities via highly specific local gene regulation.
Pvt1b represses one transcription factor downstream of another transcription
factor, thus acting as a mediator between two gene expression networks to rapidly
fine-tune cellular outputs in response to a specific cellular input. To my knowledge,
Pvt1b is the first example of a lncRNA acting in this manner, although cisregulation of transcription factors by lncRNAs may be far more commonplace (Liu
et al., 2018). The closest example I could find of a similar lncRNA mechanism is
that of NANCI (Nkx2.1-Associated Noncoding Intergenic RNA). NANCI is induced
downstream of Wnt (Wingless/Integrated) signaling, upon which it upregulates its
neighbor NKX2.1 (NK2 Homeobox 1) to influence lung epithelial development
through the activation of a plethora of NKX2.1 target genes (Herriges et al., 2014).
Differing only in whether their cis-regulation is activating or repressive, NANCI
and Pvt1b may represent the founding members of a burgeoning class of cis-acting
lncRNAs that function at the intersection of transcription programs to influence
gene expression on a broader scale. Considering the speed with which lncRNAs can
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be produced relative to proteins, lncRNAs are uniquely poised to swiftly and
dynamically respond to cellular stimuli. Cis-acting lncRNAs are even more wellsuited for this task because their site of transcription is the same as their site of
action. In this way, Pvt1b as an expeditious regulatory lever is similar to p53 itself,
which is constitutively produced and degraded, and therefore always primed for
rapid activation. Global analyses have revealed many lncRNAs expressed in close
spatial proximity to genes with roles in transcription regulation including
transcription factors and chromatin modifiers (Guttman et al., 2009; Ponjavic et
al., 2009). Such lncRNAs are co-expressed with their neighboring protein-coding
gene(s) more frequently than expected by chance, suggesting functional regulatory
relationships (Ponjavic et al., 2009). Taken together, cis-acting lncRNAs may play
outsized roles in global gene regulation and are apt candidates for transmitting
rapid feedback between cellular pathways. As such, future studies should pay
particular attention to lncRNAs adjacent to genes with broad transcription
regulatory capabilities.
One compelling discovery from my work is the identification of an isoformspecific function for Pvt1b. Traditionally, studies have viewed lncRNA loci as
discrete functional units, with many lncRNA genetic LOF models based on deletion
of either the entire lncRNA locus, or the promoter, resulting in complete loss of
lncRNA expression (see Chapter 1). In recent years, our expanding
understanding of the numerous and interconnected functional elements of lncRNA
genes has prompted the development of more targeted genetic models that attempt
to disrupt or enhance specific features of the lncRNA transcript while preserving
as much of the endogenous locus as possible (see Chapter 1). Increased attention
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to how lncRNAs produce a particular regulatory output, and whether these
functions are transcript-dependent or transcript-independent has encouraged the
use of innovative and thoughtful experimental tools and approaches. That
transcript-dependent lncRNA mechanisms can involve varied RNA-DNA, RNARNA, and RNA-protein interactions is now well-documented (reviewed in
(Statello et al., 2020)). While it is understood that the abundance and availability
of lncRNA interactors may change in different cellular contexts, little attention has
been paid thus far to how alterations in the lncRNA transcript itself might
influence function in response to cellular inputs.
The alternative splicing and processing of lncRNAs presents numerous
opportunities for the production of transcripts with diverse functions and
mechanisms of action. The sequence and/or structural motifs in a lncRNA
transcript often dictate function by specifying the molecular interactions in which
a lncRNA can engage (reviewed in (Zampetaki et al., 2018)). Therefore, it stands
to reason that the inclusion or exclusion of defined regions of a lncRNA transcript
through alternative transcript initiation, processing, or termination events may
expand, restrict, or otherwise transform a lncRNA’s regulatory repertoire. Multiexonic lncRNAs can be spliced in numerous combinations, potentially producing
transcripts with different functions due to the combination of specific sequence
motifs, or the generation of rare exon-exon junctions, which may influence the set
of possible RBPs, or other factors, a lncRNA can bind. Our analysis of splice
junctions in nascent Pvt1 RNAs revealed abundant transcripts produced from the
Pvt1 locus, composed of various combinations of exons. Similar diversity in
spliceoforms has been observed for other lncRNAs (Niemczyk et al., 2013). There
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are few examples of lncRNA isoforms executing distinct regulatory functions,
including a SNP-specific function for PCAT19 in prostate cancer (Hua et al., 2018)
and a role for a long isoform of CCAT1, CCAT1-L, in transcriptional regulation of
MYC (Xiang et al., 2014). However, Pvt1 is unique in that the tumor suppressor
function of the stress-induced Pvt1b coexists alongside the varied, and potentially
oncogenic, activities of the constitutively transcribed Pvt1a. Fortunately, advances
in the depth and sensitivity of RNA-sequencing technologies may enable more
robust identification of lncRNA isoforms moving forward, paving the way for an
improved understanding of lncRNA isoform-dependent activities.
Finally, this work has important implications for Myc-based therapeutic
interventions in cancer. Myc-driven cancers can regress upon Myc inhibition
(Soucek et al., 2002), suggesting its potency as a therapeutic target. However, drug
development efforts have been challenged by the absence of a targetable binding
pocket on the surface of Myc (Dang et al., 2017). LncRNA perturbation can provide
alternative avenues for therapeutic intervention as a way of side-stepping so-called
‘undruggable’ proteins. This therapeutic perturbation can be accomplished in
several ways, with the most common and clinic-ready approaches including: 1)
small interfering RNAs (siRNAs) and ASOs to achieve lncRNA degradation and 2)
ASOs, often in the form of locked nucleic acids (LNAs), to cause steric disruption
of lncRNA function by altering splicing, inhibiting specific lncRNA-binding
partner interactions or causing a change in secondary structure formation (Arun
et al., 2018). In principle, cis-acting lncRNAs make particularly attractive
therapeutic targets; with such confined regulatory outputs, their perturbation may
be less likely to trigger unwanted off-target effects. Theoretically, Pvt1b induction
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in p53-deficient tumors may provide a way to limit Myc expression at its source.
However, current clinic-ready technologies target RNAs for degradation and, in
practice, Myc repression via Pvt1b would instead require its upregulation from the
endogenous locus. Targeting lncRNA molecules to specific genomic locations in
vitro has been made possible by CRISPR (Shechner et al., 2015). However,
deployment of this technology in vivo is unlikely to happen for many years.
Nonetheless, the prospect of modulating Myc expression in cancer, via Pvt1b or
otherwise, is exciting and should be explored further in the future.
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Final Remarks

Previous work has often treated Pvt1 as a simple genetic unit, not always
leaving space for complex regulatory functions that may arise from its 300 Kb of
genomic information. My distinction between the Pvt1a and Pvt1b isoforms
provides an avenue to re-evaluate Pvt1 and, by extension, its relationship to Myc,
in a new light. My findings do not necessarily conflict with the body of literature
supporting a synergistic relationship between Myc and Pvt1. Rather, they raise the
possibility that Pvt1a and Pvt1b may have distinct, and perhaps opposing,
functions, with DNA elements in the Pvt1 locus and Pvt1a cooperating with Myc to
promote its expression and activity, and Pvt1b acting as a stress-specific molecular
brake for this process. This multiplicity of function may not be restricted to the
Pvt1 locus, suggesting that the lncRNA class as a whole should be re-examined for
alternative functions encoded in lncRNA loci. Our work further highlights the
potential for cis-acting lncRNAs, when expressed in close proximity to
transcription factors or other protein-coding genes with widespread influence, to
exert profound control over cellular operations. Taken together, the results
presented here implicate Pvt1b as a central node of communication between the
p53 and Myc transcription networks, which enacts selective gene repression
downstream of a broad transcriptional activator to limit cell growth and perhaps
prevent cancer before its onset. Future studies should focus on both identifying the
element(s) of Pvt1b required for Myc repression, and disentangling the intricacies
of the Pvt1 locus to illuminate its varied, and perhaps isoform-specific, functions.
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Chapter 7: Materials and Methods
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mouse strains
All animal work was conducted in accordance with a protocol approved by
the Yale University Institutional Animal Care and Use Committee. K-rasLSL-G12D/+
(K) and p53FL/FL (P) mice were previously described (Jackson et al., 2005; Jackson
et al., 2001) and obtained from the laboratory of T. Jacks (MIT). Rosa26Cas9LSL/LSL (C) mice were previously described (Platt et al., 2014) and purchased
from Jackson Laboratories (026556). Wild-type (WT) C57BL/6J mice were
purchased from Jackson Laboratories (000664). Pvt1a-PAS, Pvt1b-PAS and
Pvt1b-TWI mice were generated using CRISPR/Cas9-mediated engineering in
C57BL/6J mice in collaboration with Rick Maser and Adam Williams at the
Jackson Laboratory for Genomic Medicine. In brief, guide RNA:Cas9
ribonucleoprotein (RNP) complexes and HDR templates were introduced into
embryos via electroporation. Mice carrying successful knock-ins were identified by
PCR-based

genotyping

and

germline

transmission

was

established

by

backcrossing once to WT (C57BL/6J) mice. Guide RNA and HDR template
sequences can be found in Supplementary Table 1; genotyping primer sequences
can be found in Supplementary Table 2.
For irradiation experiments, 4-8 months-old mice were irradiated with 6 Gy
of whole body irradiation and sacrificed 6 hours post irradiation. For tumor studies,
3-6 months-old mice were used. Experiments were performed blind to gender and
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with an equal distribution of males and females in each experimental group.

Cell culture and drug treatments
WT MEFs were isolated from embryos at E13.5 from timed matings of WT
C57BL/6J animals. All MEF experiments were performed at passages 2-10. KPR8
lung adenocarcinoma cell line of the genotype K-rasG12D/+; p53LSL/LSL; RosaCreERT2 was previously established from spontaneously arising primary tumors
isolated from K-rasLA2-G12D/+; p53LSL/LSL; Rosa-CreERT2 mice, as previously
described (Feldser et al., 2010). p53-restorable p53LSL/LSL; Rosa-CreERT2 MEFs
were previously described (Ventura et al., 2007). Genotypes and Tam-mediated
restoration of p53 expression were validated by genotyping and by qRT-PCR and
immunoblotting, respectively. Puromycin-sensitive KPR8 (KPR) and p53restorable MEF clones were generated by transient transfection with a guide RNA
targeting the ORF of puromycin to inactivate the puromycin-resistance gene
expressed from the Stop cassette, cloned downstream of a U6 promoter in a
BRD004 lentiviral construct (a gift from the Broad Institute, MIT) that coexpresses spCas9 and GFP. Normal human fetal lung fibroblasts were purchased
from the NIA Aging Cell Culture Repository (TIG-1, NG06173). Primary MEFs and
human fibroblasts were maintained in DMEM (Gibco) supplemented with 15%
FBS (F0926, Sigma-Aldrich), 50 U/ml pen/strep (Gibco), 2 mM L-glutamine
(Gibco), 0.1 mM non-essential amino acids (Gibco), and 0.055 mM bmercaptoethanol (Gibco). Cancer cells and 293 viral packaging cells were cultured
in DMEM supplemented with 10% FBS, 50 U/ml pen/strep, 2 mM L-glutamine,
and 0.1 mM non-essential amino acids. All cell cultures were maintained at 37°C
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in a humidified incubator with 5% CO2. Viral titering was performed in 3TZ cells,
a derivative of 3T3 cells, expressing a LSL-LacZ transgene (generously provided by
the laboratory of T. Jacks, MIT).
To delete the loxP-STOP-loxP (LSL) cassette preventing p53 expression,
cells were treated with 0.5 µM 4-hydroxytamoxifen (Tam, Cayman Chemical
Company). To induce DNA damage, cells were treated with 0.5 µM doxorubicin
(Doxo, Sigma-Aldrich) or 50 µM etoposide (Etop, Millipore Sigma) for smRNAFISH studies. To assess protein stability, cells were treated with 50 µg/ml
cycloheximide (Chx, Sigma-Aldrich) for the indicated times. To inhibit HDAC3,
cells were treated with 14 µM RGFP966 (MedChem Express). To inhibit all HDACs,
KPR cells were treated with 50 ng/ml trichostatin A (TSA, Sigma-Aldrich) or 50
nM suberoylanilide hydroxamic acid (SAHA, Sigma-Aldrich) and p53-restorable
MEFs were treated with 25 ng/ml TSA or 75 nM SAHA, respectively.

Constructs
Mutagenesis of p53REs in cultured cells was performed with a gRNA
targeting the p53RE of Pvt1b (gDRE) or Gm26542 (g1 or g2), cloned downstream
of a U6 promoter in BRD001 or BRD004 lentiviral constructs (gifts from the Broad
Institute, MIT) that co-express spCas9 and either an IRES-driven puromycinresistance gene or GFP, respectively. Mutagenesis of Pvt1 exon 1b or the Pvt1 exon
1b splice site in cultured cells was performed with gRNAs targeting across the Pvt1
exon 1b sequence (gALT1-11) or a gRNA targeting the 3’ end of exon 1b (gdeltaSS),
respectively, each cloned into the BRD001 lentiviral construct, as previously
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described. Control gRNA targeting dTomato (Con) was used as a negative control.
Tumor-specific mutagenesis of p53REs in vivo was performed with gRNAs cloned
downstream of a U6 promoter in UGPC (U6-gRNA-PGK-Cre) lentiviral vector.
UGPC-Con targeting dTomato was used as a negative control. UGPC-p53KO
targeting the ORF of p53 was used as a positive control (Xue et al., 2014). For
CRISPRa experiments, a lentiviral vector (lenti-SAM-Hygro) was constructed to
co-express nuclease-proficient spCas9, a U6-driven 15-mer ʻdead RNAʼ (dRNA)
extended by two MS2 loops (dRNA-MS2) (Dahlman et al., 2015), the
transcriptional activator domains p65 and HSF1 fused to the MS2-binding protein
(MBP), and a hygromycin-resistance gene. All sgRNA and dRNA sequences used
in this study can be found in Supplementary Table 1.
Lentivirus was produced in 293 cells by co-transfecting the lentiviral
constructs with pCMV-dR8.2 dvpr (Addgene plasmid #8455) and pCMV-VSV-G
(Addgene plasmid #8454) viral packaging constructs. Viral containing
supernatants supplemented with 4 µg/ml polybrene (Millipore Sigma) were used
to infect WT MEFs and KPR cells by 2-3 consecutive lentiviral infections, delivered
at 24 hour-intervals. Following infections, cells were selected with 5 µg/ml (KPR)
or 2 µg/ml (MEFs) puromycin (Sigma-Aldrich) or 800 µg/ml hygromycin (Roche).
UGPC lentivirus was prepared as above, concentrated by ultracentrifugation, and
titered by infecting 3TZ cells and determining the number of viral particles based
on the fraction of LacZ-positive cells as previously described (DuPage et al., 2009).
Mutagenesis of the Pvt1b and Gm26542 p53REs was confirmed by PCR
amplification of the region, subsequent cloning into pCR-Blunt II-TOPO® vector
(Invitrogen) and Sanger sequencing. Mutagenesis of the Pvt1 exon 1b sequence and
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the Pvt1 exon 1b splice site was confirmed by PCR amplification of the region,
Sanger sequencing and Tracking of Indels by Decomposition (TIDE) analysis
(Brinkman et al., 2014). Primers used in mutagenesis efficiency estimates can be
found in Supplementary Table 2.
For overexpression experiments, full-length Pvt1a (exon 1a-10) and Pvt1b
(exon 1b-10) cDNAs were synthesized as gene blocks and cloned into pWZL Hygro
retroviral vector (Addgene plasmid #18750). 5 µg of empty vector, Pvt1a-, or
Pvt1b-expressing constructs were transfected into 1-3x106 WT MEFs using the
Amaxa Mouse/Rat Hepatocyte Nucleofector Kit (Lonza, VPL-1004) and the
Nucleofector 2b Device (Lonza). Analysis was performed at 48 hours post
transfection. Information about key plasmids used in this work can be found in
Supplementary Table 3.

METHOD DETAILS
RNA isolation and qRT-PCR
For RNA-seq and qRT-PCR analysis, RNA was isolated with the RNeasy
Mini Kit (Qiagen) and 0.5-1 µg of total RNA was reverse transcribed using the High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). SYBR Green PCR
master mix (Kapa Biosystems) was used for quantitative PCR in triplicate reactions
with primers listed in Supplementary Table 2. Relative RNA expression levels were
calculated using the ddCt method compared to GAPDH and normalized to control
samples.
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Immunoblotting
Cells were collected, counted, and lysed in 2×Laemmli buffer (100 mM TrisHCl pH6.8, 200 mM DTT, 3% SDS, 20% glycerol) at 0.5-1x104 cells/µl. Samples
were heated at 95°C for 7 minutes and passed through an insulin syringe. Protein
from 1x105 cells was separated on 10% SDS-polyacrylamide gels and transferred to
nitrocellulose membranes (Bio-Rad). After blocking (5% milk, PBST), membranes
were incubated overnight at 4°C in primary antibody, then 1hr at RT in secondary
antibody. The following antibodies were used: anti-c-Myc (1:1000, clone Y69,
ab32072, Abcam), anti-Hsp90 (1:2500, 610419, BD Transduction Laboratories),
anti-Hsp90 (1:1000, 4877S, Cell Signaling Technology), goat anti-mouse
secondary antibody (1:50000, 1706516, Bio-Rad), and donkey anti-rabbit
secondary antibody (1:50000, 711-035-152, Jackson ImmunoResearch). Protein
bands were visualized using Amersham ECL Prime Western Blotting Detection
Reagent (GE Healthcare). Quantification of Myc and Hsp90 protein levels was
performed using the rectangle selection and measure tools in FIJI and Myc levels
plotted relative to Hsp90 levels and normalized to negative control in relevant
graphs. For cycloheximide experiments, Myc levels were normalized to negative
control and half-life of Myc protein was determined using Prism8 software.

Chromatin immunoprecipitation (ChIP)
Cells were harvested by trypsinization, counted, washed once in PBS and
crosslinked in 1% methanol-free formaldehyde (Thermo Scientific) diluted in PBS
for 10 min at RT. The reaction was stopped by adding glycine to a final
concentration of 100 mM and placing the samples on ice for 5 min. Cells were
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washed twice in cold PBS and the pellet was frozen and stored at -80°C.
5-10x106 nuclei were isolated by incubating the thawed cell pellet in Cell
lysis buffer (20 mM Tris-HCl, pH 8.0, 85 mM KCl, 0.5% NP-40), supplemented
with protease inhibitors (1 mM PMSF and Mini Complete Protease Inhibitor
Cocktail Tablet, Roche) on ice for 10 min. After centrifugation, the supernatant was
removed and the nuclei were resuspended in Nuclei lysis buffer (50 mM Tris-HCl,
pH 8.0, 10 mM EDTA, 1% SDS supplemented with protease inhibitors) and
incubated for 10 min on ice. Next, chromatin was sonicated to 300-500 bp
fragment size in an ice-water slurry for 10 cycles (15” ON, 30” OFF) for p53 ChIP
and 10-12 cycles (10” ON, 30” OFF) for H3K27ac ChIP using a Bioruptor sonicator
(Diagenode). Sonicated lysates were centrifuged at 13K rpm for 20 min and diluted
in ChIP dilution buffer (0.01% SDS, 1.1% Triton- X100, 1.1 mM EDTA, 20 mM TrisHCl, pH 8.0, 167 mM NaCl, supplemented with protease inhibitors). Input aliquots
were saved at this point. The sonicated chromatin was precleared with beads
(PureProteome Protein G Magnetic Beads, Millipore Sigma) and used to set up
chromatin immunoprecipitations with a p53 antibody (P53-CM5P-L, Leica),
H3K27ac antibody (ab4729, Abcam), or control IgG (ab46540, Abcam) and
incubated overnight at 4°C on a rotator. Beads (PureProteome Protein G Magnetic
Beads, Millipore Sigma) were blocked overnight in 1% BSA in PBS supplemented
with 20 µg salmon sperm DNA (Invitrogen) per immunoprecipitation reaction.
The next day, the blocked beads were added to the immunoprecipitation reactions
and samples were incubated on the rotator for an additional hour. Beads were
washed once in each of the following washes for 5 min at 4°C on the rotator: Low
salt wash (0.1% SDS, 1% Triton-X100, 2 mM EDTA, 20 mM Tris-HCl pH 8.0, 150
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mM NaCl supplemented with protease inhibitors), High salt wash (0.1% SDS, 1%
Triton-X100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.0, 500 mM NaCl), LiCl wash
(0.25 M LiCl, 1% NP-40, 1% Na deoxycholate, 1 mM EDTA, 20 mM Tris-HCl, pH
8.0), and TE wash (10 mM Tris-HCl, pH 8.0, 1 mM EDTA).
After completely removing any remaining liquid from the washes, beads
were resuspended in Elution buffer (50 mM Tris-HCl, pH 8.0, 10 mM EDTA, pH
8.0, 1% SDS) and incubated at 65°C for 15 min with frequent vortexing to prevent
settling. After elution, the beads were pelleted, and the supernatant was
transferred to a new tube and incubated overnight at 65°C to reverse the
crosslinking. The next day, samples were treated with RNaseA or 2 hours at 37°C,
followed by a proteinase K (Roche) treatment for 30 min at 55°C. The DNA was
purified by phenol-chloroform extraction and EtOH precipitation. The DNA pellet
was air dried, resuspended in 200 µl H2O and used for quantitative PCR analysis
(ChIP-qPCR) using primers listed in Supplementary Table 2.

Single-molecule FISH (smRNA-FISH)
Quasar570 (Q570)- and Quasar670 (Q670)-conjugated Stellaris FISH
probes are listed in Supplementary Table 1 (Stellaris, LGC Biosciences). smRNAFISH was performed according to the manufacturer recommendations. Briefly,
cells were grown on coverslips and fixed for 10 min in 4% methanol-free
formaldehyde (Thermo Scientific) at RT, followed by PBS washes. Cells were
dehydrated overnight at 4°C in 70% EtOH (diluted in DEPC-H2O) and stored in
70% EtOH for up to a week at 4°C. Coverslips were transferred to a hybridization
chamber and equilibrated for 5 min in Wash Buffer A (Stellaris, LGC Biosciences)
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prepared with formamide (Millipore Sigma) according to manufacturer’s
instructions. Cells were incubated overnight at 30°C with the indicated probes
diluted 1:50 in Hybridization solution (Stellaris, LGC Biosciences) prepared with
formamide according to manufacturer’s instructions. The next day, cells were
washed 2 times for 30 min at 30°C in Wash Buffer A, incubated in Wash Buffer B
(Stellaris, LGC Biosciences) for 5 min at RT, and mounted in antifade reagent
(Vectashield Mounting medium with DAPI, Vector Laboratories). The following
probesets were used: Pvt1b (ex.1b) detecting Pvt1b isoform with 10 probes
spanning exon 1b, labeled with Q670 and false-colored in red; Pvt1a (ex.1a)
detecting Pvt1a isoform with 11 probes spanning exon 1a, labeled with Q670 and
false-colored in red; Pvt1 (ex.1a-10) detecting total Pvt1 with 48 probes spanning
exons 1a-10, labeled with Q570 and false-colored in green; Pvt1 (introns) detecting
nascent Pvt1a with 31 probes spanning intron 1 upstream of exon 1b, labeled with
Q670 and false-colored in red; and Myc (intron) detecting nascent Myc with 33
probes spanning intron 1 of Myc, labeled with Q570 and false-colored in green.
Pvt1a (ex.1a) and Pvt1b (ex.1b) probesets do not detect at the single molecule level.
Images were captured using an Axio Imager 2 microscope system (Zeiss) with a
PlanApo 63x 1.4 oil DIC objective lens (Zeiss). For KPR cells, z-stacks of 12 planes
at 0.5 µm steps were acquired and used to generate maximum intensity projections.
For WT MEFs, single plane images were acquired. All images were edited using
Adobe Photoshop.

DNA-Fluorescence in situ hybridization (FISH)
DNA-FISH was performed as previously described (Chaumeil et al., 2008).
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To generate probes, the following BAC clones were used: RP23-55F11 (Myc) and
RP24-301E22 (Chr 6) (BACPAC Resources). BAC DNA was purified with a
Nucleobond Xtra BAC kit (Takara Bio USA) and nick translated with a nick
translation system (Invitrogen) and Alexa Fluor® 488-5-UTP or Alexa Fluor®
594-5-UTP (Invitrogen) following manufacturer instructions. Final probes were
ethanol precipitated with 7.5M ammonium acetate and stored in sterile TE at 20°C.
20 ng of nick-translated probe was precipitated with 3 µg of salmon sperm
DNA (Invitrogen) and 1 µg of mouse COT1 DNA (Invitrogen) using 1/10th volume
of sodium acetate (3M, pH 5.5) and 2.5 volumes of ethanol. Probes were stored
overnight at -20°C, then centrifuged at 13K rpm for 30 min at 4°C, washed twice
with 70% ethanol, and air dried. Pellets were resuspended in formamide (Millipore
Sigma), incubated at 37°C for at least 10 min, and denatured for 7 min at 75°C.
After denaturing, an equal volume of 2X hybridization buffer (4X SSC, 20% w/v
dextran sulfate, 2 mg/mL BSA, 40 mM RVC) was added and probe-DNA mixtures
were pre-annealed for 30 min to 1 hour at 37°C.
Cells were plated on coverslips and fixed in 4% paraformaldehyde in PBS
for 10 min at RT, followed by PBS washes. Cells were permeabilized in 0.5% Triton
X-100 in PBS for 6 min, washed twice with 70% ethanol and stored in 70% ethanol
at -20°C. Cover slips were dehydrated in an ethanol series (80%, 90%, 100%), air
dried, and incubated in RNase A diluted in 2X SSC (100 µg/mL) for 1 hour at 37°C.
Cover slips were washed three times with 2X SSC for 5 min and incubated in 50
µg/mL pepsin diluted into prewarmed 0.01M HCl for 3 min at 37°C, followed by
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two 5 min PBS washes and one in 1X PBS/MgCL2. After washing, cover slips were
incubated in 1% formaldehyde (Thermo Scientific) in 1X PBS/MgCL2 for 10 min at
RT. Cover slips were next washed in PBS for 5 min and dehydrated in an ethanol
series (70%/90%/100%) and air dried. Cover slips were then denatured in
prewarmed 50% formamide in 2X SSC for 30 min at 80°C, dehydrated in an icecold ethanol series (70%/90%/100%), and incubated with denatured probe DNA
overnight at 42°C in a dark chamber humidified with 50% formamide in 2X SSC.
Following incubation, cover slips were washed three times with prewarmed 50%
formamide in 2X SSC at 42°C for 5 min and three times with prewarmed 2X SSC
at 42°C for 5 min. Cover slips were mounted on slides with antifade mounting
medium with DAPI (Vector Laboratories) and sealed with nail polish. Single plane
images were captured using an Axio Imager 2 microscope system (Zeiss) with a
PlanApo 63x 1.4 oil DIC objective lens (Zeiss).

Subcellular fractionation
Subcellular fractionation was performed as previously described (Conrad
and Orom, 2017) with slight modifications. Briefly, cells were harvested by
trypsinization, rinsed once in PBS and re-suspended in 1 mM EDTA in PBS. 1x106
cells were set aside for whole cell (WC) RNA isolation using TRIzol (Invitrogen)
following the manufacturer’s protocol. 3 x106 cells were lysed in 0.4 mL cell lysis
buffer (10 mM TrisHCl pH 7.5, 0.15% NP-40, 150 mM NaCl, 100 U/mL RNase-IN
(Promega) for 5 min on ice. Lysate was layered on a sucrose cushion (24% w/v
sucrose, 150 mM NaCl, 10 mM TrisHCl pH 7.5,100 U/mL RNase-IN) and
centrifuged for 10 min at 3,500g, yielding the cleared cytoplasmic fraction
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(supernatant) and pelleted nuclei. Nuclear pellets were washed once in PBS
supplemented with 1 mM EDTA, re-suspended in 0.25 mL glycerol buffer (50%
glycerol, 20 mM Tris-HCl pH 7.5, 75 mM NaCl, 0.5 mM EDTA, 0.85 mM DTT, 100
U/mL RNase-IN), and lysed by the immediate addition of an equal volume nuclear
lysis buffer (10 mM HEPES pH 7.6, 7.5 mM MgCl2, 0.2 mM EDTA, 300 mM NaCl,
1% NP-40, 1 mM DTT, 1M Urea, 100 U/mL RNase-IN) with 2 min incubation on
ice. Centrifugation for 2 min at 18,800g yielded the nucleoplasmic and chromatinassociated fractions in the supernatant and pellet, respectively. Chromatin pellets
were washed once in 1 mM EDTA in PBS and solubilized in 1 mL TRIzol reagent
by syringing. RNA was extracted from the cytoplasmic and nucleoplasmic fractions
using TRIzol-LS (Invitrogen) and from the chromatin-associated fraction using
TRIzol following the manufacturer’s protocols. Subcellular RNA enrichment
patterns were determined by qRT-PCR, normalizing fraction Ct values to WC Ct
values. Cytoplasmically-enriched RNA Rn7s1 and chromatin-enriched RNA
Kcnq1ot1 served as fractionation quality controls. Primer sequences can be found
in Supplementary Table 2.

Antisense knockdown
1 µM Pvt1-targeting (ASO1, ASO2, and ASO3) or control (CON) antisense
LNA Gapmers (Exiqon, Qiagen) were transfected into 1-3x106 MEFs using the
Amaxa Mouse/Rat Hepatocyte Nucleofector Kit (Lonza, VPL-1004) and the
Nucleofector 2b Device (Lonza). Knockdown of Pvt1 variants and the
corresponding effects on p21 and Myc expression were assayed at 72 hours posttransfection by qRT-PCR following the indicated treatments. The sequences of all
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ASOs are listed in Supplementary Table 1.

Chromosome Conformation Capture (3C)
Chromosome conformation capture was performed as described previously
with minor modifications (Hagege et al., 2007). Briefly, cells were harvested by
trypsinization, counted, washed once in PBS and 5-10x106 cells were crosslinked
in 1% methanol-free formaldehyde (Thermo Scientific) diluted in PBS for 10 min
at RT. The reaction was stopped by adding 1.425 ml of 1 M glycine. Cell pellets were
frozen in a bath of dry ice covered in 100% EtOH and stored at -80°C, or were
processed immediately. Cells were lysed in 5 ml cell lysis buffer (20 mM TrisHCl
pH8.0, 85 nM KCl, 0.5% NP-40, 5 mM MgCl2, 0.1 mM EGTA) including 1x
complete protease inhibitor (Roche). Cell nuclei were resuspended in 0.5 ml of 1.2x
Cutsmart restriction buffer (New England Biolabs) and SDS was added to each
tube to a final concentration of 0.3%. Following extraction with 2% Triton X-100,
chromatin was digested overnight at 37°C with 400-800 U BamHI-HF (New
England Biolabs). Ligations were performed in a total reaction volume of 6.125 mL
of 1.15x ligation buffer (10x Ligation Buffer: 600 mM Tris-HCl pH7.5, 50 mM DTT,
50 mM MgCl2, 10 mM ATP (New England Biolabs) using 100 U of T4 DNA ligase
(New England Biolabs) with incubation at 16°C for 4 h, followed by further
incubation at RT for 30 min. Reversal of crosslinking was performed by adding
300 µg proteinase K (Roche) followed by incubation at 65°C overnight. DNA was
extracted with phenol-chloroform followed by EtOH precipitation. The efficiency
of restriction enzyme digestion was examined using qRT-PCR with primer sets
spanning BamHI sites. The concentrations of 3C libraries were determined by
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qRT-PCR and compared to a genomic DNA reference of known concentration.
Samples were subsequently diluted to a concentration of 20 ng/µl and a total of 50
ng was used for each qRT-PCR reaction. Interaction frequencies were determined
using a unidirectional primer strategy with an anchor designed against the
promoter of Myc (A1) and were normalized to a control region in the Myc-Pvt1
locus. The primer sequences can be found in Supplementary Table 2.

RNA-seq
Total RNA was isolated in three biological replicates. PolyA selection and
cDNA library preparation was performed using TruSeq Stranded mRNA Library
Prep (Illumina). Paired-end 100 bp sequencing was performed on an Illumina
HiSeq 4000 instrument. RNA-seq read files were merged from technical replicates
and mapped to the mm10 genome assembly using Tophat (ver 2.0.14) (Trapnell et
al., 2009) with gencode (vM10) annotation used as the transcriptome index.
Additional transcripts were assembled using stringtie (1.2.4) (Pertea et al., 2015)
and reads within exon sequences counted using HTSeq (HTSeq-0.6.1) counts
(Anders et al., 2015). The differential expression analysis was performed with
EdgeR (3.22.3) (using general linear model settings for biological triplicates with
blocked matrix model for paired comparisons) (Robinson et al., 2010). For analysis
of Myc targets, the Hallmark Gene Set in the Molecular Signature Database (Broad
Institute) (Liberzon et al., 2015) was used and compared to randomly selected and
expression matched genes with statistical significance of differential expression
determined with a Kolmogorov-Smirnov test.
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Transcriptome-wide TimeLapse-seq
At approximately 60% cellular confluence, media was spiked with a final
concentration of 100 µM s4U (Alfa Aesar) and grown in the dark for 1 hour. Cells
were rinsed once with PBS, scraped from plates, suspended in 1 mL TRIzol
(Invitrogen), and frozen overnight at -80°C. Total RNA was purified and treated
with TimeLapse chemistry essentially as described (Schofield et al., 2018) with
minor modifications. Briefly, following chloroform extraction and isopropanol
precipitation (supplemented with 1 mM DTT) genomic DNA was depleted by
treating with TURBO DNase (Invitrogen) and total RNA was extracted with acidic
phenol:chloroform:isoamyl alcohol and EtOH precipitation. Isolated total RNA
was mixed with 600 mM TFEA, 1 mM EDTA and 100 mM sodium acetate, pH 5.2
in water. A solution of 10 mM NaIO4 was added and the reaction mixture was
incubated at 45°C for 1 hr. Chemically treated RNA was purified using Agencourt
RNAclean XP beads (1 equivalent volume, Beckman Coulter) according to
manufacturer's instructions. Purified material was then incubated in a reducing
buffer (10 mM DTT, 100 mM NaCl, 10 mM Tris pH 7.4, 1 mM EDTA) at 37°C for
30 min, followed by a second RNAclean bead purification. For each sample, 10 ng
of total RNA input was used to prepare sequencing libraries from the Clontech
SMARTer Stranded Total RNA-Seq kit Pico Input (Takara Bio USA) with
ribosomal cDNA depletion. Paired-end 100 bp sequencing was performed on an
Illumina HiSeq 4000 instrument.
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TT-TimeLapse-seq
At approximately 60% cellular confluence, media was spiked with s4U (1 µM
final, Alfa Aesar) and cells were grown in the dark for 5 min. Total RNA and DNA
isolation were performed as described above. Total RNA (50 µg) was biotinylated
with MTSEA biotin-XX (Biotium), isolation and streptavidin enrichment
essentially as described (Schofield et al., 2018). Enriched RNA was chemically
treated as described above. Library construction and sequencing were performed
essentially as described above.

TimeLapse-seq mutational analysis
Filtering and alignment to the mouse GRCm38.p5 were performed
essentially as described previously (Schofield et al., 2018). Briefly, reads were
filtered to remove duplicate sequences with FastUniq (Xu et al., 2012), trimmed of
adaptor sequences with Cutadapt v1.16 (Martin, 2011) and aligned to GRCm38
using HISAT2 v2.1.0 (Kim et al., 2015a) (with default parameters except -mp 4,2).
Reads aligning to transcripts were quantified with HTSeq (Anders et al., 2015)
htseq-count. SAMtools v1.5 (Li et al., 2009) was used to collect only read pairs with
a mapping quality greater than 2 and concordant alignment (sam FLAG = 147/99
or 83/163). Mutation calling was performed essentially as described previously
(Schofield et al., 2018). Briefly, T-to-C mutations were only considered if they met
several conditions. Mutations must have a base quality score greater than 40 and
be more than 3 nucleotides from the read’s end. Sites of likely single-nucleotide
polymorphisms (SNPs) and alignment artifacts were identified with bcftools or
from sites of high mutation levels in the non-s4U treated controls and were not
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considered in mutation calling. Browser tracks were made using STAR v2.5.3a
(Dobin et al., 2013) and normalized across samples using scale factors calculated
using RNA-seq reads using edgeR (Robinson et al., 2010) (calcNormFactors using
method = ‘upperquartile’).

Differential expression analysis
Differential expression analysis of transcriptome-wide TimeLapse-seq and
TT-TimeLapse-seq data was performed with DESeq2 (Love et al., 2014) essentially
as described previously (Schofield et al., 2018). DESeq2 expression analysis was
performed on TT-TimeLapse-seq and transcriptome-wide TimeLapse-seq data to
determine changes in transcriptional activity and mRNA expression, respectively.

Growth curve and colony assay
To generate growth curves, Con-, DRE-, sg1-, or sg2-expressing KPR cells
were grown in the presence or absence of Tam. Population doublings over
indicated time course were plotted as the average of three independent
experiments. For colony assays, 4x105 Con- or DRE -expressing KPR cells were
plated in the presence of Tam in 6 cm dishes and monitored for colony formation.
Plates were washed with PBS, fixed in 0.5% Crystal Violet; 25% MeOH for 10
minutes and washed in ddH2O. The average of three biological replicates is shown.

Tumor studies
Lung tumorigenesis was initiated in cohorts of KC and KPC mice as
described in (DuPage et al., 2009) by intratracheal infection with 1x105 pfu UGPC
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lentiviruses . Mice were analyzed at 12 or 16 weeks post tumor initiation. For
histological analyses, lungs were inflated with 4% paraformaldehyde, and fixed
overnight in 4% paraformaldehyde, prior to dehydration in 70% ethanol. Fixed
lungs were embedded in paraffin, sectioned, and stained with hematoxylin and
eosin (H&E). Tumor burden scored as tumor area relative to total lung area was
determined using the freehand selection tool and Measure feature in ImageJ on
images acquired with an Axio Imager 2 microscope system (Zeiss) with a PlanApo
10x 0.3 objective lens (Zeiss). Tumor grade was scored as previously described
(DuPage et al., 2009; Nikitin et al., 2004).

Immunohistochemistry
Immunohistochemistry on paraffin sections was performed using the ABC
Vectastain kit (Vector Labs) with an antibody to pHH3 Serine 10 (9701S, Cell
Signaling Technologies). The staining was visualized with DAB (Vector Labs) and
slides were counterstained with hematoxylin.

QUANTIFICATION AND STATISTICAL ANALYSIS
In relevant figures, figure legends convey the statistical details of
experiments including statistical tests used and type and number (n) of biological
replicates, while asterisks define degree of significance as described. All Student’s
t-tests and Mann-Whitney U-tests were analyzed in two sided. All sequencing data
were aligned to the mouse genome (GRCm38/mm10). All statistical analyses were
performed and graphics were generated using Prism8 software. Tracking of Indels
by DEcomposition (TIDE) analysis was used to estimate mutagenesis efficiency.
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DATA AND SOFTWARE AVAILABILITY
All software used in this work is listed in Supplementary Table 4. Data
generated in (Olivero et al., 2020) are available through Gene Expression Omnibus
(GEO) under accession number GEO: GSE126940. Some figures were created
using graphics from www.Biorender.com.
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Supplementary Tables
Supplementary Table 1: ASO, dRNA, gRNA, HDR template, and smRNA FISH
probe information
ASOs
Name
Con
ASO1
ASO2
ASO3

Target
N/A
Pvt1 exon 1b
Pvt1 exon 1b
Pvt1 exon 1b

Sequence
GCTCCCTTCAATCCAA
GTAACTAGCACACATC
TTTGCTCCTTCTAAAT
GAGTCCATGTGACGTT

Name
Con
A1
A2

Target
dTomato
Pvt1a TSS
Pvt1b TSS

Sequence
gCGAGTTCGAGATCGA
GGAGATCGGGGACAC
gATGGTCATAGCTAGT

Name
Con
RE
p53
sg1
sg2
sgALT1
sgALT2
sgALT3
sgALT4
sgALT5
sgALT6
sgALT7
sgALT8
sgALT9
sgALT10
sgALT11
sgdeltaSS
Puro

SpCas9 gRNAs
Target
dTomato
Pvt1b p53RE
p53 ORF
Gm26542 p53RE
Gm26542 p53RE
Pvt1 exon 1b
Pvt1 exon 1b
Pvt1 exon 1b
Pvt1 exon 1b
Pvt1 exon 1b
Pvt1 exon 1b
Pvt1 exon 1b
Pvt1 exon 1b
Pvt1 exon 1b
Pvt1 exon 1b
Pvt1 exon 1b
Pvt1 exon 1b 3’ end
Puromycin resistance gene

Sequence
GGCCACGAGTTCGAGATCGA
gATATGGGCAGTGACAAGTTT
GTGTAATAGCTCCTGCATGG
gTCTGAGGCCTGGGACTTGCC
GGACTTGCTCAGTTCTTGGA
gAAACACAAACGCTTTCCCAC
gTTCTTAAAGCTCTAGCCAGT
gAAGTCCCACTTGGAGCTCCA
gTCTATCCTTGGAGCTCCAAG
GACTTCTTAAAAGATTTAGA
gTTAGAAGGAGCAAAGCTGTC
gAGGAAATCAGAAACGTCACA
gCGTCACATGGACTCCATGAC
GACTGGGAAAAACCTCGTGG
GGTGGCCTGCTCTCAGTGCT
GATGTGTGCTAGTTACATCT
GTGTGCTAGTTACATCTCGG
gCGGGTGGCGAGGCGCACCGT

Name
sgEx1a
sgEx1b

in vivo SpCas9 gRNAs
Target
Sequence
Pvt1 exon 1a
gCTGGTCAAGCGGGCTCGGCA
Pvt1 exon 1b
gTCTATCCTTGGAGCTCCAAG

SpCas9 dRNAs

Name
Pvt1a-PAS

HDR Templates
Target
Sequence
Pvt1 exon 1a
CCGGGGCTGCCAACATCCTTTCC
ACGCGGATATCCACTCGGGGGG
CTCTGGGAATGCTAAGTTCGTAG
CTTCTCTTCATCCTGGCCTTGCCA
CACAAAAAACCAACACACAGATC
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TAATGAAAATAAAGATCTTTTAT
TCGAGCCCGCTTGACCAGTGGGT
CCATGTGCTCGGCGGCCA
CACGAGGTTTTTCCCAGTCATGG
AGTCCATGTGACGTTTCTGATTT
CCTGACAGCTTTGCTCCTTCTAA
ATCTTTTAAGAAGTCCCACTTCA
CACAAAAAACCAACACACAGATC
TAATGAAAATAAAGATCTTTTAT
TGGAGCTCCAAGGATAGAAACA
CAAACGCTTTCCCACTGGC
CGAGGTTTTTCCCAGTCATGGAG
TCCATGTGACGTTTCTGATTTCCT
GACAGCTTTGCTCCTTCTAAATCT
TTTAAGAAGTCCCACTTCAATAAA
GCTGCATTAATGCCGCGCTATCGC
GACATTACTCTGCTATTTTTGCGG
GCTTGTAACCGCTTTATTGGGAG
CTCCAAGGATAGAAACACAAACG
CTTTCCCACTG

Pvt1b-PAS

Pvt1 exon 1b

Pvt1b-TWI

Pvt1 exon 1b

Name
PVT1_exons_1
PVT1_exons_2
PVT1_exons_3
PVT1_exons_4
PVT1_exons_5
PVT1_exons_6
PVT1_exons_7
PVT1_exons_8
PVT1_exons_9
PVT1_exons_10
PVT1_exons_11
PVT1_exons_12
PVT1_exons_13
PVT1_exons_14
PVT1_exons_15
PVT1_exons_16
PVT1_exons_17
PVT1_exons_18
PVT1_exons_19
PVT1_exons_20
PVT1_exons_21
PVT1_exons_22
PVT1_exons_23
PVT1_exons_24
PVT1_exons_25
PVT1_exons_26
PVT1_exons_27
PVT1_exons_28
PVT1_exons_29
PVT1_exons_30
PVT1_exons_31
PVT1_exons_32

smRNA FISH Probes
3’ Modification
Sequence
Quasar 570
TCTGGGAATGCTAAGTTCGT
Quasar 570
CCATGTGACGTTTCTGATTT
Quasar 570
ACACATCCAAGCACTGAGAG
Quasar 570
AAATCAGACCTCCGAGATGT
Quasar 570
TTCAGGAAGTCTCCAGAGAG
Quasar 570
CAGAATTACTCCCCAGGAAA
Quasar 570
GGGTAGAGATACAATCCTCT
Quasar 570
GCTCTCAGAAACACTGCATT
Quasar 570
CTGGTTCTTCTGAGAGACTG
Quasar 570
AGGCATCTCACAGCAAAGTA
Quasar 570
TTATCACATTAGAGGACCCG
Quasar 570
ACTTGGCATCTCTTAAGTCA
Quasar 570
AGACTTCCATCTTTGCTATT
Quasar 570
CAGCTGTCTTATAGGATTGC
Quasar 570
TCTTAGGGTCAGTATCATGG
Quasar 570
AGTATTCTAGCTTGGAGCTA
Quasar 570
TTGTCACTCCATTTGGCAAA
Quasar 570
TGCTTAAAGACCACAGAGGC
Quasar 570
ATTGCTTTGGGTATTTTGGT
Quasar 570
AATGTCTACTTGTTGGCCAA
Quasar 570
TAGCAGAGTGGTTCAAAGGC
Quasar 570
AGAATTTCAGAGGGCACTCG
Quasar 570
AGACTTAGGGCATACAGGTA
Quasar 570
CTGGATTCTGTAGCTATTCT
Quasar 570
TAAAGCATCCAGGGCAGAAC
Quasar 570
TGACTCCTGTTGGAAAACCA
Quasar 570
CACGCTCATGTCCTTTAATA
Quasar 570
GTTTAGCACTATCCATCTTT
Quasar 570
TTGCTCTCCTTATGAAGAGG
Quasar 570
GAAACCTTAAGCATGAGCCA
Quasar 570
AGTGCACTCTTATACGTCAC
Quasar 570
ATCTTAAGATGGCTTGGACC
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PVT1_exons_33
PVT1_exons_34
PVT1_exons_35
PVT1_exons_36
PVT1_exons_37
PVT1_exons_38
PVT1_exons_39
PVT1_exons_40
PVT1_exons_41
PVT1_exons_42
PVT1_exons_43
PVT1_exons_44
PVT1_exons_45
PVT1_exons_46
PVT1_exons_47
PVT1_exons_48
PVT1_intron_AE1up_1
PVT1_intron_AE1up_2
PVT1_intron_AE1up_3
PVT1_intron_AE1up_4
PVT1_intron_AE1up_5
PVT1_intron_AE1up_6
PVT1_intron_AE1up_7
PVT1_intron_AE1up_8
PVT1_intron_AE1up_9
PVT1_intron_AE1up_10
PVT1_intron_AE1up_11
PVT1_intron_AE1up_12
PVT1_intron_AE1up_13
PVT1_intron_AE1up_14
PVT1_intron_AE1up_15
PVT1_intron_AE1up_16
PVT1_intron_AE1up_17
PVT1_intron_AE1up_18
PVT1_intron_AE1up_19
PVT1_intron_AE1up_20
PVT1_intron_AE1up_21
PVT1_intron_AE1up_22
PVT1_intron_AE1up_23
PVT1_intron_AE1up_24
PVT1_intron_AE1up_25
PVT1_intron_AE1up_26
PVT1_intron_AE1up_27
PVT1_intron_AE1up_28
PVT1_intron_AE1up_29
PVT1_intron_AE1up_30
PVT1_intron_AE1up_31
PVT1_Exon1a_1
PVT1_Exon1a_2
PVT1_Exon1a_3
PVT1_Exon1a_4
PVT1_Exon1a_5
PVT1_Exon1a_6
PVT1_Exon1a_7

Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670

GAGATTCGGAACTGACAGGC
AAAGAGAACGTGTCCCTTGT
TCTATTGTAGGTTGTTCCTG
AAATCCAGGCTACTTCTCAG
GCCTCCAGAGAAAACGATGA
CAGGGCTCATGAGAACAGAG
CTTACCAGGAGAAGCATCAT
CAGCACATAGAACACAGGCA
GAAGATTGTGCCAGGAACTC
CAGATCCTGGTTTAGAACGG
CTGTCATCTTCTCTTCTTTG
TCCTTAATGTGCTACCACAA
GGATTCTACTTCACCATAGG
CCAAGGCATTATGAAGTGCA
AAAGTGTCTCAGGGAATCCT
TCAGTAAGTCACAGCTGTGA
TTCCAGGGGATAAACTTGGA
AATGCAAAAGCCACTTTCCT
AAGGTTAACACGCGCTCGTG
TCGAGTCTAGTGATGAGGAA
ACACCCAAACTCTCTGGCAA
TAGAGGCCATCCTGGGAAAT
GCATAAATCCAGAATTACCT
CTGAGGAAATGGGCTCTTGA
CAAATCTGCGCTGATTGCAG
TCGTAAATGAGGCCTCCAAA
GACTAGACTCAGACTTCCAG
AAGGATGGAGGGAGCATCAC
GTTTTAGGAGATCACCTTCT
GCACAGAAAGTTTCCTGACA
CTTCCACGAACACAGGAACG
TAGCAAGGATGAAGGCGTGG
GTTAAAGCAACAAGCTATCC
TAGCCAAGAAAGGGCCAATC
CACTCATAGGTACAGCAGAA
TGGAAGTCTGCACAGTTCTC
CACATGTAGCTTCATGGCTG
ATCCATGATGTGTCTACACA
CAGATTATCACCCACTAGTA
GAACGTTCTGGAGAGCTCAA
GATTTCTCTCCTTAAGCTTC
TTCTCCCTATACTCTCTTAA
GTCAAATGACAACAACCCCT
AACAGAGACCTGCATCCTTA
CAACATCCTACCACATGCAC
GTGAACAAGCCCAAACTTGT
CTAGCTATGACCATAGGACT
GTGGCCCGTGACGTCACG
TGGTAGAGCGCGGGGCTG
CGGCCACACGCGCTCTGC
AGTGGGTCCATGTGCTCG
TTGCCGAGCCCGCTTGAC
CGTAGCTTCTCTTCATCC
GCTCTGGGAATGCTAAGT
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PVT1_Exon1a_8
PVT1_Exon1a_9
PVT1_Exon1a_10
PVT1_Exon1a_11
PVT1_Exon1b_1
PVT1_Exon1b_2
PVT1_Exon1b_3
PVT1_Exon1b_4
PVT1_Exon1b_5
PVT1_Exon1b_6
PVT1_Exon1b_7
PVT1_Exon1b_8
PVT1_Exon1b_9
PVT1_Exon1b_10
c-Myc intron_1
c-Myc intron_2
c-Myc intron_3
c-Myc intron_4
c-Myc intron_5
c-Myc intron_6
c-Myc intron_7
c-Myc intron_8
c-Myc intron_9
c-Myc intron_10
c-Myc intron_11
c-Myc intron_12
c-Myc intron_13
c-Myc intron_14
c-Myc intron_15
c-Myc intron_16
c-Myc intron_17
c-Myc intron_18
c-Myc intron_19
c-Myc intron_20
c-Myc intron_21
c-Myc intron_22
c-Myc intron_23
c-Myc intron_24
c-Myc intron_25
c-Myc intron_26
c-Myc intron_27
c-Myc intron_28
c-Myc intron_29
c-Myc intron_30
c-Myc intron_31
c-Myc intron_32
c-Myc intron_33

Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 670
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570
Quasar 570

GCGGATATCCACTCGGGG
CTGCCAACATCCTTTCCA
GACTCCGAGGTCACCGGG
AGAGGGTGGATCCAGCCG
GGCTAGAGCTTTAAGAAG
ACACAAACGCTTTCCCAC
TGGAGCTCCAAGGATAGA
TCTTTTAAGAAGTCCCAC
CAGCTTTGCTCCTTCTAA
GACGTTTCTGATTTCCTG
CCAGTCATGGAGTCCATG
GGCCACCACGAGGTTTTT
CATCCAAGCACTGAGAGC
TCCGAGATGTAACTAGCA
AAAGACCACCAGATCTGTGC
TAACCGGCCGCTACATTCAA
CCCCAACTACTCTTGAGAAA
CATCTTGACAAGTCGCTCTA
CGCTTCAAAATGCATCCCGG
CCCATAGTAACCTCGGGAAC
AAGCAAGAATGTCCAACCGG
CCCTCAAAGGACACATATCA
GATTCCAAGGGCTTTCTTTG
TAATCCCTTCTCCAAAGACC
TCTCGCTCCCAAACGCAAAA
GGTAAGTCAGAAGCTACGGA
TTTAAATGCCCTCTCAGAGA
GTCAGAAATGCACCAAGCTG
TTAAAAGGCTCAGGGACGGG
GGGGGTCAGGCTTAAATTTT
CCAACATCAAGTCCTAGTGC
AATTTTGCTTCTCCTCACTG
TCAACGAATCGGTCACATCC
CAGTCTTCCTAGCAATTCAG
TTACGGAACCGCTCAGATCA
TACACTCTAAACCGCGACGC
ATAATAAGAGACACCTCCCT
GCTATCACAAGCCTCTCGAA
TGGAGGAGAGAGCTCAGTCT
CTTTTCTTTCCGATTGCTGA
AAGGAGAAAGGCGAGAGGCG
CTAAGAGCCGAGGCGCAAAG
GAGGCGACTGTAGGGAATAC
TCCTTCGAGCAGGGACTTAG
TACTATCAGTGACGCTCGTC
AGGCATGCACTCTTTTACTC
GAGTTATCCAGCTCTGGTTG
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Supplementary Table 2: qRT-PCR and PCR primer sequences
Gene
Pvt1a (ex1a-2)
Pvt1b (ex1b-2)
Pvt1b nascent (ex1b-int)
Pvt1 (ex4-5)
Myc
p21
Rn7s1
Kcnq1ot1
Gm26542
Gapdh
Pvt1 p53RE (ChIP)
Myc promoter (ChIP)

qRT-PCR primers (mouse)
Forward sequence
Reverse sequence
ACTTAGCATTCCCAGAGCCC
TGGAGGGCATCTTCTTACCG
CCATGACTGGGAAAAACCTCG
TGGAGGGCATCTTCTTACCG
CCATGACTGGGAAAAACCTCG
CCAGCACAATAGCCCACAATG
CTGGGACACTGCCTGATTGA
TCCTTCTGGAACGCTTAAAGG
TTCATCTGCGATCCTGACGAC
CACTGAGGGGTCAATGCACTC
TCCACAGCGATATCCAGACA
GGACATCACCAGGATTGGAC
CTGTAGTGCGCTATGCCGA
GTTCACCCCTCCTTAGGCAA
GGCCAGAAGCAGAGGTGATT
CCGAGCCGTAACTGCAAAAC
CCTTGGCTGACACCCGAACC
CCGAGTTCGAGCGCGTCTTC
AGCTTGTCATCAACGGGAAG
TTTGATGTTAGTGGGGTCTCG
GGCTAAGGATGCAGGTCTC
AAACGCTTTCCCACTGGCTA
CGCGAGCAAGAGAAAATGGTC CTTTGGGAACTCGGGAGGG

Gene
PVT1a (ex1a-2)
PVT1b (ex1b-2)
MYC

qRT-PCR primers (human)
Forward sequence
Reverse sequence
TTCCAGTGGATTTCCTTGCGG
CTGACAGGCACAGCCATCTTG
GCACAAGGGCCCAACTGGA
CTGACAGGCACAGCCATCTTG
TCGGATTCTCTGCTCTCCTCG
AGGTGATCCAGACTCTGACCT

Name
BamHI-016
BamHI-015
BamHI-008
BamHI-007
BamHI001
BamHI002
BamHI003
BamHI008
BamHI009
BamHI013
BamHI014
BamHI015
BamHI016
BamHI017

3C qRT-PCR primers
Sequence
GTGCTCAGCTCCATCCTGCAAG
GACAATTC
GAGGGAACAAAATACTCATGG
GAGGAGATAC
TTGAAAAAGCCTGCTAGACAGT
CCCTGGTG
TGCACTTCCTTGAGAAGCTGGT
AGGATACC
CACAGGAGGAACATCAGGAGA
CCCAAATTC
TCAGCTGCCGGGTCCGACTCG
CCTCAC
GCAGTGAGGAGAAGCAAAATT
GGGACAGGG
TGAGTGACACCAACATCCTGGA
GCCTCAG
AACCAGGCTACTCTAACTCTCT
CTGCTCAG
CTCCTCTCAGGCTTGATGCCCC
TTCATTG
ACGAACTTAGCATTCCCAGAGC
CCCCCG
TGGAAAGGTGTCTCTTTTCTGT
TGTTTCTGG
GGCACCGACTGGGCATGTATC
CTGCTTG
GTCTCAGTGCAGCAGCCCTTGA
GTGAAAG
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BamHI018
BamHI019
BamHI020
BamHI022
BamHI024
BamHI028
BamHI029
BamHI030
BamHI031
BamHI032
BamHI033
BamHI036
BamHI042
BamHI050
Pvt1 3'E.1 BamHI003
Pvt1 3'E.1 BamHI004
Pvt1 3'E.2 BamHI003
Pvt1 3'E.2 BamHI005
BamHIctrl

TGCATTGCCACATTCCAGATTG
TCACCTTG
CAGTAGCAGAGAGCATAAGCC
TTTGTCTCC
GAGGTATGAATGTAAACATTG
TACACATACTG
GTTAATTGGGTGTTCTAGCTCT
GGAAAATGC
CTATTTTGCCCCTTTGTTCCCT
GTTCTATCC
TGTAGATCTCAACAGATGAACC
CAGGGGAC
GCAACACTTGATGACTTGACCA
AATAAACAGC
AGTTCCAAAGGTGAAAAAGCT
GTATAATCGTC
CTGCCTCTCAGCTCACGGCCAC
TGTGTC
CTTGAGAGCCTGCATATCCTTT
GAGCAGAT
CCCCAATCCTTTTCTCTACTCC
ATACCCAC
AGGCAGGGCTGGAGTTTTGTT
CTGTTTGTG
AATTGAGAAACCACCCGATAGT
AACCTGGG
CACAAGAGACAGCTACATCTG
GGTCCTTTC
CCTGTCTCCTCCCCCATCCTGA
TAGTAC
TGGTATGAGTATCCAAAGACAT
TGAGGACTC
ACTAGAGTATGTCTGCCTTTTG
TGTGGGAC
TCTTTGAGTTCATTTGTAAGGG
TATTTCCAGC
ATTAAAGGTGGAGTGAGACAT
CAGAGGTGG

Name
Pvt1 (ex1a-5)
Pvt1 (ex1b-5)

RT-PCR primers
Forward sequence
TGGATATCCGCGTGGAAAGG
CTCTAGCCAGTGGGAAAGCG

Name
Pvt1a PAS
Pvt1b PAS/TWI

Genotyping PCR primers
Forward sequence
Reverse sequence
TACCAGGCAGAGCGCGTG
CTGGGCTCCAGAGTTTCCA
ACTTGCACAGTCCTATGGTCA
CGTAAGGCACATCCTCACCT

Name
Pvt1 p53RE
Pvt1 exon 1b
Pvt1 exon 1b 3’ end

Mutagenesis efficiency PCR primers
Forward sequence
Reverse sequence
GAAGTGCATGTGGTAGGATG
GCACATCCTCACCTCCGAGA
GCCTGTTTTGCATATGGGCAG
ACAAGGCAGTCCCATACAGTC
CAGTGGGAAAGCGTTTGTG
AGCAAGAAACAGCCACCCTT
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Reverse sequence
TCCTTCTGGAACGCTTAAAGG
TCCTTCTGGAACGCTTAAAGG

Supplementary Table 3: Key plasmids and recombinant DNA used in this work
Name
pCMV-dR8.2
dvpr
pCMV-VSV-G

Source

Identifier

(Stewart et al., 2003)

Addgene #8455

(Stewart et al., 2003)

Addgene #8454

pWZL Hygro

S. Lowe, unpublished

Addgene #18750

BRD001

Broad Institute

N/A

BRD004

Broad Institute

N/A

UGPC

(Olivero et al., 2020)

N/A

lenti-SAM-hygro

(Olivero et al., 2020)

N/A

Myc BAC

BACPAC Resources Center

Cat#RP23-55F11

Chr 6 BAC

BACPAC Resources Center

Cat#RP24-301E22
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Supplementary Table 4: Software and algorithms used in this work
Resource

Source

Location

GraphPad Prism,
version 8.2.1 for
MacOS
FIJI

N/A

www.graphpad.com

N/A

https://imagej.net/Downloads

TIDE

(Brinkman
et al.,
2014)
N/A

http://shinyapps.datacurators.nl/tide/

(Trapnell
et al.,
2009)
(Pertea et
al., 2015)
(Anders et
al., 2015)
(Robinson
et al.,
2010)
(Xu et al.,
2012)
(Martin,
2011)
(Kim et al.,
2015a)
(Li et al.,
2009)
(Dobin et
al., 2013)
(Love et
al., 2014)

http://ccb.jhu.edu/software/tophat/index.shtml

Biorender
Tophat (v2.0.14)
stringtie (v1.2.4)
HTSeq (v0.6.1)
EdgeR (v3.22.3)
FastUniq
Cutadapt (v1.16)
HISAT2 (v2.1.0)
SAMtools (v1.5)
STAR (v2.5.3a)
DEseq2

www.biorender.com

https://ccb.jhu.edu/software/stringtie/
https://htseq.readthedocs.io/en/release_0.11.1/
https://bioconductor.org/packages/release/bioc/html/
edgeR.html
http://sourceforge.net/projects/fastuniq/
https://cutadapt.readthedocs.io/en/stable/
https://ccb.jhu.edu/software/hisat2/index.shtml
http://samtools.sourceforge.net
https://github.com/alexdobin/STAR
https://bioconductor.org/packages/release/bioc/html/
DESeq2.html
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